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BILL SUMMARY  
SB 11 has other aspects but also includes a benefit 
mandate, which CHBRP was asked to analyze. The 
benefit mandate would require plans and policies 
regulated by the California Department of Managed Health 
Care (DMHC) or the California Department of Insurance 
(CDI) that include a pharmacy benefit that covers 
outpatient prescription medications related to treatment of 
substance use disorders (SUDs) to place all medications 
approved by the federal Food and Drug Administration 
(FDA) and indicated for treatment of SUDs on formulary 
and on the formulary’s lowest tier and, for those 
medications, prohibit prior authorization and step therapy 
(or “fail first”) protocols. In addition, SB 11 would prohibit 
coverage denials for these medications, for counseling, 
and for “other wrap-around services” if the denial was 
related to a court order for treatment. 
Figure A notes how many Californians have health 
insurance that would be subject to SB 11. 
Figure A. Health Insurance in CA and SB 11 
 
Source: California Health Benefits Review Program, 2019. 
Notes: *Medicare beneficiaries, enrollees in self-insured products, etc. 
In order to analyze the impacts of SB 11, CHBRP has 
made several analytic assumptions, including that benefit 
coverage requirements (1) would be applicable to 
prescription-only medications generally covered through a 
pharmacy benefit — so not applicable to over-the-counter 
medications or to medications requiring a clinician for 
administration and so generally covered through a medical 
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AT A GLANCE 
The version of California SB 11 analyzed by CHBRP 
would, for many enrollees in state-regulated plans and 
policies, require on-formulary, lowest tier coverage of 
prescription medications approved by the FDA for 
treatment of substance use disorders (SUDs). CHBRP 
estimates that, in 2019, of the 23.4 million Californians 
enrolled in state-regulated health insurance, 100% will 
have insurance that required to comply with SB 11. 
 
1. Benefit coverage. Approximately 93% of 
commercial and CalPERS enrollees and all 
Medi-Cal enrollees (beneficiaries enrolled in 
DMHC-regulated plans) would see some 
change to their benefit coverage. 
2. Utilization. Among commercial and CalPERS 
enrollees, utilization would increase for many 
of the 13 medications approved by the FDA 
for SUD treatment. Among all enrollees, a 
shift to use of the more costly auto-injector 
formulation of naloxone (the opioid anti-
overdose medication) would be expected. 
Increases in some related services 
(counseling) and decrease in others (inpatient 
days) would also occur. 
3. Expenditures. Premium increases (less than 
0.1%) and a decrease (less than 0.1%) in total 
enrollee out-of-pocket expenses for covered 
benefits (cost sharing) would occur. 
4. Medical effectiveness. When successfully 
used as prescribed and directed, clear and 
convincing evidence indicates that most 
prescription-only medications approved by the 
FDA for treatment of SUD are effective. 
5. Public health. Barriers to treatment, limited 
patient willingness, and relapses will limit 
impacts, but positive health outcomes are 
expected for patients who engage in 
treatment.  
6. Long-term impacts. Increased rates of OUD 
may increase related impacts - but barriers to 
treatment, limited patient willingness, and 
relapse will continue to be limiting factors for 
impacts related to all three SUDs.  
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benefit; (2) would be applicable to covered brand name as 
well as generic medications; (3) would be applicable to all 
covered formulations of the medications. 
 
CONTEXT1 
The FDA has approved and indicated 10 prescription-only 
outpatient medications for treatment of three SUDS:  
opioid use disorder (OUD), alcohol use disorder (AUD), 
and/or tobacco use disorder (TUD). 
Treatments for SUD, however, are not limited to 
medications, and frequently also include residential, 
inpatient, and outpatient care using behavioral therapy, 
counseling and/or medication, as well as mutual help 
groups (e.g., Alcoholics Anonymous).   
Structural and attitudinal barriers to accessing any 
treatment for OUD, AUD, and TUD affect use.  Structural 
barriers include being uninsured, utilization management 
protocols when insurance is present, limited provider 
supply, and geographic access difficulties.  Attitudinal 
barriers include limited patient receptiveness to treatment. 
For many with OUD, AUD, and TUD, attitudinal barriers 
are the most significant barrier to treatment initiation and 
persistence. The stigma of addiction and the ability to 
acknowledge an addiction affects patient desire to seek 
care. Many people with OUD and/or AUD believe they can 
solve the problem themselves. Similarly, limited patient 
readiness for treatment is also a barrier for those with 
TUD: 33% of California smokers are not interested in 
quitting.  
Prior to SB 11, CHBRP estimates that only 20% (one-fifth) 
of enrollees in plans and policies regulated by DMHC or 
CDI with OUD use FDA approved and indicated 
medications for OUD. This underuse is not necessarily 
related to insurance coverage for treatment and is more 
likely due to other factors, including other structural 
barriers (such as limited numbers of providers) and limited 
willingness to enter treatment.  Prior to SB 11, less than 
1% of enrollees with AUD or TUD use these medications. 
This underuse is linked to provider practice (limited 
prescribing), limited willingness to enter treatment, and 
other treatment options that do not rely on prescription 
medications (e.g., over-the-counter nicotine replacement 
therapy, Alcoholics Anonymous). 
                                                     
1 Refer to CHBRP’s full report for full citations and references. 
It should be noted, as well, that even when a patient is 
willing, treatment adherence is difficult. Relapse rates for 
patients in treatment for AUD and OUD are significant, 
and multiple quit attempts before successful cessation is 
common for TUD. 
 
IMPACTS 
Medical Effectiveness 
As noted, there a multiple treatments for SUD, but this 
analysis focuses on the effectiveness the treatment 
addressed by SB 11: use of prescription-only outpatient 
medications approved by the FDA and indicated as 
treatments for OUD, AUD, and/or TUD that are generally 
covered through a pharmacy benefit. 
Effectiveness is considered through studies of outcomes 
and studied outcomes vary depending on the SUD. OUD 
outcomes include opioid use, participation in treatment, 
and mortality. AUD outcomes include alcohol use and 
participation in treatment. TUD outcomes include reduced 
cigarette cravings and abstinence. 
The evidence is related to use of the medications when 
prescribed and used as directed. As already noted, many 
persons with OUD, AUD, or TUD have difficulty “using as 
directed” for the recommended period due to structural 
and attitudinal barriers to treatment. In addition, many 
people relapse and need to receive treatment repeatedly 
to abstain from using opioids, alcohol, or tobacco. 
However, for prescription-only medications approved by 
the FDA for OUD used as directed for the recommended 
period: 
• There is clear and convincing evidence that 
methadone, buprenorphine, and buprenorphine-
naloxone are effective 
• There is a preponderance of evidence that orally 
administered naltrexone is not effective. 
• Evidence comparing medications is inconclusive. 
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For prescription-only medications approved by the FDA for 
AUD: 
• There is clear and convincing evidence that 
acamprosate and naltrexone are effective. 
• There is limited evidence that disulfiram is not 
effective.  
• Evidence comparing medications is inconclusive. 
For prescription-only medications approved by the FDA for 
TUD: 
• There is clear and convincing evidence that 
prescription medications are effective. 
• There is a preponderance of evidence favoring 
varenicline over nicotine replacement therapy 
(NRT). 
• There is a preponderance of evidence that there 
is no difference between NRT and bupropion. 
Benefit Coverage, Utilization, and Cost  
For this analysis, CHBRP has estimated the impacts of 
requiring on-formulary coverage for the 13 prescription-
only outpatient medications approved by the FDA and 
indicated as treat one or more of three SUDs, prohibiting 
the application of prior authorization or step therapy (“fail 
first”) protocols, and requiring tier 1 or lower cost sharing. 
As CHBRP is unaware of coverage denials related to 
court orders, no measurable impact related to the SB 11 
prohibition is expected.    
Benefit Coverage 
Approximately 95.6% of enrollees in plans and policies 
regulated by DMHC or CDI have a pharmacy benefit that 
would need to be altered to be compliant with SB 11.   
Most commercial and CalPERS enrollees have on-
formulary coverage for most of these medications; all 
would postmandate. Few of these enrollees have tier 1 (or 
no) cost sharing for most brand-name medications; all 
would postmandate. Few of these enrollees have prior 
                                                     
2 Federal law restricts methadone treatment to federally certified 
opioid treatment programs (OTP), known as methadone clinics, 
authorization or step therapy protocols applicable to their 
coverage for these medications; none would postmandate.  
All Medi-Cal beneficiaries enrolled in DMHC-regulated 
plans have coverage for these medications — though for 
OUD and AUD medications it is through a “carve-out” to 
the Medi-Cal fee-for-service (FFS) program. Excepting 
only coverage for the more costly auto-injector formulation 
of naloxone for OUD (the anti-overdose drug), the FFS 
program coverage is compliant with SB 11. Postmandate, 
these enrollees would have coverage from their DMHC-
regulated plans as well, including SB 11–compliant 
naloxone coverage. 
Utilization 
Table 1 provides mediation specific impacts on expected 
use and on the expected number of users, as well as the 
broad indirect impacts SB 11 would have on counseling, 
inpatient days, and emergency room use. 
Generally, use of the medications would increase among 
commercial enrollees and enrollees associated with 
CalPERS – and new users would be expected for some of 
the medications. The exceptions are: 
• No utilization increase is expected for lofexidine 
for OUD (used to treat short-term withdrawal 
symptoms), as the medication is newly approved 
and not likely to be much prescribed by providers 
during the initial year after implementation of SB 
11.  
• Within the increased utilization of naloxone for 
OUD (used to treat overdoses) there would be a 
shift such that the more costly auto-injector 
formulation would represent half of all filled 
prescriptions.  
• No utilization increase is expected for methadone 
for OUD because it may only be prescribed and 
delivered through federally certified centers,2 
which do not bill for medication alone (as would 
be covered by an SB 11–compliant pharmacy 
benefit). 
see Title 42 of the Code of Federal Regulations Part 8 (42 CFR § 
8) 
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• No utilization increase is expected for disulfiram 
for AUD, as providers have concerns regarding its 
lack of effectiveness. 
For Medi-Cal beneficiaries enrolled in DMHC-regulated 
plans almost all use would be unchanged, as the new SB 
11–compliant coverage would be almost identical to their 
current coverage through the Medi-Cal FFS carve-out 
program.  However, use of naloxone for OUD would shift 
towards the more costly auto-injector formulation because 
patients prefer it to other formulations of naloxone. The 
shifted utilization would be covered by the beneficiaries’ 
newly SB 11–compliant plan (rather than to the existing 
FFS carve-out program).  
A 12.5% increase in use of related counseling would be 
expected among all enrollees using OUD and AUD 
medications.  
Decreases in some related treatments and services would 
occur for some new (but not continuing) users of these 
medications. For new users of medications for OUD and 
AUD, reductions in inpatient days, detox days, and 
emergency department visits would be expected. 
Expenditures 
As noted in Table 1 and Figure B, SB 11 would result in 
premium increases of less 0.1% for all market segments 
less than a 0.1% decrease in total enrollee out-of-pocket 
expenses (cost-sharing) for covered benefits.   
Figure B. Expenditure Impacts of SB 11 
Source: California Health Benefits Review Program, 2019.  
Cost-sharing impacts among enrollees using the 
medications would range from no impact (for Medi-Cal 
beneficiaries, who have no premandate cost sharing) to 
an average annual decrease of $418.28 among enrollees 
in individual market plans and policies. 
Medi-Cal 
Medi-Cal impacts related to OUD and AUD would be 
related only to a shift of naloxone for OUD (for overdose 
treatment) use to the more costly auto-injector formulation.  
Otherwise, the Medi-Cal FFS program provides SB11-
compliant coverage, but SB 11 would make the auto-
injector more easily accessible through DMHC-regulated 
plans.  Some impact would be expected due to plans 
changing benefit coverage for TUD medications (which 
are not part of the Medi-Cal FFS carve out) to be 
compliant with SB 11. 
CalPERS 
CalPERS premiums would be expected to increase less 
than 0.1%. 
Number of Uninsured in California 
No measureable impact is expected.  
Public Health 
In the first postmandate year, CHBRP estimates the 
following public health impacts.  As enrollees may use 
more than one medication, these enrollee estimates 
reflect an upper bound. 
Approximately 3,100 enrollees with newly compliant 
benefit coverage would use FDA-approved OUD 
medications, though 40% to 60% may experience relapse. 
Health outcomes related to successfully use of these 
medications may include reducing illicit opioid use, opioid 
overdose and associated mortality, transmission of 
hepatitis C and HIV, and poor maternal-infant outcomes. 
Among those new users, SB 11 would also increase 
maintenance treatment retention and increase overdose 
reversals (through the use of naloxone).   
Approximately 2,200 enrollees with newly compliant 
benefit coverage would use FDA-approved AUD 
medications, though 50% or more may experience 
relapse. Health outcomes of successful treatment would 
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include decreases in undesirable outcomes such as 
injuries/accidents and poor pregnancy outcomes. 
Approximately 5,500 enrollees with newly compliant 
benefit coverage would use FDA-approved TUD 
medications, some of whom will relapse. Health outcomes 
of successful treatment would include increasing quit rates 
and sustaining abstinence, as well as decreases in 
undesirable outcomes, such as poor birth outcomes and 
smoking-exacerbated conditions (e.g., cancer and heart 
attacks). 
Long-Term Impacts 
Long-term utilization of FDA-approved OUD medications 
could increase as OUD prevalence increases in the state. 
CHBRP estimates that the level of use per user per year 
predicted in 2019 (see Table 1) would not change over 
time, but utilization overall would increase with additional 
use of opioids. Due to continuing structural and attitudinal 
barriers, CHBRP expects the portion of persons with OUD 
in treatment to remain limited, even as the total number of 
persons with OUD increases. In the case of AUD and TUD 
treatment, there is very low baseline utilization of the FDA-
approved prescription-only medications for the two 
conditions. Physicians and patients are not frequently 
using the prescription-only medications. As the lack of use 
does not appear to be due to restrictions imposed by 
health plans and insurers, limited use is expected to 
continue. 
A key barrier to abstinence for any SUD is patient interest 
and readiness to abstain. CHBRP anticipates the demand 
for treatment of OUD, AUD, and TUD would continue as 
relapsed patients attempt abstinence again and first-time 
initiators join the pool of patients seeking care. SB 11 
would continue to facilitate prescription medication 
treatment for some enrollees (whose insurance did not 
previously offer compliant benefit coverage), but limited 
patient readiness for SUD treatment and the demand-
supply mismatch for OUD and AUD treatment are likely to 
remain significant barriers to care in future years 
assuming no other public policies are implemented. 
Although the quantitative long-term impact of SB 11 on 
premature death associated with OUD, AUD, and TUD is 
unknown, it stands to reason, based on the effectiveness 
of FDA-approved medications for these SUDs, that there 
would be a reduction in premature deaths for those 
enrollees who successfully engage in treatment. 
Essential Health Benefits and the 
Affordable Care Act 
SB 11 would alter the terms and conditions of existing 
benefit coverage, but would not require coverage for a 
new benefit and so appears not to exceed the definition of 
EHBs in California.  
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Table 1. SB 11 Impacts on Benefit Coverage, Utilization, and Cost, 2019 
    
  Baseline Postmandate Increase/ Decrease  
Change 
Postmandate 
Benefit Coverage         
    
Total enrollees with health 
insurance subject to state-level 
benefit mandates (a) 23,433,000 23,433,000 0 0% 
    
Total enrollees with health 
insurance subject to SB 11 23,433,000 23,433,000 0 0% 
    
Percentage of enrollees with health 
insurance subject to SB 11 100% 100% 0% 0% 
    Total Enrollees with OPD Coverage 22,412,000 22,412,000 0 0% 
    
Number of enrollees with health 
insurance fully compliant with SB 11 
- Commercial Coverage 1,021,111 14,902,000 13,880,889 1359% 
    
Percentage of enrollees with health 
insurance fully compliant with SB 11 
- Commercial Coverage 7% 100% 93% 1359% 
    
Number of enrollees with health 
insurance fully compliant with SB 11 
- Medi-Cal Coverage  0 7,510,000 7,510,000 100% 
    
Percentage of enrollees with health 
insurance fully compliant with SB 11 
- Medi-Cal Coverage  0% 100% 100% 100% 
    
Number of enrollees with health 
insurance partially compliant with 
SB 11 - Commercial Coverage 13,880,889 0 -13,880,889 -100% 
    
Percentage of enrollees with health 
insurance partially compliant with 
SB 11 - Commercial Coverage 93% 0% -93% -100% 
    
Number of enrollees with health 
insurance partially compliant with 
SB 11 - Medi-Cal Coverage  7,510,000 0 0 -100% 
    
Percentage of enrollees with health 
insurance partially compliant with 
SB 11 - Medi-Cal Coverage  100% 0% 0% -100% 
              
    
Number of Enrollees (Commercial, CalPERS, and Medi-Cal) with on-formulary 
coverage for     
    Methadone 12,323,000 23,433,000 11,110,000 90% 
    Buprenorphine 12,189,000 23,433,000 11,244,000 92% 
    
Combination  
Buprenorphine/Naloxone 12,189,000 23,433,000 11,244,000 92% 
    Naloxone 12,323,000 23,433,000 11,110,000 90% 
    Nicotine - Inhaler 11,370,000 23,433,000 12,063,000 106% 
    Nicotine - Nasal Spray 11,370,000 23,433,000 12,063,000 106% 
    Varenicline 19,765,000 23,433,000 3,668,000 19% 
    Buproprion HCL SR 19,833,000 23,433,000 3,600,000 18% 
    Acamprosate 12,323,000 23,433,000 11,110,000 90% 
    Naltrexone - Oral AUD 12,323,000 23,433,000 11,110,000 90% 
    Naltrexone - Oral OUD 12,323,000 23,433,000 11,110,000 90% 
    Disulfiram 19,833,000 23,433,000 3,600,000 18% 
              
    
Percentage of Enrollees (Commercial, CalPERS, and Medi-Cal) with on-
formulary coverage for     
    Methadone 53% 100% 47% 90% 
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  Baseline Postmandate Increase/ Decrease  
Change 
Postmandate 
    Buprenorphine 52% 100% 48% 92% 
    
Combination 
Buprenorphine/Naloxone 52% 100% 48% 92% 
    Naloxone 53% 100% 47% 90% 
    Nicotine - Inhaler 49% 100% 51% 106% 
    Nicotine - Nasal Spray 49% 100% 51% 106% 
    Varenicline 84% 100% 16% 19% 
    Buproprion HCL SR 85% 100% 15% 18% 
    Acamprosate 53% 100% 47% 90% 
    Naltrexone - Oral AUD 53% 100% 47% 90% 
    Naltrexone - Oral OUD 53% 100% 47% 90% 
    Disulfiram 85% 100% 15% 18% 
Utilization and Cost         
    Number of Enrollees with SUD using OPD   
    Substance Use Disorder Medication  
    Methadone 11,696 11,696 0 0.0% 
    Buprenorphine 1,181 1,482 301 25.4% 
    
Combination 
Buprenorphine/Naloxone 7,336 9,167 1,831 25.0% 
    Naloxone 995 1,508 513 51.6% 
    Nicotine - Inhaler 203 1,554 1,351 666.3% 
    Nicotine - Nasal Spray 40 220 180 454.0% 
    Varenicline 10,966 13,121 2,155 19.7% 
    Buproprion HCL SR 18,489 20,319 1,830 9.9% 
    Acamprosate 1,637 2,020 382 23.4% 
    Naltrexone - Oral AUD 4,984 6,145 1,162 23.3% 
    Naltrexone - Oral OUD 2,124 2,619 495 23.3% 
    Disulfiram 4,379 5,058 679 15.5% 
    Percentage of Enrollees with SUD using OPD  
    Substance Use Disorder Medication        
    Methadone 0.050% 0.050% 0.000% 0.000% 
    Buprenorphine 0.005% 0.006% 0.001% 25.444% 
    
Combination 
Buprenorphine/Naloxone 0.031% 0.039% 0.008% 24.965% 
    Naloxone 0.004% 0.006% 0.002% 51.622% 
    Nicotine - Inhaler 0.001% 0.007% 0.006% 666.339% 
    Nicotine - Nasal Spray 0.000% 0.001% 0.001% 453.957% 
    Varenicline 0.047% 0.056% 0.009% 19.652% 
    Buproprion HCL SR 0.079% 0.087% 0.008% 9.896% 
    Acamprosate 0.007% 0.009% 0.002% 23.364% 
    Naltrexone - Oral AUD 0.021% 0.026% 0.005% 23.305% 
    Naltrexone - Oral OUD 0.009% 0.011% 0.002% 23.305% 
    Disulfiram 0.019% 0.022% 0.003% 15.495% 
    
Average Count of Monthly Scripts 
Supplied per User per Year         
    Substance Use Disorder Medication   
    Methadone 11.59  11.59  -    0.0% 
    Buprenorphine 4.23  4.60  0.37  8.7% 
    
Combination 
Buprenorphine/Naloxone                      6.48                       8.31  
                  
1.83  28.2% 
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  Baseline Postmandate Increase/ Decrease  
Change 
Postmandate 
    Naloxone 1.00  1.28  0.28  28.2% 
   Nicotine - Inhaler 1.55  1.59  0.04  2.6% 
   Nicotine - Nasal Spray 4.37  6.53  2.15  49.2% 
   Varenicline 2.07  2.06   (0.01) -0.5% 
   Buproprion HCL SR 3.46  3.42   (0.04) -1.2% 
   Acamprosate 1.85  2.08  0.23  12.4% 
   Naltrexone - Oral AUD 2.77  3.23  0.46  16.6% 
   Naltrexone - Oral OUD 2.30  2.94  0.63  27.6% 
   Disulfiram 2.56  2.66  0.09  3.7% 
  Average Cost / Script         
  Substance Use Disorder Medication  
  Methadone $486 $486 $0 0.0% 
  Buprenorphine $138 $138 $0 0.0% 
  
Combination 
Buprenorphine/Naloxone $388 $388 $0 0.0% 
  Naloxone $2,378 $2,378 $0 0.0% 
  Nicotine - Inhaler $485 $485 $0 0.0% 
  Nicotine - Nasal Spray $392 $392 $0 0.0% 
  Varenicline $382 $382 $0 0.0% 
  Buproprion HCL SR $26 $26 $0 0.0% 
  Acamprosate $211 $211 $0 0.0% 
  Naltrexone - Oral AUD $219 $219 $0 0.0% 
  Naltrexone - Oral OUD $581 $581 $0 0.0% 
  Disulfiram $99 $99 $0 0.0% 
    Average Annual Cost / User         
    Substance Use Disorder Medication  
    Methadone $5,637 $5,637 $0 0.0% 
    Buprenorphine $582 $633 $51 8.7% 
    
Combination 
Buprenorphine/Naloxone $2,518 $3,229 $710 28.2% 
    Naloxone $2,378 $3,048 $671 28.2% 
    Nicotine - Inhaler $753 $773 $20 2.6% 
    Nicotine - Nasal Spray $1,714 $2,557 $843 49.2% 
    Varenicline $789 $785 -$4 -0.5% 
    Buproprion HCL SR $91 $90 -$1 -1.2% 
    Acamprosate $390 $438 $48 12.4% 
    Naltrexone - Oral AUD $606 $707 $100 16.6% 
    Naltrexone - Oral OUD $1,339 $1,707 $369 27.6% 
    Disulfiram $252 $262 $9 3.7% 
    Behavioral Health Counseling         
    AUD Counseling $8,440 $11,814 $3,374 40.0% 
    TUD Counseling $93 $150 $57 61.5% 
    OUD Counseling $12,256 $15,263 $3,007 24.5% 
    Offset Usage for New Users         
    AUD Inpatient Days NA -$12,206 -$12,206 0.0% 
    AUD Detox Days NA -$7,155 -$7,155 0.0% 
    AUD Emergency Room NA -$3,871 -$3,871 0.0% 
    OUD Inpatient Days NA -$4,048 -$4,048 0.0% 
    OUD Detox Days NA -$655 -$655 0.0% 
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  Baseline Postmandate Increase/ Decrease  
Change 
Postmandate 
    OUD Emergency Room NA -$186 -$186 0.0% 
              
Expenditures         
  Premium Expenditures by Payer         
    
Private Employers for group 
insurance 
$69,302,946,000 $69,320,766,000 $17,820,000 0.0257% 
    
CalPERS HMO employer 
expenditures (c) 
$5,383,103,000 $5,383,667,000 $564,000 0.0105% 
    
Medi-Cal Managed Care Plan 
expenditures (d) (f) 
$29,259,588,000 $29,260,598,000 $1,010,000 0.0035% 
    
Enrollees for individually purchased 
insurance 
$15,358,027,000 $15,364,470,000 $6,443,000 0.0420% 
    
     Individually Purchased – Outside 
Exchange $6,539,649,000 $6,543,819,000 $4,170,000 0.0638% 
    
     Individually Purchased – 
Covered California $8,818,378,000 $8,820,651,000 $2,273,000 0.0258% 
    
Enrollees with group insurance, 
CalPERS HMOs, Covered 
California, and Medi-Cal Managed 
Care (a) (b) 
$21,267,154,000 $21,273,172,000 $6,018,000 0.0283% 
  Enrollee Expenses         
    
Enrollee out-of-pocket expenses for 
covered benefits (deductibles, 
copayments, etc.) 
$14,896,952,000 $14,885,768,000 -$11,184,000 -0.0751% 
    
Enrollee expenses for noncovered 
benefits (e) 
-- -- -- -- 
  Total Expenditures  $155,467,770,000 $155,488,441,000 $20,671,000 0.0133% 
Source: California Health Benefits Review Program, 2019. 
Notes: (a) This population includes persons with privately funded and publicly funded (e.g., CalPERS HMOs, Medi-Cal Managed 
Care Plans) health insurance products regulated by DMHC or CDI. Population includes enrollees aged 0 to 64 years and enrollees 
65 years or older covered by employment sponsored insurance. 
(b) Premium expenditures by enrollees include employee contributions to employer-sponsored health insurance and enrollee 
contributions for publicly purchased insurance. 
(c) Of the increase in CalPERS employer expenditures, about 56.2% or $317,000 would be state expenditures for CalPERS 
members who are state employees or their dependents. It should be noted, however, that should CalPERS choose to make similar 
adjustments for consistency to the benefit coverage of enrollees associated with CalPERS’ self-insured products, the fiscal impact 
on CalPERS could be greater. 
(d) Does not include enrollees in COHS. 
(e) It is possible that some enrollees paid for non-covered benefits, but CHBRP cannot estimate such use or costs.  
(f) CHBRP assumes the new SUD Treatment users for OUD seek care in Medi-Cal Managed Care postmandate. Table 1 only 
shows expenditures for Medi-Cal plans, and Drug Medi-Cal expenditures are excluded.  
Key: AUD = alcohol use disorder; CalPERS HMOs = California Public Employees’ Retirement System Health Maintenance 
Organizations; CDI = California Department of Insurance; COHS = County Operated Health System; DMHC = Department of 
Managed Health Care; OUD = opioid use disorder; SUD = substance use disorder; TUD = tobacco use disorder. 
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POLICY CONTEXT 
The California Senate Committee on Health has requested that the California Health Benefits Review 
Program (CHBRP)3 conduct an evidence-based assessment of the medical, financial, and public health 
impacts of the benefit mandate included in Senate Bill (SB) 11 Mental Health Parity and Substance Use 
Medications. 
The mandate included in SB 11 would, for many enrollees, affect the coverage of medication used to treat 
substance use disorders (SUDs). SB 11 would require plans and policies regulated by the California 
Department of Managed Health Care (DMHC) or the California Department of Insurance (CDI) that 
include a pharmacy benefit that covers outpatient prescription medications related to treatment of SUDs 
comply with the following:  
• Place all medications approved by the federal Food and Drug Administration (FDA) for treatment 
of SUDs:  
o On formulary and  
o On the formulary’s lowest tier. 
• For those medications, prohibit: 
o Prior authorization protocols and 
o Step therapy (or “fail first”) protocols. 
• Prohibit coverage denials related court orders for treatment. 
In addition, SB 11 would prohibit coverage for counseling or “other wrap-around services” related to these 
medications due to court orders for treatment. 
The full text of SB 11 can be found in Appendix A. 
Further descriptions of the utilization management protocols SB 11 would prohibit (prior authorization and 
step therapy) are included in the Background on Substance Use Disorders section of this report. 
Relevant Populations 
Although all health plans and policies regulated by DMHC or CDI would be subject to SB 11, plans and 
policies without a pharmacy benefit would not have to comply. The bill would require compliance from the 
health insurance of the 22.4 million enrollees in DMHC-regulated plans or CDI-regulated policies that 
include a pharmacy benefit (see Appendix D). This represents a little over half of all Californians and 
represents 95% of the 23.4 million Californians who will have health insurance that may be subject to any 
state health benefit law — plans and policies regulated by DMHC or CDI. Among this group are a majority 
of Medi-Cal beneficiaries, as many are enrolled in DMHC-regulated plans.4  
 
                                                     
3 CHBRP’s authorizing statute is available at http://chbrp.org/faqs.php. 
4 See Estimates of Sources of Health Insurance in California, available at 
http://chbrp.org/other_publications/index.php#revize_document_center_rz44  
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Analytic Approach  
CHBRP has focused this analysis on medications related to the treatment of three SUDs: 
• Alcohol Use Disorder (AUD) 
• Opioid Use Disorder (OUD) 
• Tobacco Use Disorder (TUD) 
As there are no medications approved by the FDA as treatments for the other SUDs (such as disorders 
related to use of amphetamines or cocaine), those disorders are not included in this analysis. 
CHBRP has focused this analysis on SB 11’s potential impacts on the coverage of prescription-only 
medications that the FDA has approved as treatments for SUD. These medications are listed in Table 2. 
The list does not include medications that may be used off-label (without approval by the FDA for the 
treatment of SUDs) and the list does not include medications available over-the-counter (without a 
prescription).  
Table 2. Medications related to SB 11 Coverage Requirements 
Substance Use Disorder (SUD) Prescription-only medication approved to treat SUD 
Opioid Use Disorder (OUD) 
Buprenorphine  
Methadone  
Naloxone  
Naltrexone (a) 
combination Buprenorphine/Naloxone 
Lofexidine (b) 
Tobacco Use Disorder (TUD) 
Nicotine Replacement Therapy - inhaler (c) 
Nicotine Replacement Therapy - nasal spray (c) 
Varenicline (b) 
Bupropion HCL SR 
Alcohol Use Disorder (AUD) 
Acamprosate 
Naltrexone – Oral (a) 
Disulfiram 
Source: California Health Benefits Review Program, 2019 
Notes: (a) Naltrexone is used to treat both OUD and AUD. (b) Not available as a generic. (c) Nicotine replacement therapy is also 
available in non-prescription, over-the-counter formulations, including patch, gum, and lozenge. 
Key: AUD = alcohol use disorder; OUD = opioid use disorder; SUD = substance use disorder; TUD = tobacco use disorder 
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Key Assumptions 
In order to complete this analysis of SB 11, CHBRP has made a number of analytic assumptions.  
As SB 11 specifies that it would apply to plans and polices that cover medications approved by the FDA 
for treatment of SUDs, CHBRP has assumed the bill would not affect the health insurance of enrollees in 
plans or policies that do not include a pharmacy benefit. Less than 5% of all enrollees in plans and 
policies regulated by DMHC or CDI have no pharmacy benefit through their state-regulated health 
insurance (see Appendix D), though the figure is higher among commercial and CalPERS enrollees, 
about 7%. For this analysis, those enrollees are considered to have health insurance compliant with SB 
11. 
As SB 11 specifies “on formulary” and “lowest tier,” terms related to pharmacy benefit coverage, CHBRP 
has assumed the bill would apply to medications covered through a pharmacy benefit, and would not 
apply to medications covered only through a medical benefit.5   
As SB 11 does not exempt from compliance coverage for methadone, CHBRP has assumed SB 11 would 
require compliant pharmacy benefit coverage for it. Although methadone is commonly on formulary as a 
treatment for pain, methadone as a treatment for OUD can only be prescribed by and delivered through 
federally certified centers (“methadone clinics”).6  As these centers do not currently bill for medications 
(as pharmacies do) and are not licensed as outpatient pharmacies, CHBRP has assumed that SB 11–
compliant pharmacy benefit coverage for methadone would not alter utilization within the first year of 
implementation.  
As SB 11 specifies “lowest tier,” CHBRP has assumed it would require relevant medications not already 
on “tier 0” (no cost sharing) or not already on “tier 1” (standard only for generics) regardless of 
generic/brand-name status to become “tier 1.” 
As SB 11 specifies that the requirements are related to “prescription” medications, CHBRP has assumed 
the bill would apply only to the coverage of medications approved by the FDA as treatments for SUD that 
are available by prescription only, and would not apply to the coverage of medications available over-the-
counter (OTC) without a prescription.7 
As SB 11 is silent regarding generic status, CHBRP has assumed that if both generic and brand-name 
versions were covered through a pharmacy benefit, all coverage would have to be as specified by SB 11. 
As SB 11 is silent regarding formulation (pill, injectable, patch, etc.), CHBRP has assumed that if multiple 
prescription-only formulations were covered through a pharmacy benefit, all coverage would have to be 
as specified by SB 11. 
The interaction of laws governing DMHC-related plans (the Health & Safety Code) and the laws 
governing the Medi-Cal program (Welfare & Institutions Code) are complex. It would require a legal 
                                                     
5 Extended-release naltrexone, buprenorphine implants, and extended-release buprenorphine (all FDA-approved, 
prescription only medications for SUD treatment) require outpatient clinical services for injection or implantation and 
are generally covered under the medical benefit. Other formulations of these medications (sublingual tablets and 
buccal film) are generally covered through a pharmacy benefit.  
6 Federal law restricts methadone treatment to federally certified opioid treatment programs (OTP), known as 
methadone clinics, see Title 42 of the Code of Federal Regulations Part 8 (42 CFR § 8) 
7 Some formulations of nicotine replacement therapy (patch, lozenge, gum) are available over-the-counter (without a 
prescription). Ohers (nasal spray, inhaler) are prescription-only. 
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analysis to be certain of the impacts of SB 11 on DMHC-regulated plans enrolling Medi-Cal beneficiaries. 
For this analysis, and based on lay-person interpretation, CHBRP has assumed these plans would be 
required to comply with the bill’s requirements. In cases where a medication is currently part of a “carve-
out” (covered by Medi-Cal through fee-for-service or other program, rather than through the DMHC-
regulated plan), CHBRP has assumed SB 11 would create “double coverage,” which would allow a 
beneficiary to access benefit coverage through the plan or through the carve-out route. However, in the 
absence of reason to believe the benefit coverage would be more desirable to the enrollee, CHBRP has 
assumed that the enrollee would continue to use the “carve-out” coverage.  
As CHBRP has located no evidence of coverage related to treatment of SUDs being denied in connection 
with a court order, CHBRP has assumed that the related prohibition included in SB 11 would have no 
measurable impact in the first year after implementation.  
Interaction with Existing Requirements 
Although a number of federal laws and regulations restrict providers in regards to the medications 
specified by SB 11 (see the Background section of this report), CHBRP is aware of few state or federal 
benefit coverage laws or regulations that would directly interact with compliance to the outpatient SUD 
prescription medication coverage requirements addressed in SB 11. 
California Policy Landscape 
California law and regulations 
CHBRP is unaware of California laws or regulations that directly address coverage of outpatient 
medications for SUD.  
CHBRP is aware that the California Department of Health Care Services (DHCS) regularly excludes from 
pharmacy benefit coverage a number of the medication listed in Table 2 when contracting with DMHC-
regulated plans. With such “carve-outs” in effect, the medications to treat OUD and some to treat AUD are 
covered for Medi-Cal beneficiaries through some other Medi-Cal program — fee-for-service (FFS) other. 
CHBRP is unaware of medications to treat TUD being included in any carve-outs. 
CHBRP is aware that California’s governor issued, on January 7, 2019, an executive order (N-01-19) that 
there be, as of 2021 a single purchaser for prescription medications for all Medi-Cal beneficiaries and 
potentially for other Californians as well. Though details are as of yet unclear, such a program could lead 
to DHCS (or another statewide program) separately managing the pharmacy benefit for Medi-Cal 
beneficiaries and perhaps some other enrollees in DMHC-regulated plans (such as enrollees associated 
with CalPERS). In such a situation DHCS, and other entities, could contract with DMHC-regulated plans 
to exclude the pharmacy benefit. This could increase the number of enrollees without a pharmacy benefit 
through their state-regulated health insurance (see Appendix D) and could decrease the number of 
enrollees with health insurance that must comply with SB 11’s coverage requirements.  
CHBRP is aware that a law passed in 20188 requires providers to offer to some patients prescriptions for 
naloxone (or other anti-overdose medications). In time, this law could increase the annual baseline 
utilization of naloxone and so increase the related impacts projected by CHBRP for SB 11. 
                                                     
8 2018’s AB 2760 altered the Business and Professions Code, Article 10.7. 
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Similar requirements in other states 
A recent Illinois bill, SB 1707, which is very similar to California’s SB 11, became law (Illinois Legislature, 
2019). Passage of the bill is too recent for its impacts to be apparent. 
Federal Policy Landscape 
Federal Mental Health Parity and Addiction Equity Act  
The federal Mental Health Parity and Addiction Equity Act (MHPAEA) addresses parity for mental health 
benefits.9 The MHPAEA requires that if mental health or substance use disorder services are covered, 
cost-sharing terms and treatment limits be no more restrictive than the predominant terms or limits 
applied to medical/surgical benefits. The MHPAEA applies to the large-group market, but the ACA 
requires small-group and individual market plans and policies purchased through a state health insurance 
marketplace to comply with the MHPAEA. This federal requirement is similar to the California mental 
health parity law,10 although the state law applies to some plans and policies not subject to the MHPAEA. 
Although CHBRP has not analyzed the non-mandate portion of SB 11 (sections 1 and 3), which deal 
directly with MHPAEA requirements, current California coverage of the medications addressed by SB 11’s 
benefit mandate (sections 2 and 4) has been influenced by compliance with the MHPAEA. 
Affordable Care Act 
A number of Affordable Care Act (ACA) provisions have the potential to or do interact with state benefit 
mandates. Below is an analysis of how SB 11 may interact with requirements of the ACA as presently 
exists in federal law, including the requirement for certain health insurance to cover essential health 
benefits (EHBs).11 
Any changes at the federal level may impact the analysis or implementation of this bill, were it to pass into 
law. However, CHBRP analyzes bills in the current environment given current law and regulations.  
Essential Health Benefits 
State health insurance marketplaces, such as Covered California, are responsible for certifying and 
selling qualified health plans (QHPs) in the small-group and individual markets. QHPs, and all other non-
grandfathered individual and small group market health insurance must cover a minimum standard of 
benefits as defined by the ACA as essential health benefits (EHBs). In California, EHBs are related to the 
benefit coverage available in the Kaiser Foundation Health Plan Small Group Health Maintenance 
Organization (HMO) 30 plan, the state’s benchmark plan for federal EHBs.12,13 
                                                     
9 Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA), as amended by the ACA. 
10 H&SC Section 1374.72; IC Section 10144.5 and 10123.15.  
11 The ACA requires nongrandfathered small-group and individual market health insurance — including but not limited 
to QHPs sold in Covered California — to cover 10 specified categories of EHBs. Resources on EHBs and other ACA 
impacts are available on the CHBRP website: http://www.chbrp.org/other_publications/index.php. 
12 The U.S. Department of Health and Human Services (HHS) has allowed each state to define its own EHBs for 
2014 and 2015 by selecting one of a set of specified benchmark plan options. CCIIO, Essential Health Benefits 
Bulletin. Available at: cciio.cms.gov/resources/files/Files2/12162011/essential_health_benefits_bulletin.pdf. 
13 H&SC Section 1367.005; IC Section 10112.27. 
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CHBRP estimates that approximately 12% of Californians have health insurance that is subject to the 
EHB requirement.14 
States may require QHPs to offer benefits that exceed EHBs.15 However, a state that chooses to do so 
must make payments to defray the cost of those additionally mandated benefits, either by paying the 
purchaser directly or by paying the QHP.16,17 State rules related to provider types, cost-sharing, or 
reimbursement methods would not meet the definition of state benefit mandates that could exceed 
EHBs.18  
SB 11 would alter the terms and conditions of existing benefit coverage, but would not require coverage 
for a new benefit and so appears not to exceed the definition of EHBs in California.  
Federally Selected Preventive Services 
The ACA requires that nongrandfathered group and individual health insurance plans and policies cover 
certain preventive services without cost-sharing when delivered by in-network providers as soon as 12 
months after a recommendation appears in any of the following:19 
• The United States Preventive Services Task Force (USPSTF) A and B recommendations; 
• The Health Resources and Services Administration (HRSA)-supported health plan coverage 
guidelines for women’s preventive services; 
• The HRSA-supported comprehensive guidelines for infants, children, and adolescents, which 
include: 
o The Bright Futures Recommendations for Pediatric Preventive Health Care; and 
o The recommendations of the Secretary’s Advisory Committee on Heritable Disorders in 
Newborns and Children; and 
• The Advisory Committee on Immunization Practices (ACIP) recommendations that have been 
adopted by the Director of the Centers for Disease Control and Prevention (CDC). 
As an A recommendation, the USPSTF recommends medications approved by the FDA to treat TUD for 
all non-pregnant adults who use tobacco (USPSTF, 2009). Through its interaction with the ACA, this 
                                                     
14 See Estimates of Sources of Health Insurance in California, available at 
http://chbrp.org/other_publications/index.php#revize_document_center_rz44 
15 ACA Section 1311(d) (3). 
16 State benefit mandates enacted on or before December 31, 2011, may be included in a state’s EHBs, according to 
the U.S. Department of Health and Human Services (HHS). Patient Protection and Affordable Care Act: Standards 
Related to Essential Health Benefits, Actuarial Value, and Accreditation. Final Rule. Federal Register, Vol. 78, No. 37. 
February 25, 2013. Available at: www.gpo.gov\fdsys\pkg\FR-2013-02-25\pdf\2013-04084.pdf. 
17 However, as laid out in the Final Rule on EHBs HHS released in February 2013, state benefit mandates enacted 
on or before December 31, 2011, would be included in the state’s EHBs and there would be no requirement that the 
state defray the costs of those state mandated benefits. For state benefit mandates enacted after December 31, 
2011, that are identified as exceeding EHBs, the state would be required to defray the cost. 
18 Essential Health Benefits. Final Rule. A state’s health insurance marketplace would be responsible for determining 
when a state benefit mandate exceeds EHBs, and QHP issuers would be responsible for calculating the cost that 
must be defrayed. 
19 A resource on this ACA requirement is available on the CHBRP website: 
www.chbrp.org/other_publications/index.php. 
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results in a prevention services benefit mandate and prohibits cost-sharing (regardless of formulary tier) 
for these medications. However, the interaction is silent in regards to:  
• Whether brand-name (as well as generic) versions must be covered,  
• Whether all formulations (lozenge, patch, nasal spray, etc.) must be covered, and 
• Whether all covered versions/formulations must be covered without applicable cost-sharing. 
In terms of its interaction with SB 11, it appears that the prevention services mandate is stricter on cost-
sharing – it completely prohibits, where SB 11 allows “lowest formulary tier” coverage, which may include 
some cost-sharing. However, the prevention services mandate may not be as broadly applicable as SB 
11 – it may not be relevant to all covered formulations of a medication or to both brand name and generic 
if both are covered, as CHBRP has assumed that SB 11 would be.  
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BACKGROUND ON SUBSTANCE USE DISORDERS 
Substance Use Disorder (SUD) is the clinical diagnosis for substance use that meets criteria per the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-5), including impaired control, social 
impairment, risky use, increased tolerance, and withdrawal symptoms (APA, 2013). The American 
Society of Addiction Medicine characterizes addiction as “the inability to consistently abstain, impairment 
in behavioral control, craving, diminished recognition of significant problems with one’s behaviors and 
interpersonal relationships, and a dysfunctional emotional response. Like other chronic diseases, 
addiction often involves cycles of relapse and remission” (ASAM, 2011).  
There are a number of licit and illicit substances that qualify for a SUD diagnosis including: opioids (heroin 
and misuse of prescription pain medications such as fentanyl and oxycodone), alcohol, cannabis, 
nicotine, inhalants, hallucinogens, amphetamine, caffeine, cocaine, and sedatives. Treatments for SUD 
include residential, inpatient, and outpatient care using behavioral therapy, counseling, and/or 
prescription medication. Mutual help groups (e.g., Alcoholics Anonymous, Narcotics Anonymous) also 
support those with SUD to quit substance use and maintain sobriety.  
SB 11 would require state-regulated plans and policies that include a pharmacy benefit to cover all 
prescription medications approved and indicated by the FDA for treatment of substance use disorders. 
SB 11 would also require placement of these medications on the lowest formulary tier and would prohibit 
prior authorization or step therapy. Ten medications are approved by the FDA for the treatment of 
opioid use disorder (OUD), alcohol use disorder (AUD), and tobacco use disorder (TUD); Table 2 
shows the only medications and disorders that meet the conditions of SB 11. 
SUD in California: Prevalence, Mortality, Health Services Use, and 
Disparities 
CHBRP reports the most recent data available and cites national data when California data are 
unavailable. In this report, misuse/abuse/dependence (or heavy drinking) rates are used as proxy 
measures when use disorder data are unavailable. Data sources and prevalence rates in California vary 
among the three use disorders: 
• OUD prevalence ranges between 0.51% and 1.1% (SAMSHA, 2018; Clemans-Cope et al., 2018) 
• AUD prevalence is 5.51% (SAMSHA, 2017) 
• TUD prevalence is 16.23% (based on all tobacco products, CDPH, 2018) 
Of note, polysubstance use is common among those diagnosed with substance use disorder, and many 
patients have more than one SUD. For example, in the U.S., among those reporting alcohol use disorder, 
23.8% also report nicotine dependence, and 3.9% report a concomitant prescription opioid use disorder. 
Among those reporting a prescription opioid use disorder, 35.2% also reported alcohol use disorder and 
45.4% reported concomitant nicotine dependence (NIDA, 2018). The diagnosis and treatment of multiple 
use disorders is complex and treatment and recovery rates for each substance use disorder may vary for 
a single patient. It is possible for a patient to be in recovery from one SUD, but not another.  
 Opioid Use Disorder (OUD) 
The DSM-5 characterizes OUD as a pattern of opioid use (e.g., oxycodone, hydrocodone, and heroin) 
that results in significant impairment or distress. People meeting at least two of 11 specified criteria within 
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a 12-month period are diagnosed with mild, moderate, or severe OUD depending on the number of 
criteria met (APA, 2013).  
In 2017, the U.S. Surgeon General declared the opioid crisis a U.S. public health emergency due to the 
escalating rates of opioid overdose, and related mortality and other harms (HHS, 2018). In addition to a 
greater risk of mortality, people with OUD are at a higher risk for developing cardiac dysrhythmias; 
respiratory depression; impairment in daily function; and premature death (Blanco et al., 2013). Additional 
conditions include HIV, hepatitis A, B, and C, tuberculosis, and endocarditis, which lead to increased use 
of health care services to treat those conditions (SAMHSA, 2016; Tsui et al., 2014).  
OUD prevalence 
Estimated prevalence rates for OUD in California range from 0.51% to 1.1%. The 2016-2017 National 
Survey on Drug Use and Health estimated a 0.51% prevalence rate for self-reported “pain reliever use 
disorder” (excluding heroin use) (SAMSHA, 2018). However, an analysis by Clemans-Cope et al (2018) 
estimated county-level OUD and treatment needs in California by adjusting rates from the 2015 NSDUH 
and CDC population counts. Their estimate is double that of the SAMSHA prevalence rate at 1.1%, or 
about 350,000 Californians with OUD. Clemans-Cope and colleagues defined OUD as abuse of or 
dependence on nonmedical use of prescription pain relievers and/or heroin by persons aged 12 years 
and older.  
OUD treatment relapse rates 
Many providers consider OUD to be a chronic condition. As with most chronic conditions, medication 
adherence and long-term control of the condition (relapse prevention) are challenging. A literature review 
by McLellan et al. compared what they called “relapse” rates (i.e., medication adherence) between four 
chronic conditions: substance use disorders (alcohol and opioid), diabetes, asthma, and hypertension. 
They found that adherence rates for medications for substance use disorders in the first year of treatment 
(40%-60%) were similar to or higher than adherence rates for medications used to manage diabetes, 
asthma, and hypertension (30%-50% for type 1 diabetes; 50%-70% for asthma and hypertension) 
(McLellan et al., 2000). Health care professionals note that relapse is common during the recovery 
process for many patients and it is important for patients to work with their provider to resume or modify 
the treatment plan (NIDA, 2017).  
Mortality 
The CDC attributes the increase in premature mortality across the U.S. since 2013 to a significant 
increase in overdose deaths associated with illicitly manufactured synthetic opioids (fentanyl). Those 
using opioids obtained illegally (on the street) are unaware of variations in strength for every dose 
purchased; illicitly manufactured fentanyl appears to remain a significant problem in 2018 (Hedegaard, 
2017). After 25 years of increasing life expectancy in the U.S., researchers from the National Center for 
Health Statistics reported that life expectancy fell from 78.9 years in 2014 to 78.6 years in 2016 
(Kochanek et al., 2017). At the population level, researchers linked this decrease in life expectancy in part 
to the opioid epidemic (Dowell et al., 2017). Increase in overall death rates were most significant for age 
groups 15 to 24 years (7.8% increase), 25 to 34 years (10.5% increase), and 35 to 44 years (6.7% 
increase) (Kochanek et al., 2017; Rudd et al., 2016).  
The California Opioid Overdose Surveillance Dashboard shows an age-adjusted mortality rate for all 
opioid overdose deaths of 5.23/100,000 Californians in 2017 (2,196 deaths) the highest annual rate yet 
reported in California (CDPH, 2018).  
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There are significant mortality rate differences among demographic groups. Native Americans, followed 
by whites, had the highest opioid overdose mortality rates in California in 2017 (17.56/100,000 and 
8.9/100,000) as compared with Asians who had the lowest opioid overdose mortality rate at 0.97/100,000 
(CDPH, 2018). California males were twice as likely to die from opioid overdose as females (7.32 
deaths/100,000 and 3.08 deaths/100,000, respectively).  
OUD-related health services use 
The California Opioid Overdose Surveillance Dashboard provides a variety of statistics about California’s 
experience with opioid use. About 10/100,000 Californians were seen in emergency departments (ED) for 
opioid (excluding heroin) overdose in 2017 (CDPH, 2019). Males and females have about the same rate 
of emergency department visits for opioid overdoses (10.4/100,000 and 10.0/100,000, respectively). 
Among various age cohorts, the Dashboard shows that Californians aged 55 to 69 years have the highest 
crude rates of emergency department visits for opioid overdose (~15/100,000), closely followed by 
younger patients (aged 20-29 years) (~14/100,000) (CDPH, 2019).  
In contrast to the pattern of mortality rates, the California Opioid Overdose Surveillance Dashboard shows 
that blacks and whites have similar rates of hospitalizations for opioid overdose (11.9/100,000 and 
11.6/100,000, respectively), followed by Native Americans (5.9/100,000), Latinos (4.3/100,000), and 
Asians 1/100,000) (CDPH, 2019). See the Benefit Coverage, Utilization, and Cost Impacts section for 
discussion about estimated cost-offsets attributable to SB 11. 
Alcohol Use Disorder (AUD) 
The DSM-5 characterizes AUD as a pattern of alcohol use (e.g., wine, beer, and spirits) that results in 
significant impairment or distress. People meeting at least two of 11 specified criteria within a 12-month 
period are diagnosed with mild, moderate, or severe AUD depending on the number of criteria met (APA, 
2013).  
AUD is the third leading cause of preventable mortality in the U.S. Excessive alcohol use increases the 
risk of developing serious acute and chronic health problems, including but not limited to brain damage 
(including dementia), liver disease, heart disease, immunosuppression and infections, hypertension, 
cancers, depression, pancreatitis, fetal alcohol syndrome, and traumatic injuries or deaths from falls, car 
accidents, physical altercations, suicide and homicide (NIAAA, 2018).  
AUD prevalence 
The 2016-2017 NSDUH estimates that 5.51% of Californians aged 12 years and older have AUD, with 
those aged 18-25 years experiencing the highest prevalence rate (9.90%) (SAMSHA, 2017).  
The national rate of AUD is estimated to be 6.2% among adults aged 18 and older (NIAAA, 2018). The 
2017 Behavioral Risk Factor Surveillance Survey data show that males and females have similar rates of 
heavy drinking20 (proxy indicator for AUD) (6.6% and 6.0%, respectively). More significant differences 
were reported by age cohort and race/ethnicity. Heavy drinking was highest among those aged 18-34 
years, followed by those aged 55-64 years (7.3% and 6.0% respectively) (CDC, 2015). Differences 
among racial ethnic groups exist with non-Hispanic whites reporting higher rates of heavy drinking than 
blacks (non-Hispanic) and Hispanics (8.7%, 4.5%, and 5.2%, respectively) (CDC, 2015).  
                                                     
20 Behavioral Risk Factor Surveillance System Survey defines heavy drinking as males consuming >14 drinks/week 
and females consuming >7 drinks/week. CHBRP uses this as a proxy indicator of AUD. 
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Nationally, the National Institute on Alcohol Abuse and Alcoholism reports that Hispanics and Blacks have 
relatively lower rates of alcohol use disorders than do non-Hispanic whites; however, ethnic and racial 
disparities still exist for alcohol-related diseases, problems, and deaths in these groups (NIAAA, 
2019). For example, Hispanics and Blacks have a higher risk for developing alcohol-related liver disease 
and subsequent cirrhosis mortality than whites. Self-reported rates of DUI are highest among mixed race 
and Native Americans and Alaska Natives (NIAAA, 2019).  
The National Institute on Drug Abuse reports a series of statistics regarding disparities in alcohol 
misuse/abuse according to sexual orientation (NIDA, 2017). For example, 2013 survey data from the U.S. 
Census Bureau showed that a more gay or lesbian adults, and bisexual adults aged 18 to 64 years 
reported past-year binge drinking (five or more drinks on a single occasion) than heterosexual adults 
(35.1%, 41.5%, and 26.0%, respectively) (Ward et al., 2014). Another analysis of LGBT people in 
treatment for SUDs found that they initiated alcohol consumption earlier than their heterosexual 
counterparts (McCabe et al., 2013).  
AUD treatment relapse rates 
Of the substance use disorders that have medication treatment options, AUD is the disorder least 
associated with medication-assisted treatment. An estimated one-third of people with AUD receive 
treatment (medication and/or counseling), of which fewer than 10% use AUD prescription drug treatment 
(Jonas et al., 2014; NIAAA, 2018). Generally, AUD is treated in specialty facilities, or patients choose to 
attempt abstinence through mutual-help organizations such as Alcoholics Anonymous. AUD is treated 
less commonly through primary care (Jonas et al., 2014).  
In addition to previously cited relapse rates from McLellan et al (2000), other studies show AUD relapse 
rates ranging from 50% to 70% of people in treatment for AUD (medication and/or counseling) relapsing 
within 3 months of treatment initiation to 60% to 85% relapsing within the first year (Brandon et al., 2007; 
Moos and Moos, 2006; Seo et al., 2013). Recent evidence demonstrates that some reduction in alcohol 
consumption can still be beneficial, even if abstinence is not achieved (Jonas et al., 2014; Mann et al., 
2017). 
AUD-related mortality 
The CDC Alcohol-Related Disease Impact database reports the number of alcohol-attributable deaths 
due to excessive alcohol consumption. In California, of the 10,671 alcohol-attributed deaths in 2013 (most 
recent data), 5,558 deaths were due to chronic conditions associated with liver disease/cirrhosis (more 
than 3,500 deaths), followed by stroke (193), hypertension (238), and cancer (325) (CDC, 2013). The 
remaining 5,113 deaths were from acute causes, including more than 1,000 motor vehicle deaths, 1,000 
homicides, 800 suicides, and 600 falls resulting in death (CDC, 2013).  
AUD-related health service use.  
Among the 119,600 non-fatal emergency room visits and 30,000 non-fatal hospitalizations for alcohol-
related injuries and poisonings in 2014, men, whites, and Hispanics experienced disproportionate 
representation similar to the death rates. Similarly, alcohol-related traffic deaths are many times more 
frequent among Native Americans or Alaska Natives than among other minorities. Hispanics are 
overrepresented among drunk drivers and DUI-related fatalities (CDPH, 2018). 
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Tobacco Use Disorder (TUD) 
The DSM-5 characterizes TUD as a pattern of tobacco use (e.g., smoking, chewing) that results in 
significant impairment or distress. People meeting at least two of 11 specified criteria within a 12-month 
period are diagnosed with mild, moderate, or severe TUD depending on the number of criteria met (APA, 
2013). As there is no known safe level of tobacco consumption, any daily use of tobacco is clinically 
considered TUD.  
Public health campaigns, smoking policy changes (tobacco taxation, tobacco sales restrictions, workplace 
restrictions, etc.), and the ACA-requirement for coverage of cessation therapies by many plans and 
policies have contributed to California having the second lowest rate of adult smoking in the U.S. (11.4%). 
However, California still has the largest number of smokers due to the size of its population (3.2 million 
adult smokers) (CDPH, 2018). Cigarette use combined with other tobacco product (e.g., cigars, chewing 
tobacco, electronic cigarettes) use gives an overall tobacco-use prevalence rate of 16.4% of adult 
Californians. CDPH also reports significant variation in smoking prevalence among subpopulations. For 
example, there is a three-fold difference between the populations with the highest and the lowest smoking 
rates: 24.2% of American Indians as compared with 8.6% of Asian/Pacific Islanders. African Americans 
have the second highest rate of smoking in California (20.7%) followed by whites (13.0%) and Hispanics 
(11.5%). The smoking rate among Medi-Cal beneficiaries is above the state average at 17.4%, as 
compared with below average rates among the employment-based insured (9.8%) and privately 
purchased insureds (9.2%) (CDPH, 2018).  
Treatment and cessation rates for TUD 
Table 3 shows the prevalence of smoking cessation methods that California smokers reported using (one 
or more) to quit smoking in the past year, based on the 2016-2017 California Adult Tobacco Survey 
(CDPH, 2018). Prior research has shown that former smokers recalled an average of 4.7 quit attempts 
before successfully abstaining (CDPH, 2018).  
Table 3. Methods (one or more) Used to Quit Cigarette Smoking in the Past Year among Adults in 
California Aged 18-64, 2016-2017 
Method 2016 2017 
Quit Cold Turkey 67.4% 67.0% 
Medication (e.g., bupropion, varenicline) 6.7% 5.7% 
Nicotine Patches, Gum, or Lozenges 18.5% 19.2% 
Counseling 4.1% 5.6% 
Self-Help Materials 5.9% 10.6% 
California Smokers’ Helpline 7.3% 4.6% 
Electronic Smoking Devices* 19.5% 14.6% 
Source: California Health Benefits Review Program, 2019, adapted from CDPH, 2018.  
* Electronic smoking devices are not an FDA-approved method of smoking cessation.  
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TUD morbidity and mortality 
Tobacco use is the leading cause of preventable illness and death in the United States and California. 
The CDC estimates that smoking and exposure to tobacco smoke account for approximately 40,000 
deaths annually in California and that 440,000 youth today will die prematurely due to tobacco 
exposure. There is a robust body of literature demonstrating poor health outcomes associated with 
smoking including cardiopulmonary disease, cancer, dental disease, and poor fetal outcomes (e.g., low 
birthweight, stillbirth, preterm delivery). Furthermore, indirect effects of smoking through second-hand and 
third-hand smoke places non-smokers at higher risk for cardiovascular disease, cancer, and stroke, and 
children at higher risk for ear infections, asthma attacks, bronchitis, and sudden infant death syndrome 
(SIDS) (CDC, ATS, 2013). The California Department of Public Health (CDPH) reported that current 
smokers have the highest rate of chronic obstructive pulmonary disease (12.7%) followed by never 
smokers (5.5%) and former smokers (4.8%). Rates of smoking-attributable mortality for lung cancer for 
men was 85% (5,175) and 64% (3,625 deaths) for women in 2016 (CDPH, 2018). Among the 10 
categories of cancer, 9 categories of cardiovascular disease, and 5 categories of respiratory disease, the 
smoking attributable mortality rate was above 60% accounting for more than 20,000 preventable deaths 
in California in 2014 (CDPH, 2018).  
Unmet Needs for OUD, AUD, and TUD Treatment 
OUD: In calculating the OUD treatment gap in California, Clemans-Cope et al (2018) estimated that about 
20% with OUD will seek medication assisted treatment based on study findings from Wu et al (2016) that 
considered opioid-related treatment received by people with OUD in the U.S. See the Structural and 
Attitudinal Barriers section for discussion about contributing factors to unmet need for treatment.  
AUD: An estimated one-third of people with AUD receive treatment (medication and/or counseling), of 
which fewer than 10% use AUD prescription drug treatment (Jonas et al., 2014; NIAAA, 2018). Generally, 
AUD is treated in specialty facilities or through mutual-help organizations such as Alcoholics Anonymous; 
it is treated less commonly through primary care (AHRQ, 2014). In 2017, 5.41% of Californians aged 12 
years and older reporting a need for but not receiving AUD treatment (and 9.93% among those aged 18-
25 years) (SAMSHA, 2017). See the Structural and Attitudinal Barriers to OUD, AUD and TUD Treatment 
section for discussion about contributing factors to unmet need for treatment.  
TUD: Based on California Health Interview Survey data, 72% percent of adult smokers in California 
thought about quitting in the next six months and 58% percent made an attempt in the past year. Table 3 
shows California smokers’ preferred quitting “cold turkey” (67%) over other methods such as over-the-
counter nicotine replacement therapy (nicotine patches, gum, or lozenges) (19%). Prescription 
medications were used by 5.7% smokers, who may report using more than one cessation method 
simultaneously (CDPH, 2018). 
Structural and Attitudinal Barriers to OUD, AUD and TUD Treatment 
Barriers to accessing treatment for OUD, AUD and TUD include drug utilization management techniques 
(see side bar), provider supply, geographic access, and patient receptiveness to treatment. According to 
the Pew Foundation, two key barriers to the use of medications for OUD are limited insurance coverage 
for medications and limited provider supply.  
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 Drug Utilization Management 
These tools help insurance carriers 
manage the cost or safety of use of 
outpatient prescription drugs. In addition 
to minimizing the use of more expensive 
prescription drugs, these techniques are 
used sometimes for clinical reasons such 
as promoting adherence to clinical 
recommendations for specific illnesses or 
protecting enrollees from outdated or 
potentially dangerous drugs (PBMI, 2015). 
As discussed further in the Benefit 
Coverage, Utilization, and Cost Impacts 
section, formulary coverage for 
prescription medications approved and 
indicated by the FDA to treat SUDs is 
common for enrollees in DMHC-regulated 
plans and CDI-regulated policies. (See 
box for definitions of utilization 
management tools.) 
Provider Supply 
Although formulary coverage and 
utilization management may provide some 
barrier to treatment, provider supply including provider attitudes and geographic access can also pose 
structural barriers to treatment and are more difficult to address through legislated benefit mandates.  
Significant prescribing restrictions limit access to OUD medications. Federal law restricts methadone 
treatment (for OUD) to federally certified opioid treatment programs (“methadone clinics”). Methadone 
must be initiated through admission to a certified methadone clinic. Initially, patients must take their daily 
methadone treatment under direct clinical supervision. Once a patient is stabilized, it is possible for some 
patients to take methadone at home in between required clinic visits. Federal guidelines recommend a 
minimum 12-month treatment plan, and many patients continue with methadone for years (SAMHSA, 
2015). (Due to the federal restrictions, CHBRP assumes SB 11 would not change administration, 
payment, or barriers to methadone treatment. See Benefit Coverage, Utilization, and Cost Impacts 
section for further discussion.) Clemans-Cope et al. (2018) reported that there are 152 SAMHSA-certified 
methadone clinics in California, which can treat 46,430 patients simultaneously.  
In order to prescribe buprenorphine for OUD, another FDA-approved treatment for OUD, federal law 
requires health care providers to receive special training and certification called a DATA 2000 Waiver. 
Providers (physicians, physician assistants, and nurse practitioners) can treat no more than 30 
simultaneous patients during first year of waiver, and must reapply to increase to 100 patients. Addiction 
medicine physicians may treat up to 275 patients at a time (SAMHSA, 2018). In 2018, there were 5,821 
physicians waivered to prescribe buprenorphine in California (CHCF, 2018). Several studies suggest that, 
of certified buprenorphine providers, only 44% to 66% actually prescribe the medication for OUD, and 
most do not choose to reach their maximum-allowed patient caseload (Hutchinson et al., 2014; Jones et 
al., 2015; Walley et al., 2008). This leads to wait lists in some areas, which have been shown to decrease 
uptake of OUD medications by people with OUD (Fisher et al., 2017). A recent treatment capacity 
Prescription Drug Benefit Management 
 
The following are used to help health plans and insurers control 
costs and manage patient safety (PBMI, 2015):  
 
Formulary. The formulary is a list of prescription drugs that the 
health plan or insurer agrees to pay for in whole or in part.  
 
Tier. Formularies divide the covered drugs into tiers, each tier 
having a distinct cost-sharing level. Prescription drugs in the 
lower tiers (0-2), usually generics and preferred brand name 
drugs, are less costly to both the enrollee and to the health plan 
or insurer than drugs listed in upper tiers (3-5).  
 
Prior Authorization. This utilization management tool requires 
providers to submit documentation of medical need to the health 
plan for approval of coverage for some prescription drugs.  
 
Step Therapy. This utilization management tool requires an 
enrollee to try and fail one or more formulary-required drugs prior 
to receiving coverage for the initially preferred drug. Step therapy 
protocols usually recommend starting with a drug that is less 
expensive (generics) and/or has more “post-marketing safety 
experience”.  
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analysis by Clemans-Cope et al. (2018) estimated that an additional 3,500 to 4,100 providers would need 
to be trained and certified to treat the OUD population in California. 
Provider willingness to treat OUD and AUD can also be limited; not all providers are comfortable 
prescribing medications to treat these conditions due to a lack of clinical knowledge, lack of office space 
and support resources, time pressure, or personal beliefs against using medications to treat OUD 
(McNeely et al., 2018; HHS, 2016). Many providers are reticent to prescribe medication to treat AUD, 
despite more than 10 years of provider education campaigns from government entities and the American 
Medical Association (SAMSHA, 2015). Other reasons for provider nonparticipation include prior training to 
refer to patients with AUD to specialty treatment centers and systemic division between physical and 
behavioral health care (SAMSHA, 2015). Wessell et al. found that key facilitators to increasing primary 
care providers’ prescribing AUD medication included provider exposure to evidence and case studies, 
limited referral options to specialty treatment clinics for their patients (provider-of-last resort), receptive 
patients, early successful patient outcomes, and low-cost (generic oral naltrexone) availability of AUD 
medication (Wessell et al., 2014).  
Medications for treating TUD and AUD do not require special provider training or waivers, thus these 
disorders do not face the same provider supply barrier described for OUD.  
Patient Attitudinal Barriers 
For many with OUD, AUD, and TUD, attitudinal barriers are the most significant barrier to treatment 
initiation and persistence (Blanco et al., 2013). The stigma of addiction and the ability to acknowledge an 
addiction affects patient desire to seek care; even more so for those who have co-occurring psychiatric 
conditions (Fisher et al., 2016; Jones et al., 2015; Verissimo and Grella, 2017). Many people with OUD 
and/or AUD believe they can solve the problem themselves (Rapp et al., 2006). Rapp et al. (2006) tested 
a Barrier to Treatment Inventory tool to assess barriers to treatment from the substance abusers’ 
perspective. They reported significant correlation among six of the seven barrier factors: absence of a 
problem; negative social support; fear of treatment; privacy concerns; time conflict; poor treatment 
availability; and admission difficulty.  
As with OUD and AUD, patient readiness for treatment also presents a barrier for those with TUD. CHIS 
data shows that a quarter of smokers in California are not interested in quitting. For those who attempt to 
quit, repeated efforts are needed, with an average of 4.7 quit attempts reported by former smokers before 
successful cessation (CDPH, 2018). 
Social Determinants of Health (SDoH) Related to Substance Use Disorder 
SDoH include factors outside of the traditional medical care system that influence health status and 
health outcomes (e.g., income, education, geography, etc.). See the Long-Term Impacts section for a full 
discussion. 
 
 
 
  
Analysis of California Senate Bill 11 
Current as of February 13, 2019 www.chbrp.org 16 
MEDICAL EFFECTIVENESS 
As discussed in the Policy Context section, SB 11 would require state-regulated health plans and policies 
that provide prescription drug benefits for the treatment of substance use disorders (SUD) to place all 
prescription medications approved by the FDA for treatment of SUDs on the lowest tier of the health 
plan’s drug formulary. The bill would also prohibit a health plan that provides outpatient prescription drug 
benefits for the treatment of SUDs from imposing any prior authorization or any step therapy 
requirements before authorizing coverage for a prescription medication approved by the FDA for the 
treatment of SUDs and from refusing to cover court-mandated treatment for a SUD. The medical 
effectiveness review summarizes findings from evidence21 on the effectiveness of medications that the 
FDA has approved for treatment of SUD and the impact of utilization management techniques on use of 
these medications and outcomes. Additional information on SUDs for which there are FDA-approved 
medications is included in the Background on Substance Use Disorders section. 
As indicated in the Background on Substance Use Disorders section, the FDA has approved prescription 
medications to treat opioid use disorders (OUD), alcohol use disorders (AUD), and tobacco use disorders 
(TUD). OUD encompasses abuse of short-acting opioids, such as heroin and morphine, and semi-
synthetic opioids such as oxycodone and hydrocodone. AUD involves compulsive use of alcohol and 
inability to control alcohol intake. Tobacco use disorder encompasses use of all forms of tobacco. (See 
the Background on Substance Use Disorders section for more detailed definitions of these SUDs.)  
The FDA has approved different medications for each of these disorders. Table 4 lists the medications 
the FDA has approved, the SUD(s) they are used to treat, their role in treatment, and how the medication 
is administered. 
Research Approach and Methods 
Studies of FDA-approved medications for OUD, AUD, and TUD were identified through searches of 
PubMed, the Cochrane Library, EMBASE, Scopus, and PsycINFO. Websites maintained by the following 
organizations that produce and/or index meta-analyses and systematic reviews were also searched: the 
Agency for Healthcare Research and Quality (AHRQ), the International Network of Agencies for Health 
Technology Assessment (INAHTA), the National Health Service (NHS) Centre for Reviews and 
Dissemination, the National Institute for Health and Care Excellence (NICE), and the Scottish 
Intercollegiate Guideline Network.  
The search was limited to abstracts of studies published in English. For OUD, the search only included 
articles published since January 2018 because CHBRP previously reviewed older literature on 
medications for OUD for its report on AB 2384 which was issued in 2018. The literature search for AUD 
included articles published from 2013 to present because CHBRP relied on a systematic review 
completed for the Agency for Healthcare Research and Quality (AHRQ) for a synthesis of older literature 
on medications for AUD (Jonas et al., 2014). The literature search for TUD included articles published 
from 2014 to present because CHBRP relied on an AHRQ systematic review for a synthesis of older 
literature on medications for TUD (Patnode el al., 2015). Of the 947 articles found in the literature review, 
65 were reviewed for potential inclusion in this report on SB 11, and a total of 56 studies were included in 
the medical effectiveness review for this report. The other articles were eliminated because they did not 
                                                     
21 The discussion below is focused on reviews of available literature. As noted in the medical effectiveness approach 
document (http://chbrp.com/analysis_methodology/medical_effectiveness_analysis.php; see p.8), in the absence of 
well-designed randomized controlled trials (RCTs) published in the peer-reviewed literature that are “fully applicable 
to the analysis”, CHBRP’s hierarchy of evidence allows for the inclusion of other evidence. 
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address FDA-approved medications for SUD, were of poor quality, or did not report findings from clinical 
research studies. A more thorough description of the methods used to conduct the medical effectiveness 
review and the process used to grade the evidence for each outcome measure is presented in Appendix 
B. 
The conclusions below are based on the best available evidence from peer-reviewed and grey literature. 
Unpublished studies are not reviewed because the results of such studies, if they exist, cannot be 
obtained within the 60-day timeframe for CHBRP reports. 
Table 4. FDA-Approved Prescription Medications for OUD, AUD, and TUD and Approved Uses 
Medication SUD(s)  Role in Treatment Mode of Administration 
Naloxone Opioid Use Disorder Reverse overdose Injection, nasal spray 
Lofexidine Opioid Use Disorder Manage withdrawal symptoms Tablet 
Buprenorphine (including 
buprenorphine-naloxone) Opioid Use Disorder 
Manage withdrawal 
symptoms, maintain 
abstinence from opioids 
Tablet, film, injection, 
implant(a)  
Methadone Opioid Use Disorder 
Manage withdrawal 
symptoms, maintain 
abstinence from opioids 
Tablet, liquid(b)  
Naltrexone 
Opioid Use 
Disorder, Alcohol 
Use Disorder 
Maintain abstinence from 
opioids or alcohol Tablet, injection(c)  
Acamprosate Alcohol Use Disorder 
Maintain abstinence from 
alcohol Tablet 
Disulfiram Alcohol Use Disorder 
Maintain abstinence from 
alcohol Tablet 
Nicotine replacement therapy Tobacco Use Disorder 
Maintain abstinence from 
tobacco use Inhaler, nasal spray(d)  
Bupropion sustained release 
(SR) 
Tobacco Use 
Disorder 
Maintain abstinence from 
tobacco use Tablet 
Varenicline Tobacco Use Disorder 
Maintain abstinence from 
tobacco use Tablet 
Source: California Health Benefits Review Program, 2019.  
Notes: (a) SB 11 only affects coverage for tablet and film formulations of buprenorphine or buprenorphine/naloxone combination. 
(b) SB 11 would affect coverage for methadone but would not affect the dispensing of methadone because federal law restricts 
methadone treatment (for OUD) to federally certified opioid treatment programs (i.e., “methadone clinics”). 
(c) SB 11 only affects coverage for the tablet formulation of naltrexone. 
(d) Other forms of nicotine replacement therapy (i.e., patch, gum, and lozenge) are available over the counter. 
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Although SB 11 would only affect coverage for FDA-approved medications for OUD, AUD, and TUD that 
are typically covered as part of a pharmacy benefit (i.e., medications that are orally or intra-nasally 
administered), the medical effectiveness review discusses medications for OUD that are typically covered 
as part of the medical benefits (i.e., implantable and injectable formulations) because providers may 
consider prescribing these medications as alternatives to medications for which SB 11 would affect 
coverage. CHBRP also did not review literature on medications that are prescribed for AUD but not 
approved for this purpose, such as baclofen, gabapentin, topiramate, and valproic acid. In addition, 
CHBRP did not review studies of bupropion extended release (XL) because that formulation of bupropion 
is not approved for treatment of TUD. CHBRP also did not review literature on the effectiveness of 
transdermal and intravenous formulations of buprenorphine because the FDA has only approved these 
formulations of buprenorphine for the treatment of chronic pain. CHBRP is unaware of prescribed/not-
approved drugs that are used to treat OUD or TUD. Finally, CHBRP did not review literature on forms of 
treatment for OUD, AUD, and TUD other than medication, such as counseling, because SB 11 only 
addresses coverage for prescription medications for these conditions. 
 
Key Questions  
CHBRP’s medical effectiveness review addressed the following questions: 
1. What is the effectiveness of FDA-approved medications for treatment of OUD, AUD, and TUD 
compared to no treatment or a placebo? 
2. What is the relative effectiveness of FDA-approved medications used treat OUD, AUD, and TUD? 
3. What are the harms associated with FDA-approved medications used treat OUD, AUD, and 
TUD? 
4. How does health plans’ use of utilization management techniques (such as prior authorization 
and step therapy) affect use of FDA-approved medications for OUD, AUD, and TUD? 
Methodological Considerations 
The systematic reviews CHBRP cited included overlapping groups of studies of FDA-approved 
medications for OUD, AUD, and TUD. Thus, their conclusions of these systematic reviews regarding the 
effectiveness of these medications are not independent of one another.  
The systematic reviews included randomized controlled trials (RCTs) and observational studies. RCTs 
maximize ability to discern whether any differences observed between intervention and comparison 
groups are due to the intervention or to other factors. However, in the case of FDA-approved medications 
for OUD, AUD, and TUD, many of the RCTs follow subjects for less than one year, which limits ability to 
assess the long-term impact of receiving these medications. Most studies that have assessed long-term 
health impacts, such as mortality, liver disease, lung disease, human immunodeficiency virus (HIV), and 
hepatitis C, are observational studies. Findings from observational studies need to be interpreted with 
more caution because observational studies are less able to control for other differences between 
intervention and comparison groups that may affect the outcome of interest. 
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Outcomes Assessed 
The outcomes assessed by studies of the impact of approved uses of FDA-approved prescription 
medications for SUDs vary depending on the disorder treated.  
FDA-Approved Prescription Medications for OUD  
Studies of FDA-approved medications for OUD have primarily examined outcomes related to opioid use 
and participation in treatment. Outcomes assessed include use of opioids during treatment, use of opioids 
at follow up, and retention in treatment. Some studies have examined effects of OUD medications on 
morbidity or mortality. Studies of effects on morbidity have addressed birth outcomes for pregnant women 
treated for OUD and effects on the likelihood of contracting HIV and hepatitis C, two contagious diseases 
for which persons who inject opioids are at elevated risk.  
FDA-Approved Prescription Medications for AUD  
Studies of FDA-approved medications for AUD have primarily examined outcomes related to alcohol use 
and participation in treatment. Outcomes assessed include drinking days, number of drinks consumed, 
and reducing lapse/relapse in drinking.  
FDA-Approved Prescription Medications for TUD  
Studies of FDA-approved medications for TUD have primarily examined outcomes related to cessation of 
tobacco use. Outcomes assessed include reduced cigarette cravings during treatment, abstinence during 
treatment, and abstinence of tobacco at follow up.  
Some studies have examined effects of TUD medications on birth outcomes for pregnant women treated 
for TUD, including rates of miscarriage, stillbirth, preterm birth (less than 37 weeks), low birthweight, 
admissions of babies to neonatal intensive care, and infant development. 
Study Findings  
FDA-Approved Prescription Medications for OUD  
Naloxone for overdose reversal 
The FDA has approved subcutaneous, intramuscular, and intranasal formulations of naloxone for reversal 
of an opioid overdose. Paramedics and emergency department clinicians have used intramuscular 
naloxone for many years and recent studies suggest that lay people can also administer the medication 
effectively. All forms of naloxone have been found to reverse opioid overdoses (Boyer 2012; Chou et al., 
2017; Kim et al., 2009). Two studies that compared intramuscular and intranasal formulations of naloxone 
found that the efficacy of intramuscular naloxone (2 mg) and intranasal naloxone (2 mg/1 mL) are similar 
(Chou et al., 2017). There were also no differences in adverse events associated with naloxone, which 
include agitation, nausea, and vomiting. CHBRP did not identify any studies that compare the auto-
injector formulation of naloxone to the intranasal and older intramuscular formulations of naloxone. 
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Lofexidine for management of withdrawal symptoms vs. placebo 
In 2018 the FDA approved lofexidine for management of symptoms of opioid withdrawal. Two RCTs have 
found that lofexidine is more effective than a placebo for alleviating withdrawal symptoms as indicated by 
scores on instruments that measure opioid withdrawal symptoms (Fishman et al., 2018; Gorodetsky et al., 
2017). People with less severe withdrawal symptoms may be more willing to abstain from using illicit 
opioids and to take other medications that the FDA has approved for maintenance treatment. Both RCTs 
found that persons who received lofexidine were more likely to complete the study than persons who 
received a placebo. 
CHBRP did not identify any studies that compared lofexidine to other medications that are used to 
alleviate opioid withdrawal symptoms. 
FDA-approved prescription maintenance medications for OUD versus placebo or no medication 
Research has demonstrated the effectiveness of FDA-approved medications to maintain abstinence from 
OUD relative to a placebo or no treatment. Most studies were conducted in adults. There is far less 
literature on effects in adolescents (Minozzi et al., 2014). 
Buprenorphine or buprenorphine-naloxone combination 
Mattick et al.’s (2014) Cochrane review of 11 RCTs (sample sizes: 40-736 people) found that persons 
who were given buprenorphine or buprenorphine-naloxone combination medication for maintenance 
treatment of OUD were more likely to be retained in treatment than people who received a placebo. The 
authors found that only high-dose buprenorphine (> 16 mg) was more effective than placebo in 
suppressing use of illegal opioids as measured by urinalysis in the trials (Mattick et al., 2014) (3 studies; 
729 people).  
Two other systematic reviews also found that persons who received buprenorphine or buprenorphine-
naloxone were more likely to be retained in treatment than people who received a placebo (Thomas et al., 
2014; Timko et al., 2016). Thomas et al.’s (2014) systematic review included 17 RCTs, a randomized 
crossover study, a study using a self-administered survey, a retrospective descriptive study, and seven 
reviews or meta-analyses (sample sizes: 12-4,497 people). Timko et al.’s (2016) review of buprenorphine 
or buprenorphine-naloxone combination included 14 randomized control trials, four quasi-experimental 
design studies, and nine cohort studies (sample sizes: 70-1,269 people). Timko et al. (2016) reported that 
65.7% of persons who received buprenorphine were retained in treatment at 6 months versus 30.9% of 
persons who received a placebo. 
In a systematic review of three prospective or retrospective cohort studies (sample sizes: 1,373-11,940 
people) in people with OUD, Sordo et al. (2017) found buprenorphine treatment is associated with 
substantial reductions in the risk for all cause and overdose mortality in people dependent on opioids 
relative to not receiving treatment. 
One systematic review examining 16 RCTs (sample sizes: 12-653 people) found that buprenorphine and 
buprenorphine-naloxone combination maintenance treatments were associated with less risk of adverse 
events and improved maternal and fetal outcomes in pregnancy compared with not receiving treatment 
(Thomas et al., 2014). 
Most studies of buprenorphine have examined the effectiveness of sublingual tablets or film that users 
must take on a daily basis. An important limitation of these forms of buprenorphine are that users may 
forget to take the medication every day, may misuse it, or sell it to others. Implantable extended-release 
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injectable formulations of buprenorphine have been developed to provide longer-acting forms of 
buprenorphine treatment that are administered in a provider’s office. SB 11 would not affect coverage for 
these forms of buprenorphine because they are covered under a health plan or health insurance policy’s 
medical benefit and not its outpatient pharmacy benefit, but providers may consider prescribing them 
instead of sublingual tablets or film. CHBRP identified one RCT (sample size: 177 people) that compared 
buprenorphine implants to sublingual buprenorphine tablets found that people who received the implants 
were more likely to abstain from opioids for six months (85.7% vs. 71.9%) (Rosenthal et al., 2016).  
Naltrexone  
A Cochrane review of 13 RCTs (1,158 total people; sample sizes: 20-280 people) (Minozzi et al., 2011) 
found that there was no statistically significant difference between treatment with oral naltrexone and 
treatment with placebo or no pharmacological agent with respect to retention, abstinence, and side 
effects.  
As with buprenorphine, an extended release intramuscular injectable formulation of naltrexone has been 
developed to provide a longer acting form of the medication that does not depend on a patient taking a 
medication on a daily basis. SB 11 would not affect coverage for the injectable formulation of naltrexone. 
Findings from one systematic review (Jarvis et al., 2018) found limited evidence that extended-release 
naltrexone decreases opioid use relative to a placebo. In contrast to methadone and buprenorphine, 
which can be administered while a person tapers off illicit use of opioids, people must complete 
detoxification before receiving naltrexone. Many people with OUD do not successfully initiate treatment 
with naltrexone because they are unable to completely abstain from using opioids. 
CHBRP did not identify any studies that compared oral naltrexone to extended-release naltrexone for 
treatment of OUD.  
Methadone 
As discussed in the Benefit Coverage, Utilization, and Cost Impacts section, SB 11 will affect coverage 
for methadone but will not change the manner in which methadone is dispensed because federal law 
requires that methadone be administered only by federally certified opioid treatment programs (i.e., 
“methadone clinics”). For these reasons, SB 11 is likely to have a limited impact on costs associated with 
methadone treatment. CHBRP decided to include methadone in its medical effectiveness review despite 
SB 11’s limited impact on its use because it has been used to treat OUD for many years and providers 
and patients may consider it as an alternative to buprenorphine. 
Two systematic reviews of overlapping groups of studies have compared methadone maintenance 
treatment to a placebo or no treatment for OUD (Fullerton et al., 2014; Mattick et al., 2009). Fullerton 
(2014) included 7 RCTs, 2 quasi-experimental studies (sample sizes: 81-319 people) and 15 reviews or 
meta-analyses of multiple studies. Mattick et al. (2009) assessed 11 RCTs (sample sizes: 32-382 people). 
Both systematic reviews concluded that methadone is more effective than a placebo or no treatment for 
retaining patients in treatment and reducing use of illegal opioids as measured by self-report and 
urine/hair analysis. Mattick et al. (2009) also found that methadone was statistically significantly more 
effective in the suppression of heroin use as measured by self-report and urine/hair analysis.  
Fullerton et al.’s systematic review (2014) found two systematic reviews and one RCT that addressed the 
impact of methadone on HIV risk. The authors concluded that receipt of methadone maintenance 
treatment was associated with lower risk of injecting opioids and engaging in sexual behaviors that 
elevate a person’s risk of contracting HIV. A systematic review of nine studies (with a sample that 
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included 819 incident HIV infections over 23,608 person years of follow-up) concluded that receipt of 
methadone maintenance treatment reduces risk of HIV transmission (MacArthur et al., 2012). 
The authors of one systematic review of RCTs found no statistically significant difference in mortality 
between persons receiving methadone maintenance treatment and persons who received a placebo or 
no treatment (4 studies) (Mattick et al., 2009). In a subsequent systematic review of 18 prospective or 
retrospective cohort studies (sample sizes: 56-122,885 people) that had longer follow-up periods than the 
studies included in Mattick et al.’s (2009) systematic review, Sordo et al. (2017) found methadone 
maintenance treatment is associated with substantial reductions in the risk for all cause and overdose 
mortality in people dependent on opioids. In patients using methadone maintenance treatment there are, 
on average, 25 fewer deaths/1000 person years than in patients who do not receive methadone 
maintenance treatment.  
Methadone or buprenorphine 
A systematic review of 38 observational studies (sample sizes: 18-726 people) found that receipt of either 
methadone or buprenorphine was associated with less injection drug use, less sharing of injection 
equipment, less exchange of sex for drugs, and lower likelihood of having multiple sex partners among 
people with OUD (Gowing et al., 2011). Two cohort studies found that receipt of methadone or 
buprenorphine was associated with lower risk of hepatitis C among persons with OUD (Nolan et al., 2014; 
Tsui et al., 2014). 
Summary of findings regarding the effects of FDA-approved prescription medication versus 
placebo or no medication for treatment of OUD: There is clear and convincing evidence from ten 
systematic reviews and five RCTs that buprenorphine (including buprenorphine-nalaxone) and 
methadone are more effective than a placebo or no treatment with regard to retention in treatment for 
OUD, reduction in use of illicit opioid drugs, relapse, lower likelihood of engaging in behaviors associated 
with elevated risk for HIV and hepatitis C, better birth outcomes, and lower mortality rates. Findings from 
RCTs of oral naltrexone indicate that it does not improve retention in treatment and abstinence from 
opioids relative to a placebo or no treatment. 
Figure 1. FDA-approved OUD Medication Versus Placebo or No Medication – Methadone and 
Buprenorphine 
 
Figure 2. FDA-approved OUD Medication Versus Placebo or No Medication – Naltrexone 
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Comparison of FDA-Approved Prescription Medications for Maintaining Abstinence from 
Opioids  
Buprenorphine or buprenorphine-naloxone combination vs. Methadone 
A large number of studies have compared the effectiveness of methadone to buprenorphine or 
buprenorphine-naloxone combination for maintenance treatment of OUD. A smaller number of studies 
have compared naltrexone to buprenorphine or buprenorphine-naloxone combination treatment for 
maintenance or induction to treatment with extended release naltrexone. Comparative studies of 
maintenance medications have examined effects on retention in treatment, abstinence from use of 
opioids, and birth outcomes. CHBRP did not identify any studies that examined the relative effectiveness 
of maintenance medications used to treat OUD on transmission of hepatitis C or HIV or on engagement in 
behaviors that increase risk for contracting hepatitis C or HIV. CHBRP also did not identify any studies of 
the relative impact of maintenance medications used to treat OUD on mortality. 
A Cochrane review by Mattick et al. (2014) compared methadone to different formulations of 
buprenorphine (i.e., sublingual solution, sublingual tablets, combined buprenorphine-naloxone sublingual 
tablet and an implant). The authors found that compared to methadone, buprenorphine retains fewer 
people in treatment when doses are flexibly delivered (adjusted to participant need) (5 studies; 788 
people; RR=0.83; 95% CI: 0.72 to 0.95) and at low fixed doses (3 studies; 253 subjects; RR=0.67; 95% 
CI: 0.52 to 0.87). If fixed medium or high doses are used, buprenorphine and methadone are equally 
effectiveness for retaining people in treatment (7 studies; 780 people; RR=0.87; 95% CI: 0.69 to 1.10) 
and suppressing illicit opioid use (4 studies; 476 people; SMD 0.25; 95%CI: -0.08 to 0.58).  
A systematic review of four studies (three RCTs and one systematic review; sample sizes: 196-1,497 
people) concluded that the efficacy of buprenorphine is dose dependent. For comparisons at medium-
dose ranges, evidence is mixed. Some studies showed similar effects of methadone and buprenorphine 
but others suggest that methadone improved treatment retention or reduces illicit opioid use. Only one 
RCT (sample size: 220 people) reviewed in this study compared high doses of buprenorphine and 
methadone, and it showed similar outcomes in terms of days in treatment (mean of 96 and 105 days, 
respectively) or percentage of patients with 12 or more consecutive negative opioid screens (26% versus 
28%, respectively) (Thomas el al., 2014).  
Timko et al. (2016) identified three RCTs that compared methadone to buprenorphine or buprenorphine-
naloxone. The authors found that methadone was associated with better retention in treatment than 
buprenorphine-naloxone at 4 months (73.9% versus 45.9%) and at 6 months (74.0% versus 46.0%; 
57.6%).  
An RCT published after the RCTs included in the systematic reviews compared outcomes for persons 
treated with buprenorphine or buprenorphine-naloxone to persons treated with methadone for an average 
of 4.5 years following 24 weeks of treatment (Hser et al., 2016). The authors reported that persons 
treated with buprenorphine or buprenorphine-naloxone were less likely to abstain from using opioids than 
people treated with methadone (57.2% vs. 68.3%) because they received less ongoing treatment after 
the 24-week trial ended. The RCT found no statistically significant difference in mortality between people 
treated with the two medications. 
In a systematic review of six RCTs (607 people) that addressed the impact of MAT on people who are 
addicted to legal opioid prescription drugs (as opposed to heroin and other illegal opioids), Nielsen et al. 
(2016) found no difference between the effects of methadone and buprenorphine or buprenorphine-
naloxone in self-reported opioid use (RR=0.37; 95% CI: 0.08 to 1.63) or opioid positive urine drug tests 
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(RR=0.81; 95% CI: 0.56 to 1.18), retention in treatment (RR=0.69; 95% CI: 0.39 to 1.22), and adverse 
events (RR=1.10; 95% CI: 0.64 to 1.91).  
Three systematic reviews compared the effectiveness and safety of buprenorphine and methadone for 
maintenance treatment of pregnant women with OUD. Minozzi et al. (2013) and Thomas et al. (2014) 
found that when the medication was dosed adequately, methadone and buprenorphine or buprenorphine-
naloxone combination treatment showed similar reduction in illicit opioid use among pregnant women but 
that pregnant women treated with methadone were more likely to remain in treatment. Thomas (2014) 
also found that rates of neonatal abstinence syndrome were similar for infants born to mothers treated 
with buprenorphine or methadone but that symptoms were less severe for infants whose mothers were 
treated with buprenorphine. Zedler (2016) found that buprenorphine and buprenorphine-naloxone were 
associated with lower risk of preterm birth, greater birth weight, and larger head circumference than 
methadone and that rates of fetal spontaneous deaths and fetal/congenital abnormalities were similar for 
the two medications. In a review of 4 RCTs, Minozzi et al. (2013) found three RCTs that compared birth 
weight. Birth weight was higher in the buprenorphine group in the two trials that could be pooled (mean 
difference (MD) -365.45 g; 95% CI: -673.84 to -57.07; 2 studies, 150 people). The third double blind RCT 
reported that there was no statistically significant difference between buprenorphine and methadone 
groups (sample size: 18). The reported APGAR score (2 studies, 163 people) and number of newborns 
treated for neonatal abstinence syndrome (3 studies, 166 subjects) did not differ significantly between 
groups. One RCT (sample size: 131 subjects) comparing methadone with buprenorphine reported side 
effects. For the mother there was no statistically significant difference; for the newborns in the 
buprenorphine group there were significantly fewer serious side effects (RR=4.77; 95% CI: 0.59 to 38.49). 
Buprenorphine-naloxone combination vs. extended-release naltrexone 
Two RCTs have compared the effectiveness of extended-release naltrexone and buprenorphine-
naloxone. Although SB 11 would not affect coverage for extended-release naltrexone, the FDA has 
approved it for treatment of OUD and providers may present it to patients as an alternative to methadone 
or to orally administered buprenorphine. One RCT assessed outcomes after 12 weeks of treatment 
(Tanum et al., 2017) and found no statistically significant difference in the length of time people remained 
in treatment or their abstinence from use of illicit opioids (as measured by negative urine tests). Persons 
who received extended-release naltrexone reported less craving for heroin but were more likely to report 
symptoms of withdrawal. A second RCT examined outcomes after 24 weeks of treatment (Lee et al., 
2018). The authors found that participants were less likely to successfully initiate treatment with 
extended-release naltrexone than with buprenorphine-naloxone which led extended-release naltrexone 
patients to have a higher relapse rate than patients who received buprenorphine-naloxone. This finding is 
consistent with findings of studies that have compared extended-release naltrexone to a placebo (Jarvis 
et al., 2018). Among patients who successfully initiated treatment, there were no statistically significant 
differences in relapse rates or in abstinence from use of opioids as (measured by negative urine tests and 
self-report) (Lee et al., 2018).  
Summary of findings regarding the comparative effectiveness of different medications used to 
treat OUD: There is inconclusive evidence from seven systematic reviews and four RCT published after 
the systematic reviews about the impact of methadone relative to buprenorphine or buprenorphine-
naloxone on retention in treatment and abstinence from opioids. There is limited evidence that 
buprenorphine and buprenorphine-naloxone are associated with better birth outcomes than methadone 
but women receiving buprenorphine or buprenorphine-naloxone were less likely to remain in treatment 
than women who receive methadone. One of two RCTs that compare extended-release injectable 
naltrexone to orally administered buprenorphine-naloxone have found that people have more difficulty 
initiating treatment with extended-release naltrexone and were more likely to relapse. 
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Figure 3. Comparative Effectiveness of Different FDA-approved Medications Used to Treat Opioid Use 
Disorder – Methadone vs. Buprenorphine 
 
Figure 4. Comparative Effectiveness of Different FDA-approved Medications Used to Treat Opioid Use 
Disorder – Buprenorphine vs. Extended-Release Naltrexone (Favors Buprenorphine) 
 
 
Harms Associated with Use of FDA-Approved Prescription Medications for OUD 
Patients who take methadone or buprenorphine to treat OUD may experience side effects that are similar 
to those of opioids, such as nausea, vomiting, constipation, muscle aches, cramps, constipation, fever, 
cravings, irritability, and inability to sleep (SAMHSA, 2018). People using methadone may also 
experience difficulty breathing, lightheadedness, hives, rash, chest pain, rapid heart rate, and 
hallucinations (SAMHSA, 2018). They also have an increased risk of overdose during the first few weeks 
of treatment (Sordo et al., 2017).  
There is also a risk that people will misuse methadone or buprenorphine due to their opioid effects 
(SAMHSA, 2018). This risk is higher with buprenorphine than methadone because people are often 
prescribed a supply of buprenorphine to take on their own, whereas people receiving methadone are 
usually required to take their medication at a methadone clinic. There is less risk of misuse of extended-
release injectable formulations of buprenorphine and naltrexone, coverage for which would not be 
affected by SB 11, because they are administered in physicians’ offices. 
Initiation and discontinuation of treatment with naltrexone carries added risk of harm. Unlike methadone 
and buprenorphine, which can be used safely while a patient continues to use opioids, patients must 
withdraw from all opioids before beginning treatment with any formulation of naltrexone. Some patients 
are unable to do this and may overdose on opioids during the withdrawal period. Lee et al. (2018) found a 
higher risk of overdose during initiation of treatment among persons slated to receive extended-release 
injectable naltrexone than among people receiving orally administered buprenorphine. In addition, 
patients treated with naltrexone who discontinue treatment and resume use of opioids may be sensitive to 
lower doses of opioids, which could increase their risk of overdose (SAMHSA, 2015). Because relapse is 
common among people who receive all forms of treatment for OUD, risk of overdose when a person 
resumes consumption of opioids should be considered when treatment decisions are made (Saucier et al. 
2018). 
SAMHSA has concluded that the benefits of these medications with regard to mortality, HIV transmission, 
hepatitis C infection, and birth outcomes outweigh the harms associated with them (SAMHSA, 2015). 
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Summary of findings regarding harms associated with FDA-approved prescription medications for 
OUD: People treated with methadone and buprenorphine may experience side effects similar to those of 
opioids. People who receive methadone have a greater risk of overdose during the first few weeks of 
treatment. Naltrexone is associated with a higher risk of overdose because people must abstain from 
opioids before initiating treatment and may be sensitive to lower doses of opioids if they relapse. 
SAMHSA has concluded that the benefits of these medications outweigh the harms. 
Effects of Utilization Management on Use of FDA-Approved Prescription Medications for 
OUD and Outcomes 
CHBRP found two studies that addressed the impact of utilization management on use of medications to 
treat OUD or patient outcomes. Clark et al. (2014) examined the effects of a change in the Massachusetts 
Medicaid program’s prior authorization requirements for coverage of buprenorphine-naloxone (n=2,049 
people). Under the policy, prior authorization was required for doses greater than 16 mg per day. After the 
prior authorization policy was implemented the number of people prescribed doses of buprenorphine-
naloxone greater than 24 mg per day decreased while the number prescribed lower doses per day 
increased. The relapse rate increased temporarily and the increase was most pronounced among people 
who received doses greater than 16 mg/day. The relapse rate returned to previous levels within 3 
months. The authors did not report any other outcomes. A major limitation of this study is that it assessed 
the effects of instituting a prior authorization requirement. It does not address the impact of prohibiting 
prior authorization. This study also does not provide any information about the effects of other utilization 
management techniques.  
Accurso et al. (2018) conducted a retrospective study (n=297 people) on the effect of a change in insurer 
policy, in which the insurer of a subset of patients in an office-based practice imposed a prior 
authorization requirement for sublingual buprenorphine dose of 16mg/day, which led physicians in the 
practice to increase the daily dose for patients on higher daily doses. These patients were compared to 
other patients in the practice whose insurers did not require prior authorization for higher doses of 
buprenorphine. The rate of positive urine drug tests among patients who experienced a dose decrease 
rose from 27.5% to 34.2% (p=0.043). Persons in comparison groups who did not experience a change in 
buprenorphine dose showed no significant change in positive drug test rates. Moreover, all persons who 
were prescribed buprenorphine doses greater than 16 mg/day displayed lower rates of positive urine drug 
tests than groups prescribed lower doses. Retention in treatment was also highest among those 
prescribed greater than 16 mg/day (Accurso et al., 2018). 
Summary of findings regarding the effects of utilization management for FDA-approved 
medications for OUD: There is insufficient evidence to assess the impact of utilization management on 
use of FDA-approved medications to treat OUD and patient outcomes. Buprenorphine is the only 
medication that has been assessed and studies have only examined the effects of prior authorization for 
high doses. 
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Figure 5. Impact of Utilization Management on Use of FDA-approved Prescription Medications for OUD 
 
FDA-Approved Prescription Medications for AUD  
FDA-approved prescription medications for AUD versus placebo or no medication 
Acamprosate 
A systematic review (122 RCTs, 1 cohort study; 22,803 people) comparing acamprosate to placebo found 
that significantly fewer subjects treated with acamprosate returned to any drinking (19 trials) and had 
significantly fewer drinking days (13 trials) than those treated with placebo. There was no significant 
difference for return to heavy drinking (7 trials), drinking days (1 trial), or drinks per drinking day (1 trial) 
between acamprosate and placebo (Jonas et al., 2014).  
A meta-analysis (Donoghue et al., 2015) (22 RCTs; 5,236 people) of the efficacy of acamprosate found 
the risk of returning to any drinking at 6 months was significantly lower for people receiving acamprosate 
than for people receiving a placebo. There was little difference in the risk of participants discontinuing 
treatment for any reason. 
Naltrexone 
A systematic review (122 RCTs, 1 cohort study; 22,803 people) comparing naltrexone to placebo found 
significantly fewer subjects treated with naltrexone returned to any drinking (21 trials), returned to heavy 
drinking (23 trials), had significantly fewer drinking days than those treated with placebo (19 trials), had 
fewer heavy drinking days than those treated with placebo (11 trials), and had fewer drinks per drinking 
day than those treated with placebo (11 trials) (Jonas et al., 2014). Forty of the 44 studies of naltrexone 
included in this systematic review assessed the effectiveness of the orally administered for which SB 11 
would affect coverage. 
One meta-analysis (Donoghue et al., 2015) (27 RCTs; 4,199 people) that examined the efficacy of orally 
administered naltrexone found the risk of individuals returning to any drinking at approximately 3 months 
was reduced significantly for the naltrexone group, as was the risk of individuals relapsing to heavy 
drinking at 3 months. There was no statistically significant difference in the risk of discontinuing treatment 
for any reason. 
A systematic review (4 studies; 798 people; 273 diagnosed with a psychotic disorder) (Sawicka and 
Tracy; 2017) of orally administered naltrexone in individuals with both psychosis and AUD, found most 
studies, including those that were more robust methodologically, concluded that people who received 
naltrexone had fewer drinking days and fewer heavy drinking days than people who received a placebo.  
Disulfiram  
A systematic review (122 RCTs, 1 cohort study; 22,803 people) with 3 RCTs (729 people) comparing 
disulfiram to placebo found there was no significant difference in return to any drinking and no statistically 
significant difference in percentage of drinking days between disulfiram and placebo (Jonas et al., 2014). 
Analysis of California Senate Bill 11 
Current as of February 13, 2019 www.chbrp.org 28 
Summary of findings regarding the effects of FDA-approved prescription medications versus 
placebo or no medication for treatment of AUD: There is clear and convincing evidence from three 
systematic reviews that acamprosate and naltrexone are more effective than a placebo or no treatment 
with regard to return to drinking, return to heavy drinking, percentage of drinking days, and percentage of 
heavy drinking days. There is limited evidence that disulfiram does not reduce the risk that a person will 
return to drinking or have a lower percentage of drinking days. 
Figure 6. FDA-approved AUD Medication Versus Placebo or No Medication – Acamprosate and 
Naltrexone 
 
Figure 7. FDA-approved AUD Medication Versus Placebo or No Medication – Disulfiram 
 
 
Comparison of FDA-approved prescription medications for maintaining abstinence from alcohol 
Acamprosate vs. naltrexone 
A systematic review (122 RCTs, 1 cohort study; 22,803 people) found that both acamprosate and oral 
naltrexone were both associated with reduction in return to drinking but found no statistically significant 
difference between the two medications for return to any drinking (3 studies; 800 participants), return to 
heavy drinking (4 studies; 1141 people), and percentage of drinking days (2 studies; 720 people) (Jonas 
et al., 2014).  
Naltrexone vs. disulfiram 
A systematic review (Jonas et al., 2014) (122 RCTs, 1 cohort study; 22,803 people) included 1 RCT (254 
participants) that directly compared naltrexone to disulfiram. The trial reported no statistically significant 
difference between disulfiram and naltrexone for number of subjects achieving total abstinence, the 
percentage of days abstinent, or the percentage of heavy drinking days.  
A systematic review (4 studies; 561 people; 128 diagnosed with a psychotic disorder) (Sawicka and 
Tracy, 2017) synthesized findings from two studies that compared orally administered naltrexone to 
disulfiram for treatment of AUD and two studies that compared a combination of naltrexone and disulfiram 
to either naltrexone or disulfiram alone. None of the four studies found a statistically significant difference 
in the number of drinking days and the number of heavy drinking days. 
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Summary of findings regarding the relative effectiveness of different medications used to treat 
AUD: There is inconclusive evidence from three systematic reviews about the relative effectiveness of 
acamprosate, naltrexone, and disulfiram for treatment of AUD. Findings from two studies suggest that 
acamprosate and naltrexone are equally effective. Studies that compared naltrexone and disulfiram did 
not find any differences in effects on abstinence from alcohol or heavy drinking days. No studies were 
identified that compared acamprosate to disulfiram. 
Figure 8. Comparative Effectiveness of Different FDA-approved Medications Used to Treat Alcohol Use 
Disorder 
 
 
Harms associated with use of FDA-approved prescription medications for AUD 
Acamprosate 
A systematic review (Jonas et al., 2014) (122 RCTs, 1 cohort study; 22,803 people) of 10 RCTs (sample 
sizes: 100 to 612 people) examining acamprosate found, compared with placebo, patients treated with 
acamprosate had a statistically significant higher risk of anxiety, diarrhea, and vomiting. No clinically 
significant differences were found for quality of life for acamprosate compared with placebo. 
Naltrexone 
Jonas et al. (2014) reported results from 10 trials (31 to 618 people) on health outcomes for naltrexone 
compared to placebo. Those treated with naltrexone had a statistically significant higher risk of dizziness, 
nausea, vomiting, aftertaste, blurred vision, confusion, constipation, drowsiness, dry mouth, loss of 
appetite, and tremors relative to persons who received a placebo. Six RCTs of naltrexone reported 
mortality rates; no study found more than one death in each treatment group.  
One systematic review (Donoghue et al., 2015) (27 RCTs; 4,199 people) found there was a significantly 
greater risk of participants in the naltrexone group discontinuing treatment due to adverse events 
compared to placebo. 
Disulfiram  
Jonas et al. (2014) reported results from one study (254 people) comparing disulfiram combined with 
naltrexone, disulfiram combined with placebo, naltrexone alone, and placebo alone showed that patients 
who received disulfiram had side effects including aftertaste, blurred vision, confusion, constipation, 
drowsiness, dry mouth, loss of appetite, nausea, and tremors more often than patients in the placebo 
group. There were no statistically significant between-group differences for other adverse events. 
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Summary of findings regarding harms associated with FDA-approved prescription medications for 
AUD: Use of FDA-approved prescription medications for AUD is associated with mild to moderate side 
effects, including aftertaste, anxiety, blurred vision, confusion, constipation, diarrhea, dizziness,  
drowsiness, dry mouth, loss of appetite, nausea, tremors, and vomiting. 
Effects of utilization management on use of FDA-approved prescription medications for AUD 
and outcomes 
No studies were identified that assessed the impact of utilization management on use of FDA-approved 
prescription medications for AUD or treatment outcomes. 
 
FDA-Approved Prescription Medications for TUD  
FDA-approved prescription medications for TUD versus placebo or no medication 
Nicotine replacement therapy 
Two systematic reviews (Hartmann-Boyce el al., 2018; Patnode et al., 2015 ;) found that nicotine 
replacement therapy is associated with greater likelihood of smoking cessation than placebo or 
psychotherapy alone. These systematic reviews included RCTs of nicotine inhalers and nicotine nasal 
spray, the two forms of nicotine replacement therapy for which a prescription is required, as well nicotine 
patches, gum, and lozenges, which are available without a prescription. 
A systematic review (Hartmann-Boyce el al., 2018) (136 studies) comparing any type of nicotine 
replacement therapy) and a placebo or non-nicotine replacement therapy control group concluded that 
there is high-quality evidence that nicotine replacement therapy increases quit rates at six months or 
longer in adults. The systematic review (131 trials, 133 comparisons; 64,600 people) found that each of 
the six forms of nicotine replacement therapy studied (gum, patch, inhalator, tablets/lozenges, intranasal 
spray, oral spray) significantly increased the rate of cessation compared to placebo or no nicotine 
replacement therapy. Pooled estimates from four RCTs of nicotine inhalers indicate that people who were 
treated with nicotine inhalers were 1.9 times as likely to abstain from smoking as people who received a 
placebo. Pooled estimates from four RCTs of nicotine nasal spray indicate that people treated with 
nicotine nasal spray were twice as likely to abstain from smoking as people who received a placebo. 
A systematic review of reviews (54 systematic reviews) (Patnode el al., 2015) comparing any type of 
nicotine replacement therapy with placebo or no nicotine replacement therapy (9 reviews; 51,265 people) 
included Four of the RCTs included in these systematic reviews examined nicotine inhalers and four 
examined nicotine nasal spray. The authors concluded that all forms of nicotine replacement therapy, 
including inhalers and nasal spray, significantly increased the rate of smoking cessation compared with 
placebo or no nicotine replacement therapy. Participants who received some type of nicotine replacement 
therapy were 1.6 times more likely to achieve abstinence at 6 months or longer compared with 
participants in a control group. Seventeen percent of persons who received any form of nicotine 
replacement therapy abstained from smoking for six months or more versus 10% of people who received 
a placebo or no nicotine replacement treatment. 
Six of the RCTs included in these systematic reviews included in Patnode et al. (2015) review of reviews 
directly compared different types of nicotine replacement therapy (e.g., patch versus nasal spray). None 
of these RCTs found statistically significant differences in rates of abstinence from smoking, which 
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suggests that the benefits of forms of nicotine replacement therapy for which a prescription is required are 
similar to those of forms of nicotine replacement therapy that are available without a prescription. Nine 
trials (n=4,664) that compared people who received two types of nicotine replacement therapy to people 
who received a single type of nicotine replacement therapy were 1.4 times more likely to abstain from 
smoking. 
Bupropion SR 
In a systematic review of reviews (54 systematic reviews) (Patnode el al., 2015) (3 reviews; 13,728 
people) found a statistically significant benefit to taking bupropion SR versus taking a placebo or no 
pharmacotherapy on smoking abstinence at 6 months.  
A meta-analysis (6 trials; sample size: 5-61) comparing bupropion SR to placebo in people with tobacco 
use disorder who also have a serious mental illness, found bupropion SR more effective (defined as self-
reported sustained smoking cessation, verified biochemically at the longest reported time-point) than 
placebo (Roberts et al., 2016). 
One small RCT of 65 pregnant women (Nanovskaya et al., 2017) found individual smoking cessation 
counseling along with bupropion SR sustained release increased smoking cessation rates and reduced 
cravings and total nicotine withdrawal symptoms during the treatment period. However, there was no 
significant difference in abstinence rates between groups at the end of bupropion treatment and at the 
end of pregnancy, perhaps because of the small sample size. 
Varenicline 
A systematic review (Cahill et al., 2016) found high-quality evidence that participants who received 
varenicline at standard dose (1.0 mg twice a day) had between a two-and a three-fold chance of 
successful long-term smoking cessation compared to participants who received a placebo (27 trials, 
12,625 people). Varenicline at lower or variable doses was also shown to be effective (4 trials, 1,266 
people) and lower dose regimens reduced the incidence of adverse events (4 trials).  
These findings were consistent with those of a previous systematic review of reviews (Patnode et al., 
2015). The authors conducted a meta-analysis and concluded that participants who received varenicline 
were twice as likely abstain from smoking six months or more after treatment ended than participants who 
received a placebo (14 trials, 6,166 people). 
A systematic review (3 RCTs;744 people) on the effectiveness of varenicline in smokeless tobacco 
cessation found significantly higher 7-day point prevalence of smokeless tobacco abstinence at 12 weeks 
(48% vs. 33%) but not at 26 weeks (49% vs. 39%) among participants who received varenicline than 
among participants who received a placebo (Schwartz et al., 2016).  
One small RCT (60 participants) of clinically stable adult patients with bipolar disorder found significantly 
more subjects quit smoking with varenicline than with placebo (48.4% v 10.3%) at 3-months. At the end of 
non-treatment follow up at 6-months, a higher percentage of varenicline-treated subjects remained 
abstinent compared to placebo (19.4% v 6.9%), while psychopathology scores remained stable 
(Chengappa et al., 2015). 
One small RCT (33 participants) found varenicline to be effective for increasing smoking abstinence rates 
in smokers with alcohol abuse or dependence. This study showed varenicline may also decrease alcohol 
consumption in this population of smokers (Hurt et al., 2018). 
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Three meta-analyses found varenicline appears to be significantly more effective than placebo in 
assisting with smoking cessation and reduction in people with severe mental illness (Ahmed et al., 2018; 
Roberts et al., 2016; Wu et al., 2016). A meta-analysis (8 studies; 398 people) comparing varenicline to 
placebo in people found that persons with severe mental illness who received varenicline were more 
likely to abstain from smoking and smoked fewer cigarettes per day than persons with severe mental 
illness who received a placebo (mean reduced daily cigarettes was 6.39) (Wu et al., 2016). Another meta-
analysis (5 RCTs; sample size: 5-128) comparing varenicline to placebo in people with TUD who also 
have a mental illness, found varenicline more effective (defined as self-reported sustained smoking 
cessation, verified biochemically at the longest reported time-point) than placebo (Roberts et al., 2016).  
A meta-analysis (4 RCTs; 239 people) of patients with schizophrenia, found varenicline treatment 
significantly reduced the number of cigarettes consumed per day and expired carbon monoxide levels  
relative to placebo (Ahmed et al., 2018). One systematic review found varenicline is not superior to 
placebo for smoking cessation in people with schizophrenia (Kishi et al., 2015). Moreover, there was no 
significant difference in the discontinuation rate due to all causes, clinical deterioration, or side effects 
between varenicline and placebo (Kishi et al., 2015). The difference between Kishi et al (2015) conclusion 
and those of the other three meta-analyses reflect differences in the RCTs included in the meta-analysis. 
Kishi et al. only included RCTs that enrolled persons with schizophrenia whereas Wu et al (2016) and 
Roberts et al (2016) also included RCTs that enrolled people with bipolar disorder. Kishi et al (2015) also 
did not include an RCT that Ahmed et al (2018) included in their meta-analysis because the RCT had not 
been published at the time Kishi et al. completed their analysis.  
Summary of findings regarding the effects of FDA-approved prescription medications versus 
placebo or no medication for treatment of TUD: There is clear and convincing evidence from one 
systematic review of reviews, nine systematic reviews, and three RCTs that people who use nicotine 
replacement therapy, bupropion SR, or varenicline have higher rates of smoking cessation than people 
who receive a placebo or no medication for smoking cessation.  
Figure 9. FDA-approved TUD Medication Versus Placebo or No Medication 
 
Comparison of FDA-approved prescription medications for maintaining abstinence from 
tobacco 
Nicotine replacement therapy vs. bupropion SR 
A systematic review of reviews (Patnode et al., 2015) identified two systematic reviews of studies that 
compared nicotine replacement therapy to bupropion SR. Neither review found a statistically significant 
difference in the rates of smoking cessation six months or more after treatment ended, suggesting that 
the effectiveness of nicotine replacement therapy and bupropion SR do not differ (8 RCTs; 4,086 people). 
Nicotine replacement therapy vs. varenicline 
There is evidence that varenicline is more effective than nicotine replacement therapy (Baker et al., 2016; 
Cahill et al., 2016; Chang et al., 2016; Rohsenow et al., 2017). 
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A systematic review (Cahill et al., 2016) found moderate evidence of that varenicline is more effective 
than nicotine replacement therapy as measured by point prevalence abstinence at 24 weeks (8 RCTs; 
6,264 people). Participants who received varenicline were 1.25 times (95% CI: 1.14-1.37) more likely to 
abstain from smoking at 24 weeks than participants who received nicotine replacement therapy. 
Three studies not included in the systematic reviews found varenicline more effective than nicotine patch 
for tobacco cessation (Chang et al., 2016; Gray et al., 2015; Rohsenow et al., 2017). One comparative 
effectiveness study (Chang et al., 2016) (11,968 participants), found varenicline was associated with 
greater odds of abstinence compared with nicotine replacement patch, at 1 week, 1 month and 6 months 
after initiation of treatment. Varenicline was also associated with higher odds of abstinence in 6 months, 
in both smokers with severe dependence on tobacco and smokers with light/moderate dependence. A 4‐
week RCT (140 females) showed that relative to the nicotine patch varenicline, more than doubled the 
odds of abstinence upon completion of treatment, although this difference diminished at post-treatment 
follow-up and was no longer statistically significant (Baker et al., 2015). Another RCT (Rohsenow et al., 
2017; 137 people) found varenicline improved the odds of achieving at least 3 months of smoking 
abstinence in smokers with substance use disorders who were trying to stop, compared with transdermal 
nicotine patches and that the effect was independent of whether a person had a history of major 
depressive disorder. 
Two studies found no difference in smoking abstinence or quit rates between nicotine replacement 
therapy and varenicline. One RCT (1,086 people) found that treatment, including 12 weeks of open label 
treatment with nicotine patch, varenicline, or combination nicotine replacement therapy (nicotine patch + 
nicotine lozenges) produced no significant differences in biochemically confirmed rates of smoking 
abstinence at 26 or 52 weeks (Baker et al., 2016). One RCT (737 people, including those with medical 
and psychiatric comorbidities) found that participants who received varenicline were more likely to be 
continuously abstinent from smoking at 22 weeks after initiation of treatment than participants who 
received nicotine replacement monotherapy or combination nicotine replacement therapy but that the 
difference was no longer statistically significant at 52 weeks following initiation of treatment (Tulloch et al., 
2016). 
Bupropion SR vs. varenicline 
A systematic review (Cahill et al., 2016) found high-quality evidence (5 RCTS; 5877 people) that 
varenicline is superior to bupropion for sustained abstinence at six months post treatment.  
Another systematic review (Roberts et al., 2016) found both varenicline and bupropion had superior 
treatment efficacy to placebo and were not different from each other. In the review, one trial found when 
comparing varenicline with bupropion, in terms of treatment efficacy, there was no significant advantage 
for one treatment over the other.  
Nicotine replacement therapy vs. nicotine replacement therapy plus bupropion SR 
Thurgood et al.’s (2016) systematic review of RCTs of smoking cessation treatment for persons who have 
both TUD and another SUD, identified two RCTs (253 participants) that compared receipt of nicotine 
replacement therapy alone to receipt of nicotine replacement therapy plus bupropion SR. The RCTs 
found no statistically significant difference in point prevalence and continuous abstinence from smoking 
between the two groups. 
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Varenicline vs. nicotine replacement therapy plus varenicline 
One meta-analysis (3 RCTs; 904 participants) examined both early outcomes (rate of abstinence from 
tobacco assessed before or at the end of treatment) and late outcomes (assessed after the end of the 
treatment). The authors identified one RCT that found that nicotine replacement therapy plus varenicline 
is more effective than varenicline alone, if nicotine patch treatment is administered prior to a participant’s 
target date for tobacco cessation (Chang et al., 2015). Two RCTs in which nicotine patch treatment was 
not administered prior to a participant’s target quit date found no statistically significant difference in 
abstinence rates before, at, or after the end of treatment. 
Varenicline vs. bupropion SR plus varenicline 
One systematic review (Vogeler et al., 2016) of three prospective clinical trials and one retrospective 
outcome research study (N=1,193 people) found combination bupropion SR and varenicline displayed 
greater efficacy in smoking cessation than varenicline monotherapy as measured by 4-week smoking 
abstinence and prolonged abstinence (continuous abstinence from week 2 to weeks 12 and 26 of the 
study). One retrospective study included in the systematic review found that combination bupropion SR 
and varenicline was associated with a higher rate of continuous abstinence at 52 weeks than varenicline 
monotherapy (55% vs. 32%) but this finding was not replicated in the prospective trials.  
Summary of findings regarding the comparative effectiveness of different medications used to 
treat TUD: The preponderance of evidence from studies that have compared nicotine replacement 
therapy to varenicline suggests that varenicline is more effective than nicotine replacement therapy. 
RCTs that have compared nicotine replacement therapy to bupropion SR have found no statistically 
significant differences in tobacco cessation outcomes. There is limited evidence that combining 
varenicline with bupropion SR may improve abstinence from smoking relative to varenicline alone. 
Figure 10. Comparative Effectiveness of Varenicline and Nicotine Replacement Therapy for TUD 
 
Figure 11. Comparative Effectiveness of Nicotine Replacement Therapy and Bupropion SR for TUD 
 
 
Harms associated with use of FDA-approved prescription medications for TUD 
Nicotine replacement therapy 
One Cochrane review (Hartmann-Boyce el al., 2018) found adverse events from using NRT were related 
to the type of product, and include skin irritation from patches and irritation to the inside of the mouth from 
gum and lozenges. Persons who received nicotine replacement therapy had higher odds of chest pains or 
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palpitations relative to control. However, the authors found that chest pains and palpitations were rare in 
both groups and serious adverse events were extremely rare. 
One systematic review (Coleman et al., 2015) (8 studies; 2,199 participants) found no statistically 
significant differences in birth outcomes, including rates of miscarriage, stillbirth, preterm birth (less than 
37 weeks), low birthweight, mean birthweight, admissions of babies to neonatal intensive care or neonatal 
deaths. One RCT (1,050 participants) of women whose infants were followed to two years of age, found 
those born to women who had been randomized to NRT were more likely to have healthy development. 
(Coleman et al., 2015). 
In a systematic review of possible serious adverse health effects of nicotine replacement therapy, Lee 
and Farris (2017) evaluated 34 epidemiological studies and clinical trials regarding the effect of exposure 
to nicotine replacement therapy on risk of cancer, reproductive/developmental effects, cardiovascular 
disease, stroke and/or other SAHEs. The authors found many limitations in the evidence, most 
significantly short-term exposure (≤12 weeks) and follow-up to NRT product use in most of the studies, 
failure to control for changes in smoking behavior following NRT use, and limited information on SAHEs 
by type of NRT product used. The only SAHE associated with NRT exposure was an increase in 
respiratory congenital abnormalities reported in one study. Limited evidence indicated a lack of effect 
between NRT exposure and SAHEs for CVD and various reproduction/developmental endpoints. For 
cancer, stroke and other SAHEs, the evidence was insufficient. 
Bupropion SR 
In a systematic review of reviews (54 systematic reviews) (Patnode el al., 2015), 2 reviews examined the 
harms associated with bupropion SR. One review (Mills et al., 2014; n=10,402) suggested no significant 
increased risk of any cardiovascular event for bupropion SR versus placebo. Another study (Hughes et 
al., 2014; n=9,631) found no statistically significant increase risk in the rate of serious adverse events, 
serious psychiatric events, or serious cardiovascular events among participants who received bupropion 
sustained SR versus placebo. There were 10 cases of seizures within seven trials that comprised 
between 100 and 502 individuals receiving bupropion SR (over 13,000 total participants). 
Varenicline 
A Cochrane review (Cahill et al., 2016) found high-quality evidence that the main adverse effect of 
varenicline was nausea (32 studies; 14,963 participants), which was generally mild to moderate and 
diminished over time. The authors also found that people who used varenicline were not at greater risk of 
neuropsychiatric adverse events, such as depressed mood, agitation, suicidal ideation, and suicidal 
behavior than persons who did not use varenicline. 
One meta-analysis comparing nicotine replacement therapy plus varenicline to varenicline alone (3 RCTs; 
904 participants) found the most common adverse events were nausea, insomnia, abnormal dreams, and 
headache but there were no significant differences in odds of these adverse events between nicotine 
replacement therapy plus varenicline and varenicline alone (Chang et al., 2015). 
Another meta-analysis (Schwartz et al., 2016) comparing varenicline to placebo for smokeless tobacco 
cessation found no statistically significant differences in adverse events reported, including nausea, sleep 
disturbance, and mood disorders but interpretation is limited by high heterogeneity across studies 
included in the meta-analysis. 
One systematic review of RCTs found there was no statistically significant difference in risk of 
neuropsychiatric adverse events, including risk of suicide or attempted suicide, suicidal ideation, 
Analysis of California Senate Bill 11 
Current as of February 13, 2019 www.chbrp.org 36 
depression, irritability, aggression, or death, between participants who received varenicline and 
participants who received a placebo (39 RTCs; 10,761 participants). Varenicline was associated with an 
increased risk of sleep disorders, insomnia, abnormal dreams, and fatigue but a reduced risk of anxiety 
(Thomas et al., 2015).  
Summary of findings regarding harms associated with FDA-approved prescription medications for 
TUD: Use of FDA-approved prescription medications for TUD is not associated with increased risk of 
serious adverse events, including poor birth outcomes, cancer, cardiovascular disease, stroke, and 
neuropsychiatric events. Varenicline is associated with mild to moderate side effects, including abnormal 
dreams, fatigue, headache, insomnia, nausea, and sleep disorders. 
 
Effects of utilization management on use of FDA-approved prescription medications for TUD 
and outcomes 
Findings from one retrospective cohort analysis study (N=15,597) found that prior authorization and step-
therapy requirements for varenicline reduced the likelihood that people would fill a prescription for any 
pharmacotherapy for TUD. Among persons enrolled in health plans included in the study, 63.9% of 
persons who had a claim for varenicline rejected due to a requirement for prior authorization filled a 
prescription for any pharmacotherapy for TUD. Among those who faced a step therapy requirement, 46% 
filled a prescription for any pharmacotherapy for TUD. This study also found that people who had higher 
out-of-pocket costs for pharmacotherapy for TUD had lower odds of filling a prescription. There was a 
statistically significant reduction in the odds of filling a prescription for all levels of out-of-pocket costs 
above $0 to $5 (Zeng et al., 2011). 
One retrospective cohort study (15,452 participants) found that among Medicare beneficiaries newly 
initiated on varenicline, greater out of pocket cost was associated with lower adherence, as measured by 
the proportion of days for which a person had medication available, and lower odds of refilling a 
prescription for varenicline (Suehs et al., 2014). 
Summary of findings regarding the effects of utilization management for FDA-approved 
medications for TUD: There is limited evidence that higher cost sharing is associated with lower rates of 
adherence to varenicline. This finding suggests that requiring health plans to place varenicline in the 
lowest tier on its formulary, which SB 11 would require, may improve adherence to varenicline. CHBRP 
did not identify any studies of effects of utilization management or cost sharing on use of nicotine 
replacement therapy or bupropion SR. 
Figure 12. Impact of Utilization Management on Use of FDA-approve Prescription Medications for TUD 
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Summary of Findings 
Table 6 summarizes evidence of the effectiveness of FDA-approved prescription medications for OUD, 
AUD, and TUD when prescribed and used as directed. Evidence is reported separately for (1) 
prescription medication versus a placebo or no treatment, and (2) comparison of different prescription 
medications used to treat OUD, AUD, and TUD. Findings differ substantially by comparison. There is 
clear and convincing evidence from multiple RCTs that, with the exception of orally administered 
naltrexone for OUD and disulfiram for AUD, medications are more effective than a placebo or no 
treatment for abstinence from opioids, alcohol, or tobacco. Evidence regarding the relative effectiveness 
of different medications for OUD, AUD, and TUD differs depending on the medications that are compared 
to one another. Most harms associated with medications for OUD, AUD, and TUD are mild with the 
exception of naltrexone. This medication is associated with a higher rate of overdose prior to initiation of 
treatment because users must be abstinent from opioids before starting treatment whereas methadone 
and buprenorphine treatment can be initiated before a person is weaned off other opioids. There is 
insufficient evidence to determine the impact of prohibiting prior authorization and step therapy and 
requiring that all FDA-approved pharmacotherapies for SUD be placed on the lowest tier of a health 
plan’s formulary. 
Figure 133. Summary of Findings 
Type of SUD 
Medication vs. 
Placebo or No 
Treatment  
Comparison of 
Different Medications 
Impact of Utilization 
Management  
OUD 
Clear and convincing 
evidence favors 
methadone, 
buprenorphine (including 
buprenorphine-nalaxone); 
preponderance of 
evidence that orally 
administered naltrexone is 
not effective 
Inconclusive evidence Insufficient evidence 
AUD 
Clear and convincing 
evidence favors 
acamprosate and  
naltrexone; limited 
evidence that disulfiram is 
not effective 
Inconclusive evidence Insufficient evidence 
TUD 
Clear and convincing 
evidence favors 
prescription medications 
Preponderance of 
evidence favors 
varenicline over nicotine 
replacement therapy; no 
difference between 
nicotine replacement 
therapy and bupropion 
Limited evidence that 
higher cost sharing 
reduces use of 
varenicline. 
Source: California Health Benefits Review Program, 2019.  
Key: AUD = alcohol use disorder, OUD = opioid use disorder, TUD = tobacco use disorder 
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BENEFIT COVERAGE, UTILIZATION, AND COST IMPACTS 
As discussed in the Policy Context section, SB 11 would require DMHC-regulated health plans, including 
non-County Organized Health Systems (COHS) Medi-Cal managed care plans, and CDI-regulated 
policies that include a pharmacy benefit to (1) cover outpatient prescription medications approved by the 
FDA for treatment of substance use disorders (SUD), (2) move those medications to tier 1 (i.e., the lowest 
tier) of the formulary, (3) not require step therapy (or “fail first” protocols) or prior authorization for the 
medications, and (4) not deny coverage due to related court orders for treatment.  
Approximately 95.6% of enrollees in all (commercial and Medi-Cal managed care) DMHC-regulated plans 
and CDI-regulated policies have pharmacy benefit coverage and would be subject to SB 11. Of the 
remaining enrollees, 1.4% have no pharmacy benefit and 3.0% have pharmacy benefit coverage that is 
not regulated by DMHC or CDI. SB 11 does not address these forms of health insurance and so no 
mandate-related change in benefit coverage or utilization would be expected for these enrollees. CHBRP 
treats commercial DMHC- and CDI-regulated plans that have no pharmacy benefit, which represent 7% of 
enrollees in commercial DMHC or CDI-regulated plans, as compliant with SB 11 because they do not 
have to make any changes in response to SB 11. The remaining 93% of commercial enrollees in plans 
with a pharmacy benefit are partially compliant because they already comply with at least one component 
of SB 11, but not all. See Appendix D for a further discussion of pharmacy benefit coverage.  
This section reports the potential incremental impacts of SB 11 on estimated baseline benefit coverage, 
utilization, and overall cost. The benefit coverage, utilization and cost impacts discussed here are based 
upon published evidence (see the Medical Effectiveness section and several key assumptions in addition 
to those described in the Policy Context section about the scope of SB 11.  
The estimates are based upon the following core assumptions informed by existing claims data on 
practice patterns, use of SUD treatments. The Medical Effectiveness section, and consultation with a. 
context expert: 
• CHBRP anticipates that enrollees who gain coverage for opioid use disorder (OUD) drugs due to 
SB 11 (i.e., new users) would experience care commensurate with the typical pattern of care 
seen in patients already getting OUD treatment through their insurance plans in terms of dosing, 
frequency of refills, and patient needs. The impact of changes to prior authorization, step therapy, 
and cost sharing are in addition to this coverage-related increase and discussed below. 
• There will be no additional use of methadone or injectable buprenorphine for treatment of OUD 
because SB 11 does not address prescription medications that are administered by clinicians and 
reimbursed through the medical benefit. 
• Use of prescriptions for FDA-approved drug treatment for OUD, except in the case of oral 
naltrexone (due to preponderance of evidence that it is not effective, see Medical Effectiveness 
section), will increase by 10% for both new and existing commercial enrollees due to the removal 
of prior authorization and step therapy (i.e., fail first) requirements resulting in an overall increase 
in use of OUD treatment services including behavioral therapy and medication when associated 
with use of those medications. 
• The proportion of Medi-Cal managed care OUD enrollees receiving most FDA-approved drug 
treatment for their OUD will not increase because of existing coverage with limited treatment 
authorization request requirements for each drug. The one exception is the auto-injector version 
of naloxone, which is expected to increase in use due to the removal of current barriers to use. 
CHBRP anticipates that the removal of prior authorization and step therapy requirements will 
increase auto-injector naloxone use such that it represents 50% of the prescriptions for naloxone, 
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with the nasal spray representing the remaining prescriptions for OUD enrollees. OUD enrollees 
would be able to fill these prescriptions via their Medi-Cal managed care plan without restriction, 
when compared to the fee-for-service Medi-Cal program, which requires a prior authorization. 
• Use of FDA-approved drug treatment for alcohol use disorder (AUD), except in the case of 
disulfiram (due to limited evidence of ineffectiveness, see Medical Effectiveness section), will 
increase by 10% for both new and existing commercial enrollees due to the removal of prior 
authorization and step therapy (i.e., fail first) requirements resulting in an overall increase in use 
of most AUD treatment services including behavioral therapy and medication when associated 
with use of those medications.  
• The proportion of Medi-Cal managed care AUD enrollees receiving most FDA-approved drug 
treatment for their AUD will not increase because of existing coverage with limited treatment 
authorization request requirements for each drug.  
• Use of FDA-approved drug treatment for TUD, except in the case of nicotine nasal spray, will 
increase by 10% for both new and existing commercial and Medi-Cal managed care enrollees 
due to the removal of prior authorization and step therapy (i.e., fail first) requirements resulting in 
an overall increase in use of most TUD treatment services including behavioral therapy and 
medication when associated with use of those medications.  
• Reductions in cost sharing due to movement of a drug onto tier 1 of the formulary could shift use 
for both existing users and new users of OUD (commercial enrollees only), AUD (commercial 
enrollees only), and tobacco use disorder (TUD) (commercial and Medi-Cal managed care 
enrollees) to more effective or expensive services that are now required to be covered without 
prior authorization or step therapy requirements and via tier 1 of the formulary. 
• In the postmandate absence of prior authorization or step therapy requirements for medications, 
CHBRP assumes utilization of supportive counseling services by persons with OUD and AUD will 
increase by 12.5% from the baseline utilization level among enrollees with commercial health 
insurance subject to SB 11. While SB 11 does not explicitly remove utilization management 
requirements for use of counseling, the increase in enrollees seeking and obtaining medication 
treatment is likely to result in a marginal increase in counseling services related to OUD and AUD 
treatment. 
Other considerations: 
• Prior to SB 11, only 20% of enrollees with OUD (which has a 0.51% to 1.1% prevalence rate in 
the overall population) receive FDA-approved medications. This underuse of OUD treatment is 
not necessarily related to insurance coverage for treatment and is more likely due to other 
factors, such as willingness to enter treatment. 
• Prior to SB 11, less than 1% of enrollees with AUD and TUD received FDA-approved medications 
despite a 5.51% prevalence rate for AUD and 16.23% prevalence rate for TUD. Underuse of 
drugs to treat both conditions is linked to provider practice patterns, willingness to enter 
treatment, and other options available that do not rely on prescription drugs (e.g., over-the-
counter nicotine replacement therapy, Alcoholics Anonymous). 
• CHBRP consulted the literature and a content expert regarding physician practice patterns 
around AUD and TUD treatment. It appears that the low use of AUD and TUD drugs is not 
necessarily driven by insurance benefits coverage, utilization management, or cost sharing. It is 
partially related to physician practices around prescribing and treatment of these two conditions, 
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which results in relatively low utilization of FDA-approved medications, which is unlikely to change 
due to SB 11. 
CHBRP anticipates cost and utilization offsets for OUD and AUD enrollees who become new users of 
FDA-approved medications. These offsets are described in the Potential Cost Offsets or Savings in the 
First 12 Months After Enactment section. 
For further details on the underlying data sources and methods, please see Appendix C. 
Baseline and Postmandate Benefit Coverage 
Current coverage of medication for OUD, AUD, and TUD was determined by surveying the largest (by 
enrollment) providers of health insurance in California, including DMHC-regulated Medi-Cal managed 
care plans. Responses to the survey related to SUD medication coverage represent 89% of enrollees 
with commercial market health insurance and 57% of enrollees in the DMHC-regulated Medi-Cal 
managed care market that can be subject to state mandates. Due to the fee-for-service Medi-Cal carve-
out for specific pharmacy services for treatment of OUD and AUD, prior to SB 11 there was no coverage 
in the regulated Medi-Cal managed care plans, though 100% of Medi-Cal enrollees had coverage for the 
AUD and OUD drugs via the fee-for-service Medi-Cal carve-out. TUD is already included in the benefits 
required of Medi-Cal managed care plans. As noted in Table 1, 93% of commercial enrollees have health 
insurance that is partially compliant with SB 11 because they have a pharmacy benefit, cover some or all 
of the FDA-approved medications for SUD treatment, and have prior authorization or step therapy 
restrictions attached to their coverage one or more medications. No plans reported restricting access to 
SUD services for court ordered treatment. 
Opioid Use Disorder (OUD) Outpatient Medication Coverage 
Table 5 demonstrates that the vast majority of commercial enrollees have on-formulary coverage for the 
FDA-approved medications for treatment of OUD. 80% or more of enrollees have coverage for OUD 
medications (buprenorphine, methadone, naloxone, naltrexone, and combination 
buprenorphine/naltrexone), except for lofexidine which is only covered for 11% of enrollees. Table 5 
demonstrates that most commercial enrollees are not subject to prior authorization for OUD-related 
medications (ranges from 0% for naloxone and naltrexone to 16% for lofexidine). Most enrollees are not 
subject to step therapy for OUD-related medications (ranging from 0% for naltrexone, lofexidine, and 
combination buprenorphine/naloxone to 4% for buprenorphine, methadone, and naloxone). 
Currently, 0% of Medi-Cal beneficiaries enrolled in managed care plans have health insurance fully 
compliant with the proposed mandate due to the existing Medi-Cal carve-out. It is important to note that 
SB 11 would leave the existing carve-out in place for fee-for-service Medi-Cal with existing utilization 
management requirements (like treatment authorization requests) and formulary limitations, and set up 
parallel coverage by Medi-Cal managed care plans without those same barriers to utilization for enrollees 
(Table 6). However, based on content expert input, CHBRP determined that a shift from Medi-Cal fee-for-
service to Medi-Cal managed care plans for treatment and payment would be unlikely due to the 
comprehensive coverage of the FDA-approved drugs for OUD with limited utilization review, prior 
authorization, step therapy requirements, and no cost sharing. The only drug subject to significant prior 
authorization via Medi-Cal fee-for-service is auto-injector naloxone, which CHBRP estimated would 
increase in use via the Medi-Cal managed care plans new parallel coverage and lack of prior 
authorization or step therapy requirements.  
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Alcohol Use Disorder (AUD) Outpatient Medication Coverage 
Table 5 demonstrates that the vast majority of commercial enrollees have on-formulary coverage for the 
FDA-approved medications for treatment of AUD mentioned in SB 11. 82% of enrollees have coverage 
for AUD medication (acamprosate, naltrexone, and disulfiram). Table 5 demonstrates that most enrollees 
already have access to AUD medications on tier 1 of the formulary (ranging from 63% for acamprosate to 
82% for disulfiram and naltrexone). In addition, no enrollees with coverage are subject to prior 
authorization for naltrexone and disulfiram. Only 1% need prior authorization for acamprosate). No 
enrollees are subject to step therapy for AUD-related medications. Despite fairly comprehensive coverage 
for the AUD drugs and virtually no prior authorization or step therapy requirements, use of these FDA-
approved drugs to treat AUD remains very low. 
Currently, 0% of Medi-Cal beneficiaries enrolled in managed care plans have health insurance fully 
compliant with the proposed mandate due to the existing Medi-Cal carve-out. It is important to note that 
SB 11 would leave the existing carve-out in place for fee-for-service Medi-Cal with existing utilization 
management requirements (like treatment authorization requests) and formulary limitations, and set up 
parallel coverage by Medi-Cal managed care plans without those same barriers to utilization for enrollees. 
However, based on content expert input, CHBRP determined that a shift from Medi-Cal fee-for-service to 
Medi-Cal managed care plans for treatment and payment would be unlikely due to the comprehensive 
coverage of the FDA-approved drugs for AUD with limited utilization review, prior authorization, step 
therapy requirements, and no cost sharing.  
Tobacco Use Disorder (TUD) Outpatient Medication Coverage 
Table 5 demonstrates that fewer commercial enrollees have on-formulary coverage for the FDA-approved 
medications for treatment of TUD mentioned in SB 11. While 81% of enrollees have coverage for 
varenicline and 82% have coverage for buproprion HCL SR, 27% have coverage for Nicotine inhalers or 
nasal spray. Buproprion HCL SR is on tier 1 of the formulary for 76% of enrollees, while varenicline is on 
tier 1 of the formulary for 60% of enrollees with coverage for the medication. Only 6% of those with 
coverage for the nicotine inhaler and nasal spray have access to the two medications on tier 1 of the 
formulary. However, no plans reported restricting utilization of any TUD medications that were covered via 
step therapy or prior authorization requirements. 
TUD medications are not subject to the Medi-Cal carve-out in place for OUD and AUD medications. Table 
7 demonstrates that 100% of enrollees have coverage for all TUD medications. However, prior 
authorization and step therapy requirements vary. 8% of enrollees have prior authorization requirements 
to access Buproprion HCL SR, although no enrollees are subject to step therapy requirements. For 
varenicline, nicotine inhaler and nasal spray, 21% of enrollees are subject to prior authorization and 8% 
are subject to step therapy requirements (Table 6). 
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Table 5. SB 11 Treatment-Specific Baseline Benefit Coverage for Commercial Enrollees and CalPERS 
Medication % of enrollees 
with on-
formulary 
medication 
coverage  
% of enrollees with on-formulary medication 
coverage that is… 
 …on tier 1 of 
the formulary 
(commonly the 
tier for 
generics) 
…Subject to 
prior 
authorization 
requirements  
… Subject to 
step therapy, 
fail-first,  
protocols  
Buprenorphine 80% 0% 5% 4% 
Methadone 82% 0% 1% 4% 
Naloxone 82% 0% 0% 4% 
Naltrexone 80% 0% 0% 0% 
Combination 
Buprenorphine/Naloxone 
80% 0% 1% 0% 
Lofexidine 11% 0% 16% 0% 
Nicotine - Inhaler 27% 6% 0% 0% 
Nicotine - Nasal Spray 27% 6% 0% 0% 
Varenicline 81% 60% 0% 0% 
Buproprion HCL SR 82% 76% 0% 0% 
Acamprosate 82% 63% 1% 0% 
Naltrexone - Oral 82% 82% 0% 0% 
Disulfiram 82% 82% 0% 0% 
Source: California Health Benefits Review Program, 2019. 
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Table 6. SB 11 Treatment-Specific Baseline Benefit Coverage for Medi-Cal Managed Care Plans 
Medication % of enrollees with 
on-formulary 
medication 
coverage 
% of enrollees with on-formulary medication 
coverage that is… 
 …Subject to prior 
authorization 
requirements  
… Subject to step 
therapy, or fail-first 
protocols 
Buprenorphine Carved Out* Carved Out* Carved Out* 
Methadone Carved Out* Carved Out* Carved Out* 
Naloxone Carved Out* Carved Out* Carved Out* 
Naltrexone Carved Out* Carved Out* Carved Out* 
Combination 
Buprenorphine/Naloxone 
Carved Out* Carved Out* Carved Out* 
Lofexidine Carved Out* Carved Out* Carved Out* 
Nicotine - Inhaler 100% 21% 8% 
Nicotine - Nasal Spray 100% 21% 8% 
Varenicline 100% 21% 8% 
Buproprion HCL SR 100% 8% 0% 
Acamprosate Carved Out Carved Out Carved Out 
Naltrexone - Oral Carved Out Carved Out Carved Out 
Disulfiram 100% 8% 0% 
Source: California Health Benefits Review Program, 2019. 
Notes: (*) Carved Out” refers to the fact that Opioid use disorder and alcohol use disorder medication–related coverage for Medi-Cal 
beneficiaries is generally carved out from their DMHC-regulated plan coverage but available through fee-for-service Medi-Cal. 
Baseline and Postmandate Utilization 
Commercial (large group, small group, and individual market) and CalPERS enrollees, as well as a 
majority of Medi-Cal beneficiaries are enrolled in DMHC-regulated plans which would be subject to SB 
11. Additional commercial enrollees are enrolled in CDI-regulated policies, which would also be subject to 
SB 11. Baseline FDA-approved medication and counseling costs and associated utilization for the private 
insurance market were based on 2016 Milliman commercial claims and enrollment data for the state of 
California with few exceptions. The Medi-Cal medication and counseling costs and associated utilization 
were based upon Medi-Cal claims and encounter data for a subset of counties in the state, collected by 
Milliman. 
Opioid Use Disorder Utilization 
Enrollees with OUD with coverage for medications in commercial plans use approximately 11.59 
methadone, 4.23 buprenorphine, 6.48 combination buprenorphine-naloxone, 2.3 naltrexone, and 1.0 
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naloxone prescriptions per year (see Table 1). Enrollees with OUD could be receiving treatment through 
multiple modalities within a 1-year period of time, but are typically receiving one to two distinct treatments 
at any given time. For example, someone who is receiving buprenorphine treatment may also have 
obtained naloxone preventively for overdose reversal in emergency situations. 
Except in the case of methadone, postmandate utilization of OUD-related FDA-approved maintenance 
medications would be expected to increase due to the removal of prior authorization and step therapy 
requirements and movement of FDA-approved treatments to tier 1 of the formulary in 93% of plans. This 
would result in existing users experiencing a slight increase in use, while new users of services would 
experience an equivalent level of use. Overall, due to the mix of plans use of drug coverage restrictions, 
prior authorization, step therapy, and formulary tiers, would result in varying increases in the use of 
specific drugs: 8.7% increase in Buprenorphine, compared with 28.2% increase in combination 
buprenorphine/naloxone. In addition, Behavioral therapy is anticipated to increase by 12.5% in overall 
visit per year based upon new users of OUD medication seeking out behavioral therapy services related 
to their new receipt of FDA-approved OUD treatment (see Table 1).  
Alcohol Use Disorder Utilization 
Enrollees with AUD with coverage for medications in commercial plans use approximately 1.85 
Acamprosate, 2.77 Naltrexone, and 2.56 Disulfiram prescriptions per year (see Table 1). Enrollees with 
AUD could be receiving treatment through multiple modalities within a 1-year period of time, but are 
typically receiving one distinct treatment at any given time.  
Postmandate utilization of AUD medications would be expected to increase due to the removal of prior 
authorization and step therapy requirements in 93% of plans resulting in new users of services, along with 
the movement of all drugs to tier 1 of the formulary. Due to the variation in coverage for the AUD drugs, 
along with prior authorization, step therapy and formulary differences CHBRP estimates the use of 
Acomprosate would increase by 12.4% to 2.08 prescriptions per user per year while that of Naltrexone 
would increase by 16.6% to 3.23. Disulfiram would only increase by 3.7%, partially due to the already 
high levels of coverage for the drug and issues with physician prescribing, patient compliance and 
adherence.  
Tobacco Use Disorder Utilization 
Based on current Milliman commercial and Medi-Cal claims analysis, enrollees with TUD with coverage 
for medications use approximately 3.46 buproprion HCL SR, 1.55 nicotine inhaler, 4.37 nicotine nasal 
spray, and 2.07 varenicline prescriptions per year (see Table 1).  
Postmandate utilization of TUD medications are estimated to increase by 2.6% for nicotine inhalers and 
49.2% for nicotine nasal spray due to the new coverage of the drugs (only 27% of enrollees had coverage 
prior to the mandate) and movement to tier 1 on the formulary resulting in new users of services. 
However, these same changes are estimated to result in slight reductions in use of varenicline (-0.5%) 
and buproprion HCL SR (-1.2%) due to medication changes and cost-sharing differences. 
Baseline and Postmandate Per-Unit Cost  
Table 1 provides an estimate of 30-day costs of each type of FDA-approved SUD medication based upon 
Milliman analysis of current use by commercial enrollees with OUD and Medi-Cal claims for those on TUD 
medications. The actual unit cost of services would not be anticipated to change postmandate, though the 
frequency of services would increase due to new users and removal of prior authorization, step therapy, 
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and limited formulary coverage. Due to the removal of utilization management related to brand-name 
medication use, CHBRP assumes that emergency doses of naloxone provided to OUD patients being 
treated with FDA-approved medication for “rescue” overdose reversal purposes would shift to easier to 
use methods (i.e., nasal spray and auto-injectors) due to lack of prior authorization, step therapy, and 
formulary limitations. The postmandate increase in naloxone prescribed to OUD medication patients 
would be split 50/50 between nasal spray and auto-injectors in both the commercial and Medi-Cal 
managed care enrollees due to the prior authorization requirements being removed and the substantial 
reduction in cost sharing due to being moved to tier 1 on the formulary. 
Baseline and Postmandate Expenditures 
Table 8 and Table 9 present baseline and postmandate expenditures by market segment for DMHC-
regulated plans and CDI-regulated policies. The tables present per member per month (PMPM) 
premiums, enrollee expenses for both covered and noncovered benefits, and total expenditures 
(premiums as well as enrollee expenses). 
SB 11 would increase total net annual expenditures by $20,671,000 or 0.0133% for enrollees with 
DMHC-regulated plans and CDI-regulated policies. This increase is primarily driven by an increase of 
$17,820,000 (0.0257%) in spending by private employers for group insurance and $6,018,000 (0.0283%) 
in spending by enrollees with group insurance, CalPERS HMOs, and small group Covered California 
policies. 
Premiums 
Changes in premiums as a result of SB 11 would vary by market segment (Table 9). In the commercial 
market, premium increases will occur in all commercial DMHC- and CDI-regulated plans, ranging from a 
high of 0.1354% in the individual CDI-regulated market to a low of 0.0110% in the CDI-regulated small 
group market. Among publicly funded plans, CalPERS HMO premiums would increase by 0.0105% while 
Medi-Cal managed care premiums would increase by 0.0041% for the under 65 population.  
Overall, there is a net 0.0227% increase in total health insurance premiums paid by employers, enrollees, 
and Medi-Cal for newly covered benefits. These differences in premium increases are driven by the 
underlying variation in coverage of specific drugs, use of prior authorization and step therapy, and 
formulary restrictions at baseline. In some market segments, plans were already in compliance and would 
therefore experience very limited changes in utilization, expenditures, and premiums, while in other 
market segments with limited compliance, the relative cost would be higher. 
Enrollee Expenses 
SB 11-related changes in enrollee expenses for covered benefits (copays and coinsurance) vary by 
market segment. Note that such changes are related to the number of enrollees (see Table 1, Table 8, 
and Table 9) with health insurance that would be subject to SB 11 expected to use the prescription 
medications during the year after enactment. 
CHBRP projects a reduction in copayments or coinsurance rates for users and an increase in prescription 
medications. However, because cost sharing requirements are limited by the SB 11 requirement to move 
drugs to tier 1 of the formulary, there is a decrease in total enrollee cost sharing. Enrollee out-of-pocket 
expenses are expected to decrease by $11,184,000 (-0.0751%) overall. Due to limitations on Medi-Cal 
managed care plans use of cost sharing, the enrollee cost sharing changes are concentrated on the 
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commercial market and relate to the overall increase in service use and associated cost sharing for new 
services used by OUD, AUD, and TUD users. 
Decreases in commercial enrollee per member per month expenses for covered benefits are estimated 
from a low of -$0.0167 in CalPERS HMOs to a high of -$0.2939 in CDI-regulated individual commercial 
plans (Table 10).  
Out-of-Pocket Spending for Covered and Noncovered Expenses 
When possible, CHBRP estimates the marginal impact of the bill on out-of-pocket spending for covered 
and noncovered expenses, defined as uncovered medical expenses paid by the enrollee as well as out-
of-pocket expenses (e.g., deductibles, copayments, and coinsurance). CHBRP estimates are based on 
claims data and may underestimate the cost savings for enrollees due to carriers’ ability to negotiate 
discounted rates that are unavailable to patients and their families. 
As noted in Table 1, SB 11’s would decrease total enrollee out-of-pocket spending for covered benefits 
(cost-sharing) by less than 0.1%. For enrollees using medications approved by the FDA for SUDs, SB 
11’s coverage requirements (on formulary and subject to tier 1 or no cost sharing) would create varied 
impacts. As noted in Table 7, cost-sharing impacts among enrollees using the medications would range 
from no impact (for Medi-Cal beneficiaries, who have no premandate cost sharing) to an average annual 
decrease of $418.28 among enrollees in individual market plans and policies. 
Table 7. Cost Sharing Impact of SB 11 
  Large Group 
Small 
Group 
Individual CalPERS 
HMO MediCal 
HMO 
% of Enrollees with Cost Sharing Impact 
from the Mandate (a) 
 
 
0.4% 0.4% 0.4% 0.3% 0.0% 
Avg Annual Cost Sharing Impact Enrollees 
using FDA approved medications for 
SUDs (b) 
 $     (85.82)  $    (306.66)  $    (418.28)  $     (74.79)  $           -    
Source:  California Health Benefits Review Program, 2019 
Notes: (a) Not including impacts on premiums; (b) Benefit coverage for Medi-Cal beneficiaries does not generally include any cost-
sharing, which would not be changed by SB 11.   
It is possible that some enrollees incurred expenses related to treatment and prescription medications for 
which coverage was denied, but CHBRP cannot estimate the frequency with which such situations occur 
and so cannot offer a calculation of impact. In the case of SB 11, enrollees for TUD may be using over-
the-counter nicotine replacement therapy products that could be replaced by prescription drugs to treat 
TUD. However, due to patient and physician attitudes, compliance and adherence CHBRP does not 
estimate a shift in use of those treatment options. 
Potential Cost Offsets or Savings in the First 12 Months After Enactment 
Results indicate that almost all commercial enrollees have on-formulary coverage for the listed drugs and 
counseling services – but no enrollees had benefit coverage entirely free of the utilization management 
tools SB 11 would prohibit or with all SUD drugs on tier 1 as required by SB 11 (see Tables 6 and 7). The 
removal of utilization management and reduction of cost-sharing is expected to increase the number of 
users of SUD drugs and associated counseling services by approximately 10% for commercial OUD and 
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AUD members, and by approximately 10% for commercial and Medi-Cal managed care TUD members. 
CHBRP assumed no change in utilization for disulfiram, oral naltrexone for OUD, injectable 
buprenorphine and methadone. 
Postmandate Offset Services – Inpatient, Outpatient, and Professional 
There are likely to be changes in the utilization of non-SUD-related services as a result of receiving SUD 
treatment. Mohlman et al. (2016) indicated reductions in inpatient, emergency, medical specialist, and 
imaging services and increases in PCP visits and surgical specialist visits. Any side effects or harms 
associated with increased use of SUD medications are not measurable in terms of increased health 
service use or spending. The Mohlman et al. (2016) study included data on utilization offsets that would 
have included additional office visits or services that may have resulted from both minimal side effects 
(i.e., redness or swelling at injection sites) and larger harms, like increased risk of overdose when patients 
treated with naltrexone who discontinue treatment may be sensitive to lower doses of opioids, which 
could increase their risk of overdose (SAMHSA, 2015). In general, the utilization and cost offsets 
calculated in this report take into consideration added health services use and spending, regardless of 
whether it is associated with the direct cost of the treatment or additional services associated with side 
effects. Please see Medical Effectiveness section for literature on other harms. 
Unit costs were estimated using a combination of the Mohlman estimates, CHSD data, and relationships 
between commercial and Medi-Cal unit costs. CHBRP relied upon CHSD data for commercial and Medi-
Cal utilization and cost estimate. There is no assumed differential in average cost per service pre- and 
postmandate.  
Table 8. Selected Offsets: Avoided Inpatient Days, Inpatient Detoxification, and Emergency Department 
Visits 
 
Average 
Utilization 
Change per SUD 
Treatment User 
Commercial Unit 
Cost  
Medi-Cal Unit 
Cost 
OUD Inpatient 
Days -1.46 $8,360  $3,356 
OUD Detox 
Days -1.46 $1,379  $2,795 
OUD ED Visits -1.04 $3,723  $400 
AUD Inpatient 
Days -0.436 $9,285  $3,308 
AUD Detox 
Days -0.457 $1,433  $2,682 
AUD ED Visits -0.044 $4,225  $393 
Source: California Health Benefits Review Program, 2019. 
Generally, the literature suggests that OUD treatment with methadone, buprenorphine, naloxone, or 
naltrexone lead to better outcomes and reduced overall spending when compared with no use (McCarty, 
2010; Tkacz, 2014). Despite sizeable costs of OUD medication services, the recipients in the articles 
mentioned above experienced 43% lower spending on average for inpatient and outpatient services. 
These studies suggest in aggregate that OUD medication services are likely to result in short- and long-
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term savings (see the Long-Term Impacts section). CHBRP used literature focused on utilization change 
due to OUD medication treatment to inform its cost model estimates. 
To estimate the cost offsets for OUD medication likely to occur due to SB 11. CHBRP relied on one article 
that isolates the impact of Medication-Assisted Treatment (MAT) on health services utilization in the 
Vermont Medicaid program (Mohlman et al., 2016). The article suggests that increases in MAT are offset 
by decreases in spending on inpatient days and stays, emergency room visits, and imaging. However, 
Mohlman et al. found an increase in the use of other services, including surgical appointments and 
primary and specialty care services. 
CHBRP applied estimated utilization and cost offsets based on published evidence (Mohlman et al., 
2016; Mark et al., 2010) on the impact of OUD-related medication and counseling treatment on 
emergency room use, inpatient services, outpatient physician services, inpatient detoxification, and other 
OUD-related services. There is evidence that TUD prescription medications, specifically Varenicline, are 
prescribed less often than indicated and that adherence is low, despite existing coverage by insurance 
benefits (Burke et al., 2016). For both OUD and AUD, CHBRP estimates that use of outpatient counseling 
services would increase by 0.5 visit per year for new users, although it would be subject to prior 
authorization and other utilization review unlike the FDA-approved medications covered by SB 11. 
These cost offsets for new users only are reflected in Table 1 and the estimates for expenditures and 
premium changes in 2019.  
Postmandate Administrative Expenses and Other Expenses 
CHBRP estimates that the increase in administrative costs of DMHC-regulated plans and/or CDI-
regulated policies would remain proportional to the increase in premiums. CHBRP assumes that if health 
care costs increase as a result of increased utilization or changes in unit costs, there is a corresponding 
proportional increase in administrative costs. CHBRP assumes that the administrative cost portion of 
premiums is unchanged. All health plans and insurers include a component for administration and profit in 
their premiums. 
Other Considerations for Policymakers 
In addition to the impacts a bill may have on benefit coverage, utilization, and cost, related considerations 
for policymakers are discussed below. 
Postmandate Changes in the Number of Uninsured Persons22 
Because the change in average premiums does not exceed 1% for any market segment (see Table 10. 
Postmandate Per Member Per Month Premiums and Total Expenditures by Market Segment, California, 
2019), CHBRP would expect no measurable change in the number of uninsured persons due to the 
enactment of SB 11. 
Changes in Public Program Enrollment 
CHBRP estimates that the mandate would produce no measurable impact on enrollment in publicly 
funded insurance programs due to the enactment of SB 11. 
                                                     
22 See also CHBRP’s Criteria and Methods for Estimating the Impact of Mandates on the Number of Uninsured, 
available at www.chbrp.org/analysis_methodology/cost_impact_analysis.php.  
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How Lack of Benefit Coverage Results in Cost Shifts to Other Payers 
Currently, the carved out Medi-Cal benefit for OUD and AUD is used to deliver some of the services 
covered by SB 11. Medi-Cal does cover all of the OUD and AUD medications and services, with limited 
utilization management restrictions. Due to the duplication in coverage proposed by SB 11 and 
comprehensive coverage of the FDA-approved drugs for OUD and AUD that already exists in the Medi-
Cal fee-for-service carve-out with limited utilization management, CHBRP only estimated an increase in 
Medi-Cal managed care plans covering new use of auto-injector naloxone due to the treatment 
authorization request requirements in Medi-Cal fee-for-service and the relative high cost of the drug. By 
removing any prior authorization requirement and moving it to tier 1 of the formulary, obtaining the auto-
injector version of naloxone will be much easier in Medi-Cal managed care plans due to SB 11. CHBRP 
anticipates other OUD will continue to be delivered through the fee-for-service carve-out, which is not 
impacted by SB 11. 
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Table 9. Baseline Per Member Per Month Premiums and Total Expenditures by Market Segment, California, 2019 
 
    DMHC-Regulated   CDI-Regulated     
    
Commercial Plans (by Market) 
(a)   Publicly Funded Plans   
Commercial Plans (by 
Market) (a)     
    
Large 
Group 
Small 
Group Individual   
CalPERS 
HMOs 
(b) 
MCMC  
(Under 65) 
(c) 
MCMC  
(65+) (c)   
Large 
Group 
Small 
Group Individual 
  TOTAL 
Enrollee Counts                           
  
Total enrollees in 
plans/policies subject to 
state mandates (d) 9,371,000 3,117,000 2,081,000   887,000 6,832,000 678,000   214,000 133,000 120,000 
  
23,433,000 
  
Total enrollees in 
plans/policies subject to 
SB 11 9,371,000 3,117,000 2,081,000   887,000 6,832,000 678,000   214,000 133,000 120,000 
  
23,433,000 
Premium Costs                           
  
Average portion of 
premium paid by 
Employer $482.65 $343.93 $0.00   $505.74 $276.66 $808.46   $557.12 $459.26 $0.00 
  
$103,945,637,000 
  
Average portion of 
premium paid by 
Employee $122.24 $158.45 $588.53   $82.33 $0.00 $0.00   $175.81 $167.30 $459.20 
  
$36,625,181,000 
  Total Premium $604.88 $502.38 $588.53   $588.07 $276.66 $808.46   $732.93 $626.56 $459.20   $140,570,818,000 
Enrollee Expenses                           
  
Enrollee expenses for 
covered benefits 
(Deductibles, copays, 
etc.) $48.13 $111.60 $159.72   $50.14 $0.00 $0.00   $133.93 $176.39 $112.74 
  
$14,896,952,000 
  
Enrollee expenses for 
noncovered benefits (e) $0.00 $0.00 $0.00   $0.00 $0.00 $0.00   $0.00 $0.00 $0.00 
  
$0 
Total Expenditures $653.02 $613.98 $748.25   $638.21 $276.66 $808.46   $866.86 $802.95 $571.95   $155,467,770,000 
Source: California Health Benefits Review Program, 2019. 
Note: (a) Includes enrollees with grandfathered and nongrandfathered health insurance, both on Covered California and outside the exchange. 
(b) As of September 2017, 56% of CalPERS HMO members were state retirees under age 65, state employees or their dependents. CHBRP assumes the same ratio for 2019. 
(c) Medi-Cal Managed Care Plan expenditures for members over 65 include those who also have Medicare coverage. This population does not include enrollees in COHS. 
(d) This population includes both persons who obtain health insurance using private funds (group and individual) and through public funds (e.g., CalPERS HMOs, Medi-Cal Managed Care Plans). Only 
those enrolled in health plans or policies regulated by the DMHC or CDI are included. Population includes all enrollees in state-regulated plans or policies aged 0 to 64 years, and enrollees 65 years or 
older covered by employer-sponsored health insurance. 
Analysis of California Senate Bill 11 
Current as of February 13, 2019 www.chbrp.org 51 
(e) Includes only those expenses that are paid directly by enrollees or other sources to providers for services related to the mandated benefit that are not currently covered by insurance. This only includes 
those expenses that will be newly covered, postmandate. Other components of expenditures in this table include all health care services covered by insurance. 
Key: CalPERS HMOs=California Public Employees’ Retirement System Health Maintenance Organizations; CDI=California Department of Insurance; DMHC=Department of Managed Health Care; 
COHS=County Operated Health Systems; MCMC = Managed Care Medi-Cal 
 
  
Analysis of California Senate Bill 11 
Current as of February 13, 2019 www.chbrp.org 52 
Table 10. Postmandate Per Member Per Month Premiums and Total Expenditures by Market Segment, California, 2019 
 
    DMHC-Regulated . CDI-Regulated   
    Commercial Plans (by Market) (a)   Publicly Funded Plans   Commercial Plans (by Market) (a)   
    
Large 
Group 
Small 
Group Individual   
CalPERS 
HMOs (b) 
MCMC  
(Under 
65) (c) 
MCMC 
(65+) (c)   
Large 
Group 
Small 
Group Individual TOTAL 
Enrollee Counts                         
  
Total enrollees in 
plans/policies subject to state 
Mandates (d) 9,371,000 3,117,000 2,081,000   887,000 6,832,000 678,000   214,000 133,000 120,000 23,433,000 
  
Total enrollees in 
plans/policies subject to SB 11 9,371,000 3,117,000 2,081,000   887,000 6,832,000 678,000   214,000 133,000 120,000 23,433,000 
Premium Costs                         
  
Average portion of premium 
paid by Employer $0.0940 $0.1765 $0.0000   $0.0530 $0.0112 $0.0112   $0.2191 $0.0506 $0.0000 $19,394,000 
  
Average portion of premium 
paid by Employee $0.0238 $0.0813 $0.2221   $0.0086 $0.0000 $0.0000   $0.0692 $0.0185 $0.6218 $12,461,000 
  Total Premium $0.1179 $0.2578 $0.2221   $0.0616 $0.0112 $0.0112   $0.2883 $0.0691 $0.6218 $31,855,000 
Enrollee Expenses                         
  
Enrollee expenses for covered 
benefits (Deductibles, copays, 
etc.) -$0.0238 -$0.1099 -$0.1372   -$0.0167 $0.0000 $0.0000   -$0.1245 -$0.0329 -$0.2939 
-
$11,184,000 
  
Enrollee expenses for 
noncovered benefits (e)  $0.0000 $0.0000 $0.0000   $0.0000 $0.0000 $0.0000   $0.0000 $0.0000 $0.0000 $0 
  Total Expenditures $0.0941 $0.1479 $0.0849   $0.0449 $0.0112 $0.0112   $0.1638 $0.0362 $0.3280 $20,671,000 
Postmandate Percent 
Change                         
  
Percent change insured 
premiums 0.0195% 0.0513% 0.0377%   0.0105% 0.0041% 0.0014%   0.0393% 0.0110% 0.1354% 0.0227% 
  
Percent Change total 
expenditures 0.0144% 0.0241% 0.0113%   0.0070% 0.0041% 0.0014%   0.0189% 0.0045% 0.0573% 0.0133% 
Source: California Health Benefits Review Program, 2019. 
Note: (a) Includes enrollees with grandfathered and nongrandfathered health insurance, both on Covered California and outside the exchange. 
(b) As of September 2017, 56% of CalPERS HMO members were state retirees under age 65, state employees or their dependents. CHBRP assumes the same ratio for 2019. 
(c) Medi-Cal Managed Care Plan expenditures for members over 65 include those who also have Medicare coverage. This population does not include enrollees in COHS. 
(d) This population includes both persons who obtain health insurance using private funds (group and individual) and through public funds (e.g., CalPERS HMOs, Medi-Cal Managed Care Plans).  
Only those enrolled in health plans or policies regulated by the DMHC or CDI are included. Population includes all enrollees in state-regulated plans or policies aged 0 to 64 years, and enrollees 65 years 
or older covered by employer-sponsored health insurance. 
Analysis of California Senate Bill 11 
Current as of February 13, 2019 www.chbrp.org 53 
(e) Includes only those expenses that are paid directly by enrollees or other sources to providers for services related to the mandated benefit that are not currently covered by insurance. This only includes 
those expenses that will be newly covered, postmandate. Other components of expenditures in this table include all health care services covered by insurance. 
Key: CalPERS HMOs=California Public Employees’ Retirement System Health Maintenance Organizations; CDI=California Department of Insurance; DMHC=Department of Managed Health Care; 
COHS=County Operated Health Systems; MCMC = Managed Care Medi-Cal 
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PUBLIC HEALTH IMPACTS 
As discussed in the Policy Context section, SB 11 addresses the benefit coverage of enrollees who have 
a pharmacy benefit that covers a medication that is FDA-approved for treatment of a substance use 
disorder (SUD). For these enrollees’ health insurance, SB 11 would mandate coverage of all FDA-
approved medications for substance use disorders. SB 11 would require these medications to be placed 
on the lowest tier of the formulary and would prohibit use of prior authorization and step therapy utilization 
management tools for these medications. The public health impact analysis includes estimated impacts in 
the short term (within 12 months of implementation) and in the long term (beyond the first 12 months 
postmandate).  
This section estimates the short-term impact of SB 11 on health outcomes and potential population 
disparities. See Long-Term Impacts for discussion of premature death, economic loss, and social 
determinants of health.  
Estimated Public Health Outcomes 
There are FDA-approved prescription medications for three substance use disorders: opioid use disorder 
(OUD), alcohol use disorder (AUD), and tobacco use disorder (TUD). As presented in Medical 
Effectiveness (Figure 13), there is clear and convincing evidence of effectiveness for most of the FDA-
approved SUD medications. The OUD, AUD, and TUD medications promote treatment retention, prevent 
relapse, and improve birth outcomes. Additionally, evidence shows OUD medications reduce illicit use 
opioid use  (misuse of prescription opioids or use of heroin and illicitly manufactured fentanyl); reverse 
opioid overdose thus reducing associated mortality; and reduce risk behaviors associated with 
transmission of HIV or Hepatitis C (see Long-Term Impacts section for further discussion about morbidity 
and mortality). CHBRP’s medical effectiveness review found limited evidence regarding the impact of 
prohibiting utilization management strategies on reducing enrollee barriers to care. 
As presented in Benefit Coverage, Utilization, and Cost Impacts, CHBRP estimates a marginal increase 
of up to 10,800 people with OUD, AUD, or TUD newly accessing FDA-approved medications to treat their 
disorders were SB 11 implemented. Please note, concomitant use of medications by some enrollees may 
occur, and so these enrollee estimates reflect an upper bound. 
Opioid Use Disorder (OUD) 
Given the effectiveness of all five OUD medications (buprenorphine (-naloxone), methadone, and 
naltrexone for maintenance treatment; lofexidine for withdrawal; and naloxone for overdose reversal), 
CHBRP anticipates an increase in opioid overdose reversals and maintenance treatment for the 3,100 
enrollees with OUD projected to have new access to these FDA-approved medications. Corresponding 
decreases in illicit opioid use, opioid overdose and its associated mortality, poor maternal-infant 
outcomes, and a reduction in behaviors associated with elevated risk of hepatitis B and C, and HIV 
(unprotected sex and shared injection drug equipment).  
Improving access to OUD treatment is especially important for reducing risk of hepatitis B and C and HIV. 
A minority of people with OUD become injection drug users (IDU) either to improve the high from misused 
prescription opioids or because they have turned to heroin, which is cheaper and easier to obtain than 
prescription opioids (NIDA, 2018). National estimates of hepatitis C infection rates among IDU ranges 
from 60% to 90% (Tsui et al., 2014) indicating a high likelihood of transmitting the infection when sharing 
contaminated drug equipment. In 2015, about 18% of California females with HIV contracted the infection 
through IDU (opioid and other drugs) compared with 5% of HIV+ males (although males comprise 88% of 
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the HIV population) (CHDP, 2015). Based on the evidence, injection drug users who take medications to 
treat OUD could avert contracting HIV and/or hepatitis C and prevent transmission to others.  
In addition to the preventable health burdens, pharmacotherapy for OUD also reduces use of health 
services. The Background on Substance Use Disorders and Benefit Coverage, Utilization, and Cost 
Impacts sections described research showing decreased emergency room use and hospitalizations for 
patients being treated for OUD as compared with patients with untreated OUD (Mohlman et al., 2016). In 
the case of SB 11, CHBRP estimates that in the first year postmandate, there would be cost offsets 
attributable to fewer OUD-related services per OUD user. Specifically, 1.46 fewer days in both OUD 
inpatient days and OUD detox days, plus one less OUD-related ED visit per OUD user (see Table 8 in the 
Benefit Coverage, Utilization, and Cost Impacts section for estimated changes). 
The public health impact of SB 11 within a year postmandate may be limited for several reasons. In 
addition to a relapse rate of 40% to 60% (see Background on Substance Use Disorders section), other 
significant attitudinal and structural barriers contribute to lower OUD treatment rates than OUD treatment 
needs. As discussed in the Background on Substance Use Disorders section, patient attitudinal barriers 
are strong deterrents to seeking treatment. Namely the nature of addiction precludes some people with 
OUD from recognizing their need for help, with an estimated 11% seeking treatment in the first year after 
onset of the disorder and 24% within 10 years of onset (Blanco et al., 2013). OUD stigma from family, 
friends, and employers produces another significant barrier, as does provider willingness to prescribe and 
treat. Moreover, structural barriers prevent some who seek medication treatment from obtaining it due to 
a mismatch between the supply of trained providers and health care settings, and patient demand 
(Clemens-Cope et al., 2018; Knudsen et al., 2017). 
In the first year postmandate, CHBRP estimates that about 3,100 enrollees with newly compliant benefit 
coverage would use FDA-approved prescription drugs for the treatment of opioid use disorder, 40%-60% 
of whom may experience relapse. As supported by clear and convincing evidence, outcomes of such 
treatment would include reducing illicit opioid use, opioid overdose and associated mortality, acquisition  
and transmission of hepatitis C and HIV, and poor maternal-infant outcomes. Among those new users, 
SB 11 would also increase maintenance treatment retention and increase overdose reversals (through 
the use of naloxone).  
Impact on disparities 
Disparities are differences between groups that are modifiable, and insurance benefit mandates that 
impose coverage parity among state-regulated plans and policies may change an existing disparity.27 As 
presented in the Background on Substance Use Disorders section, disparities occur within many 
demographic categories in California. Disparities in opioid overdose mortality rates, hospitalizations, and 
emergency department use exist among racial/ethnic groups (highest among whites and Native 
Americans); age cohorts (highest among ages 25-35 yrs); and by gender (males have two times the 
mortality rate of females). The LGBT population is twice as likely as the heterosexual population to report 
misusing prescription opioids.  
The demographic composition of the estimated 3,100 enrollees projected to start OUD treatment 
medication(s) is undefined; therefore, the impact of SB 11 on existing disparities in opioid use, mortality, 
and related health services use is unknown. 
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Alcohol Use Disorder (AUD) 
As presented in Medical Effectiveness, there is clear and convincing evidence that two of the three23 
FDA-approved AUD medications (acamprosate and naltrexone) are effective in reducing alcohol 
consumption or supporting abstention from alcohol. There is insufficient evidence of effectiveness for 
outcomes related to quality of life, injury, and mortality (Jones et al., 2014). As presented in the Benefit 
Coverage, Utilization, and Cost Impacts section, CHBRP estimates about 2,200 enrollees with newly SB 
11-compliant benefit coverage will use FDA-approved medications for the treatment of AUD. 
There is well-established evidence of a causal link between alcohol misuse/abuse and higher rates of 
injury, cancers, fetal alcohol spectrum disorder, stroke, cardiovascular disease, liver cirrhosis, high risk 
behaviors, and other physical and mental health conditions (Rehm et al., 2010; NIAAA, 2019). Although 
longitudinal studies on the effectiveness of these medications improving health outcomes is lacking, 
epidemiologic evidence indicates that reductions in alcohol consumption would translate to lower rates of 
acute and chronic conditions such as fetal alcohol spectrum disorder; miscarriage; AUD-associated injury 
and mortality (e.g., motor vehicle accidents, falls, suicides, sexual assault); and risky sexual behavior 
leading to unintended pregnancy or sexually transmitted infections (CDC, 2018) (see the Long-Term 
Impacts section for discussion of cardiovascular and liver disease and cancer).  
Two examples of the negative health effects of untreated AUD include poor pregnancy outcomes and 
injuries/accidents: 
• Pregnant women who misuse/abuse alcohol increase the risk of poor birth outcomes. Fetal 
alcohol spectrum disorder (FASD), defined by permanent physical and intellectual disabilities 
and/or behavioral problems in newborns, is caused exclusively by alcohol. In 2014, SAHMSA 
showed that, nationally, 2.7% of pregnant women aged 15 to 44 reported binge drinking, and 
0.3% reported heavy drinking, which greatly increases the risk of FASD. SAMSHA also reported 
that about 200,000 cases of FASD occur annually in the U.S. Studies from specific U.S. sites 
report the prevalence of FASD ranging between 20 to 50 cases per 1,000 births annually (NIAAA, 
2018).  
• Alcohol misuse/abuse also causes a significant number of injuries/accidents. The CDC hosts the 
Alcohol-related Disease Impact database, which reports the number of alcohol-attributable deaths 
due to excessive alcohol consumption. In California, of the 5,113 acute causes of death, more 
than 1,000 motor vehicle deaths; 1,000 homicides; 800 suicides; and 600 falls resulting in death 
were alcohol related in 2012 (CDC, 2013).  
Treating AUD with medication may help decrease the incidence of these negative health outcomes. 
Additionally, higher rates of emergency room use and hospitalizations are also associated with AUD (see 
Background section). In the case of SB 11, CHBRP estimates cost offsets associated with reduction in 
AUD related services, Specifically, about a half day reduction in AUD inpatient days and a half day 
reduction in AUD detox days per AUD patient (see Table 8 in Cost section for estimated changes). 
As discussed in the Background on Substance Use Disorders section, attitudinal barriers are strong 
deterrents to seeking treatment. First, the nature of addiction precludes some people with AUD from 
recognizing their need for help. Additionally, stigma from family, friends, and employers may also play a 
role in patient reluctance to initiating and maintaining a treatment regimen (Fisher et al., 2016; Jones et 
al., 2015; Verissimo and Grella, 2017). Finally, many providers are reticent to prescribe medication to 
                                                     
23 Naltrexone, which helps manage withdrawal symptoms and blocks effects of alcohol and opioids; and 
acamprosate, which helps reduce cravings, are found to be effective; whereas there is insufficient evidence of the 
effectiveness of disulfiram.  
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treat AUD, despite more than 10 years of provider education campaigns from government entities and the 
American Medical Association (Jonas et al., 2014; SAMSHA, 2015). Reasons for provider 
nonparticipation include prior training to refer to patients with AUD to specialty treatment centers, lack of 
familiarity with medications, systemic division between physical and behavioral health care, and limited 
referral options to specialty treatment clinics for their patients (provider-of-last resort) (SAMSHA, 2015; 
Wessell et al., 2014). Wessell et al. found that key facilitators to increasing primary care providers’ 
prescribing AUD medication included provider exposure to evidence and case studies, receptive patients, 
early successful patient outcomes, and low cost (generic oral naltrexone) availability of AUD medication 
(Wessell et al., 2014).  
In the first year postmandate, CHBRP estimates that approximately 2,200 enrollees with newly compliant 
benefit coverage would use FDA-approved prescription drugs for the treatment of alcohol use disorder, of 
which 50% or more may experience relapse within the first year of treatment. Based on clear and 
convincing evidence that two of the three FDA-approved AUD medications are effective in reducing 
alcohol consumption, CHBRP projects that these enrollees would experience decreases in negative 
health outcomes such as injuries/accidents and poor pregnancy outcomes in the first year postmandate.  
Impact on disparities 
As described in the Background on Substance Use Disorders section, AUD-related disparities among 
racial/ethnic groups exist in California with whites and Native Americans exhibiting the highest rates of 
heavy drinking, although Hispanics and blacks have higher rates of alcohol-related liver disease and 
cirrhosis mortality. Similar to other substance use disorders, younger cohorts (ages 18-34 years) report 
higher rates of heavy drinking as compared with other ages; similarly, the LGBT population reported 
higher rates of binge drinking than the heterosexual population.  
The demographic composition of the estimated 2,200 enrollees projected to start AUD treatment 
medication(s) is undefined; therefore, the impact of SB 11 on reducing existing disparities in alcohol use, 
pregnancy outcomes, injuries/accidents, and related health services use is unknown. 
Tobacco Use Disorder (TUD) 
As presented in Medical Effectiveness, there is clear and convincing evidence that all three FDA-
approved TUD medications are effective in promoting smoking cessation. As presented in the Benefit 
Coverage, Utilization, and Cost Impacts section, CHBRP estimates that there would be about 5,500 
enrollees with newly SB 11 compliant benefit coverage will use FDA-approved medications for the 
treatment of TUD.  
Smoking is a known cause of significant morbidity and mortality. A deep and comprehensive literature link 
smoking to a multitude of conditions and diseases including cancers, cardiopulmonary disease, and poor 
birth outcomes (HHS, 2014). A comprehensive epidemiological study reported that about 50% of deaths 
from 12 types of cancer are attributable to smoking, with more than 80% of lung cancer deaths 
attributable to smoking (Siegel et al., 2015). Despite having the second lowest smoking rate in the U.S. 
(11.3%), lung cancer remains the leading cause of cancer deaths in California with more than 12,000 
deaths occurring in 2014 (ACS, 2017; CDC, 2017). (See the Long-Term Impacts section for more 
discussion of long-term effects of smoking.) Additionally, secondhand smoke increases non-smokers’ risk 
of developing lung cancer, bronchitis, and pneumonia; exacerbating asthma; and causing poor birth 
outcomes (CDPH, 2018) all of which can lead to an increase in preventable health services utilization. 
California has the lowest prevalence rate nationally of women who smoke any time during pregnancy 
(about 2%) according to analysis of 2014 birth certificates (Curtin et al., 2016). 
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Public health campaigns, smoking policy changes (tobacco taxation, tobacco sales restrictions, workplace 
restrictions, etc.), and the ACA-requirement for coverage of cessation therapies by many plans and 
policies have contributed the second lowest state-smoking rate (11.4%) in the U.S. Table 3 shows the 
prevalence of smoking cessation methods that California smokers reported using (one or more) to quit 
smoking in the past year (based on the 2016-2017 California Adult Tobacco Survey) (CDPH, 2018). Data 
from the 2017 California Health Information Survey reports a smaller percentage (55%) of smokers quit 
for one or more days in the past year (CHIS, 2017). Research has shown that former smokers recalled an 
average of 4.7 quit attempts before successfully abstaining (CDPH, 2018). 
CHBRP estimates that about 5,500 enrollees with newly compliant benefit coverage would use FDA-
approved prescription drugs for the treatment of tobacco use disorder, some of whom will relapse within 
the first year of treatment initiation. This estimate is supported by clear and convincing that the three 
FDA-approved medications are effective in increasing quit rates and sustaining abstinence. Thus, 
reductions in poor birth outcomes and smoking-exacerbated conditions (e.g., asthma and heart attacks) 
would be expected in the first year post-mandate. (See Long-Term Impacts for discussion of premature 
mortality.) 
Impact on disparities 
Disparities are differences between groups that are modifiable, and insurance benefit mandates that 
impose coverage parity among state-regulated plans and policies may change an existing disparity. As 
described in the Background on Substance Use Disorders section, there are disparities in smoking 
prevalence by gender, race/ethnicity, age, and sexual orientation.  
The demographic composition of the estimated 5,500 enrollees projected to start TUD treatment 
medication(s) is undefined; therefore, the impact of SB 11 on reducing existing disparities in tobacco use, 
and tobacco-related health outcomes is unknown.  
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LONG-TERM IMPACTS 
In this section, CHBRP estimates the long-term impact24 of SB 11, which CHBRP defines as impacts 
occurring beyond the first 12 months after implementation. These estimates are qualitative and based on 
the existing evidence available in the literature. CHBRP does not provide quantitative estimates of long-
term impacts because of unknown improvements in clinical care, changes in prices, implementation of 
other complementary or conflicting policies, and other unexpected factors. 
Long-Term Utilization and Cost Impacts 
Utilization Impacts  
Long-term utilization of FDA-approved OUD medications could increase as OUD prevalence increases in 
the state. CHBRP estimates that the level of use per user per year predicted in 2019 (see Table 1) would 
not change over time, but utilization overall would increase with additional use of opioids. Due to 
continuing structural and attitudinal barriers (see the Background on Substance Use Disorders section), 
CHBRP does not forecast that the level of those with OUD receiving services would increase to more 
than 22% per year. 
As new medications approved by the FDA are adopted in clinical practice, shifts in utilization could occur. 
For example, the new lofexadine for OUD approved in late 2017 could alter the market for buprenorphine 
administration and increase use of the injectable version over sublingual versions (FDA, 2017). Currently, 
no paid claims are present to investigate current use, few plans have started covering the medication, 
and CHBRP’s context expert suggested physicians are not yet prescribing the medication readily. 
In the case of AUD and TUD treatment, there is very low baseline utilization of the FDA-approved 
medications for the two conditions. Because plans reported few restrictions to obtaining these 
medications, it appears physicians and patients are not using them frequently to treat AUD or TUD and 
therefore CHBRP does not expect long-term changes in prescribing practices or patient use.  
Cost Impacts 
OUD maintenance treatment needs with FDA-approved medication would continue and possibly increase 
if incidence of OUD increases over time. The constraints on the supply of providers (Clemans-Cope et al., 
2018) would limit the level of increase associated with new users, However, new, more expensive brand-
name medications coming to market are required to be covered by SB 11 without utilization management, 
which could result in long-term shifts in use towards more expensive options, which would increase per 
user costs and per unit costs for certain medications. However, if those medications are more effective 
than current OUD medications, they could come with cost offsets and increased adherence that would 
limit average cost increases. Currently, lofexidine is not being readily prescribed but that could change 
over a longer timeline. 
CHBRP does not anticipate increased long-term spending on AUD or TUD if prevalence rates do not 
increase substantially and if practice patterns do not change, which will not necessarily be changed by SB 
11 given existing coverage and use of TUD and AUD medications. 
                                                     
24 See also CHBRP’s Criteria and Guidelines for the Analysis of Long-Term Impacts on Healthcare Costs and Public 
Health, available at http://www.chbrp.org/analysis_methodology/cost_impact_analysis.php.  
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Shifts for Medi-Cal 
CHBRP anticipates that the prohibition on prior authorizations and step therapy will make auto-injector 
naloxone relatively easier to access by Medi-Cal beneficiaries enrolled in DMHC-regulated plans. In 
addition, the lack of prior authorization and step therapy requirements could, in future years, shift some 
Medi-Cal beneficiaries who would have chosen to access coverage for OUD through fee-for-service Medi-
Cal carve-out programs to access newer, more expensive FDA-approved medications like lofexidine 
through a Med-Cal managed care plan due to the SB 11–compliant absence of utilization management 
tools that would limit their ability to obtain the services through the carve-out (i.e., Treatment Authorization 
Requests). CHBRP does not anticipate this would happen for most OUD drugs which are already 
comprehensively covered by Medi-Cal fee-for-service with limited or no utilization management and no 
cost sharing. 
Long-Term Public Health Impacts 
Some interventions in proposed mandates provide immediate measurable impacts (e.g., maternity service 
coverage or acute care treatments) while other interventions may take years to make a measurable 
impact (e.g., coverage for tobacco cessation or vaccinations). When possible, CHBRP estimates the long-
term effects (beyond 12-months postmandate) to the public’s health that would be attributable to the 
mandate, including impacts on social determinants of health, premature death, and economic loss.  
In the case of SB 11, CHBRP estimates that up to 10,000 enrollees would newly access FDA-approved 
prescription drug treatments for SUD in the first year of the mandate. For the portion of these and future 
new users who are able to sustain abstinence, SB 11 would contribute to reductions in substance use-
related morbidity and mortality such as cardiovascular disease, cancer, HIV and hepatitis C. (See the 
Public Health Impacts section for discussion of potential reductions in acute conditions such as poor birth 
outcomes and injuries.) 
As discussed in the Background on Substance Use Disorders and Public Health Impacts sections, a key 
barrier to abstinence for any substance use disorder is patient interest and readiness to abstain. CHBRP 
anticipates the demand for treatment of OUD, AUD, and TUD would continue as relapsed patients 
attempt abstinence again and first-time initiators would join the pool of patients seeking care. The SB 11 
mandate to place the FDA-approved medications (Table 4) on tier 1 of formularies and remove insurer 
utilization management tools would continue to facilitate prescription medication treatment for some 
enrollees whose insurance did not previously offer coverage due to those barriers.  
However, limited patient readiness for SUD treatment and the demand-supply mismatch for OUD and 
AUD treatment remain significant barriers to care. Other policy options to address the (under) supply of 
properly distributed buprenorphine-waivered and methadone providers may improve in the future as 
newly funded provider training programs take effect through the California Department of Public Health 
and Department of Health Care Services (CDPH, 2016) and as California’s 58 counties implement the 
new Drug Medi-Cal Organized Delivery System for Medi-Cal beneficiaries (Joshi et al., 2017).  
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Impacts on the Social Determinants of Health25  
Taken as a whole, treatment of SUDs is inextricably linked bi-directionally with many important social 
determinants of health (SDoH). SDoH, such as quality of built environment, proximity to crime, 
educational opportunities, self-efficacy, and income levels can influence a person’s risk for substance use 
disorders (Mooney at al., 2018; Sudhinaraset et al., 2016). Conversely, substance use disorders can also 
alter a person’s baseline SDoH namely through the consequences of addiction, such as involvement with 
the criminal justice system, job loss, unstable housing or family situations, and discrimination against 
those with treated or untreated substance use disorder (Krebs et al., 2016).  
Periodically, health insurance mandates may influence social determinants of health (SDoH), which can 
mediate health inequities. The impact of SB 11 on SDoH is unknown; however, it stands to reason that for 
those enrollees who are adherent to OUD or AUD prescription medication treatment could see reduced 
interactions with the criminal justice system and/or improvements in family and housing stability.  
Impacts on Premature Death  
Premature death is often defined as death occurring before the age of 75 years (Cox, 2006). There are an 
estimated 5,700 years of potential life lost (YPLL) before age 75 per 100,000 Californians (United Health 
Foundation, 2019). Overdose deaths, injuries/accidents, chronic diseases, and violence related to OUD, 
AUD and TUD are contributing factors to that rate.  
OUD: Opioid-related mortality is considered a public health crisis, with more than 2,000 unintentional 
opioid deaths occurring in California in 2016 (Clemans-Cope et al., 2018; HHS, 2018). In terms of years-
of-life-lost (YLL), Tomes et al. estimated the national burden of opioid deaths in 2016 represented 1 in 65 
deaths (5.2 YLL/1,000 population), or about a quarter of the YLL due to cancer, the second leading cause 
of death in the U.S. Males experience twice the rate of YLL as females (7.0 YLL/1,000 population versus 
3.4 YLL/1,000 population); and the opioid-related YLL for males aged 25-34 years (18.1/1,000 population) 
represented about a quarter of all YLL in the U.S. in 2016 (Tomes, et al., 2018). 
AUD: The CDC reported the “average annual alcohol attributable years of life lost” as 823/100,000 
Californians. Fifty-four alcohol conditions were included in the calculation including acute and chronic 
conditions such as motor vehicle accidents, cancers, and cardiovascular diseases (Gonzales et al., 
2014). California males experienced triple the rate of YLL as compared with their female counterparts 
(1,215/100,000 versus 434/100,000). Blacks had the highest YLL (1,187/100,000), followed by Hispanics 
(915/100,000), whites (858/100,000), Alaska Native/American Indian (691/100,000) and Asians 
(309/100,000) (Gonzales et al., 2014). 
TUD: Max et al. estimated that 17.1 years of potential life were lost per smoker due to smoking-related 
disease in California with no statistical difference between males and females (Max et al., 2009). Causes 
of premature death included premature birth, low birth weight, sudden infant death syndrome (SIDS), 
respiratory stress syndrome, lung cancer, heart disease, and asthma.  
There is evidence that smoking cessation can reverse negative health effects from tobacco and can 
produce similar reductions in morbidity and mortality that would be achieved through pharmaceutical 
interventions commonly prescribed for heart disease patients (Critchley and Capewell, 2003; Suskin et 
al., 2001). Other studies show that smoking cessation can boost life expectancy; cessation at age 35 
                                                     
25 For more information about SDoH, see CHBRP’s publication Incorporating Relevant Social Determinants of Health 
into CHBRP Benefit Mandate Analyses at 
http://chbrp.com/analysis_methodology/public_health_impact_analysis.php.  
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years resulted in a predicted additional 7 to 8 years of life for men and a predicted additional 6 to 7 years 
of life for women (Jha et al., 2013; Taylor et al., 2002). 
The quantitative long-term impact of SB 11 on premature death associated with OUD, AUD, and TUD is 
unknown; however, it stands to reason, based on the effectiveness of FDA-approved medications, that 
there would be a reduction in premature deaths for those enrollees who undergo treatment for their 
substance use disorder(s). 
Economic Loss 
Economic loss associated with disease is generally presented in the literature as an estimation of the 
value of the YPLL in dollar amounts (i.e., valuation of a population’s lost years of work over a lifetime). In 
addition, morbidity associated with the disease or condition of interest can also result in lost productivity 
by causing a worker to miss days of work due to illness or acting as a caregiver for someone else who is 
ill. 
The National Institute of Drug Abuse reports that substance abuse in the U.S. produces an estimated 
economic loss of $740 billion annually. Illicit drugs (including opioids) and misuse of prescription opioids 
account for $37 billion, alcohol accounts for $27 billion, and tobacco accounts for $168 billion in direct 
health care costs. The remaining $507 billion accounts for indirect costs, such as lost work productivity 
and crime (NIDA, 2017 April). 
CHBRP is unable to estimate the impact of SB 11 on the economic loss associated with substance use 
disorders in California. 
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APPENDIX A TEXT OF BILL ANALYZED 
On December 6, 2018, the California Senate Committee on Health requested that CHBRP analyze the 
benefit mandate included SB 11 (see sections 2 and 4). 
 
SENATE BILL  No. 11 
 
Introduced by Senator Beall  
December 3, 2018  
 
An act to add Sections 1374.77 and 1374.78 to the Health and Safety Code, and to add Sections 
10144.41 and 10144.42 to the Insurance Code, relating to health care coverage.  
LEGISLATIVE COUNSEL’S DIGEST 
SB 11, as introduced, Beall. Health care coverage: mental health parity.  
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure 
and regulation of health care service plans by the Department of Managed Health Care and 
makes a willful violation of the act a crime. Existing law provides for the regulation of health 
insurers by the Department of Insurance. Existing law requires health care service plan contracts 
or health insurance policies issued, amended, or renewed on or after July 1, 2000, to provide 
coverage for the diagnosis and medically necessary treatment of severe mental illnesses, as 
defined, and of serious emotional disturbances of a child, as specified, under the same terms and 
conditions applied to other medical conditions.  
Existing federal law, the federal Paul Wellstone and Pete Domenici Mental Health Parity and 
Addiction Equity Act of 2008 (MHPAEA), requires group health plans and health insurance 
issuers that provides both medical and surgical benefits and mental health or substance use 
disorder benefits to ensure that financial requirements and treatment limitations applicable to 
mental health or substance use disorder benefits are no more restrictive than the predominant 
requirements or limitations applied to substantially all medical and surgical benefits. Existing 
state law subjects nongrandfathered individual and small group health care service plan 
contracts and health insurance policies that provide coverage for essential health benefits to 
those provisions of the MHPAEA.  
This bill would require a health care service plan and a health insurer to submit an annual report 
to the Department of Managed Health Care or the Department of Insurance, as appropriate, 
certifying compliance with state and federal mental health parity laws, as specified. The bill 
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would require the departments to review the reports submitted by health care service plans to 
ensure compliance with state and federal mental health parity laws, and would require the 
departments to make the reports and the results of the reviews available upon request and to post 
the reports and the results of the reviews on the departments’ Internet Web site. The bill would 
also require the departments to report to the Legislature the information obtained through the 
reports and the results of the review of the reports and on all other activities taken to enforce 
state and federal mental health parity laws.  
Existing law authorizes a health care service plan and a health insurer to utilize formularies, 
prior authorization, step therapy, or other reasonable medical management practices, as 
specified, in the provision of outpatient prescription drug coverage.  
The bill would prohibit a health care service plan and a health insurer that provides prescription 
drug benefits for the treatment of substance use disorders from, among other things, imposing 
any prior authorization requirements on, or any step therapy requirements before authorizing 
coverage for, a prescription medication approved by the federal Food and Drug Administration 
for the treatment of substance use disorders.  
Because a willful violation of the bill’s provisions by a health care service plan would be a 
crime, the bill would impose a state-mandated local program.  
The California Constitution requires the state to reimburse local agencies and school districts for 
certain costs mandated by the state. Statutory provisions establish procedures for making that 
reimbursement.  
This bill would provide that no reimbursement is required by this act for a specified reason.  
 
Digest Key 
 
Vote:   MAJORITY.  Appropriation: NO. Fiscal committee: YES. Local program: YES 
 
 
Bill Text 
 
THE PEOPLE OF THE STATE OF CALIFORNIA DO ENACT AS FOLLOWS: 
 
SECTION 1. Section 1374.77 is added to the Health and Safety Code, to read: 
1374.77. (a) A health care service plan shall submit an annual report to the department on or 
before March 1 of each year certifying compliance with Sections 1374.72, 1374.76, and 
1374.78, and the federal Paul Wellstone and Pete Domenici Mental Health Parity and Addiction 
Equity Act of 2008 (Public Law 110-343), hereafter referred to as the MHPAEA, its 
implementing regulations, and all related federal guidance. The department shall make the 
report available upon request and shall post the report on the department’s Internet Web site. 
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(b) A health care service plan shall include, but not be limited to, all of the following information 
in the annual report required pursuant to subdivision (a): 
 
(1) A description of the process used to develop or select the medical necessity criteria for mental 
health and substance use disorder benefits and the process used to develop or select the medical 
necessity criteria for medical and surgical benefits. 
 
(2) Identification of all nonquantitative treatment limitations (NQTLs) that are applied to both 
mental health and substance use disorder benefits and medical and surgical benefits within each 
classification of benefits. 
 
(3) The results of an analysis that demonstrates that for the medical necessity criteria described 
in paragraph (1) and for each NQTL identified in paragraph (2), as written and in operation, the 
processes, strategies, evidentiary standards, or other factors used in applying the medical 
necessity criteria and each NQTL to mental health and substance use disorder benefits within 
each classification of benefits are comparable to, and are applied no more stringently than, the 
processes, strategies, evidentiary standards, or other factors used in applying the medical 
necessity criteria and each NQTL to medical and surgical benefits within the corresponding 
classification of benefits. At a minimum, the results of the analysis shall do all of the following: 
 
(A) Identify the factors used to determine that an NQTL will apply to a benefit, including factors 
that were considered, but rejected. 
 
(B) Identify and define the specific evidentiary standards used to define the factors and any other 
evidence relied upon in designing each NQTL. 
 
(C) Provide the comparative analyses, including the results of the analyses performed to 
determine that the processes and strategies used to design each NQTL, as written, and the written 
processes and strategies used to apply the NQTL to mental health and substance use disorder 
benefits are comparable to, and are applied no more stringently than, the processes and strategies 
used to design each NQTL, as written, and the written processes and strategies used to apply the 
NQTL to medical and surgical benefits. 
 
(D) Provide the comparative analyses, including the results of the analyses performed to 
determine that the processes and strategies used to apply each NQTL, in operation, for mental 
health and substance use disorder benefits are comparable to, and are applied no more stringently 
than, the processes or strategies used to apply each NQTL, in operation, for medical and surgical 
benefits. 
 
(E) Disclose the specific findings and conclusions reached by the health care service plan that the 
results of the analyses described in this paragraph indicate that the health care service plan is in 
compliance with the MHPAEA, its implementing regulations, and all related federal guidance. 
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(c) A report submitted to the department pursuant to this section shall not include any information 
that may individually identify insureds, including, but not limited to, medical record numbers, 
names, and addresses. 
 
(d) The department shall review the reports submitted by health care service plans pursuant to 
subdivision (a) to ensure compliance with this section, Sections 1374.72, 1374.76, and 1374.78, 
and the MHPAEA, its implementing regulations, and all related federal guidance. The department 
shall make the results of the review available upon request and shall post the review of the reports 
on the department’s Internet Web site. 
 
(e) (1) The department shall annually report to the Legislature the information obtained through 
the reports and the results of the review of the reports and on all other activities taken to enforce 
this section, Sections 1374.72, 1374.76, and 1374.78, and the MHPAEA, its implementing 
regulations, and all related federal guidance. 
 
(2) The California State Auditor shall review the department’s implementation of this section, 
and shall report its findings from the review to the Legislature. 
 
(3) A report submitted pursuant to this subdivision shall be submitted in accordance with Section 
9795 of the Government Code. 
 
(f) For purposes of this section, “nonquantitative treatment limitations” or “NQTL” means those 
limitations described in the implementing regulations of the MHPAEA. 
 
SEC. 2. Section 1374.78 is added to the Health and Safety Code, to read: 
1374.78. Notwithstanding any other law, a health care service plan that provides prescription 
drug benefits for the treatment of substance use disorders shall place all prescription 
medications approved by the federal Food and Drug Administration (FDA) for the treatment of 
substance use disorders on the lowest tier of the drug formulary developed and maintained by 
the health care service plan, and shall not do any of the following: 
 
(a) Impose any prior authorization requirements on any prescription medication approved by 
FDA for the treatment of substance use disorders. 
 
(b) Impose any step therapy requirements before authorizing coverage for a prescription 
medication approved by the FDA for the treatment of substance use disorders. 
(c) Exclude coverage for any prescription medication approved by the FDA for the treatment of 
substance use disorders and any associated counseling or wraparound services on the grounds that 
those medications and services were court ordered. 
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SEC. 3. Section 10144.41 is added to the Insurance Code, to read: 
10144.41. (a) A health insurer shall submit an annual report to the department on or before 
March 1 of each year certifying compliance with Sections 10144.4, 10144.42, and 10144.5, and 
the federal Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act 
of 2008 (Public Law 110-343), hereafter referred to as the MHPAEA, its implementing 
regulations, and all related federal guidance. The department shall make the report available 
upon request and shall post the report on the department’s Internet Web site. 
 
(b) A health insurer shall include, but not be limited to, all of the following information in the 
annual report required pursuant to subdivision (a): 
 
(1) A description of the process used to develop or select the medical necessity criteria for mental 
health and substance use disorder benefits and the process used to develop or select the medical 
necessity criteria for medical and surgical benefits. 
 
(2) Identification of all nonquantitative treatment limitations (NQTLs) that are applied to both 
mental health and substance use disorder benefits and medical and surgical benefits within each 
classification of benefits. 
 
(3) The results of an analysis that demonstrates that for the medical necessity criteria described 
in paragraph (1) and for each NQTL identified in paragraph (2), as written and in operation, the 
processes, strategies, evidentiary standards, or other factors used in applying the medical 
necessity criteria and each NQTL to mental health and substance use disorder benefits within 
each classification of benefits are comparable to, and are applied no more stringently than, the 
processes, strategies, evidentiary standards, or other factors used in applying the medical 
necessity criteria and each NQTL to medical and surgical benefits within the corresponding 
classification of benefits. At a minimum, the results of the analysis shall do all of the following: 
 
(A) Identify the factors used to determine that an NQTL will apply to a benefit, including factors 
that were considered, but rejected. 
 
(B) Identify and define the specific evidentiary standards used to define the factors and any other 
evidence relied upon in designing each NQTL. 
 
(C) Provide the comparative analyses, including the results of the analyses performed to 
determine that the processes and strategies used to design each NQTL, as written, and the written 
processes and strategies used to apply the NQTL to mental health and substance use disorder 
benefits are comparable to, and are applied no more stringently than, the processes and strategies 
used to design each NQTL, as written, and the written processes and strategies used to apply the 
NQTL to medical and surgical benefits. 
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(D) Provide the comparative analyses, including the results of the analyses performed to 
determine that the processes and strategies used to apply each NQTL, in operation, for mental 
health and substance use disorder benefits are comparable to, and are applied no more stringently 
than, the processes or strategies used to apply each NQTL, in operation, for medical and surgical 
benefits. 
 
(E) Disclose the specific findings and conclusions reached by the health insurance policy that the 
results of the analyses described in this paragraph indicate that the health insurance policy is in 
compliance with the MHPAEA, its implementing regulations, and all related federal guidance. 
 
(c) A report submitted to the department pursuant to this section shall not include any information 
that may individually identify insureds, including, but not limited to, medical record numbers, 
names, and addresses. 
 
(d) The department shall review the reports submitted by health insurers pursuant to subdivision  
(a) to ensure compliance with this section, Sections 10144.4, 10144.42, 10144.5, and the 
MHPAEA, its implementing regulations, and all related federal guidance. The results of the 
review shall be made available upon request and shall be posted on the department’s Internet Web 
site. 
 
(e) (1) The department shall annually report to the Legislature the information obtained through 
the reports and the results of the review of the reports, and on all other activities taken to enforce 
this section, Sections 10144.4, 10144.42, and 10144.5, and the MHPAEA, its implementing 
regulations, and all related federal guidance. 
 
(2) The California State Auditor shall review the department’s implementation of this section, 
and shall report its findings from the review to the Legislature. 
 
(3) A report submitted pursuant to this subdivision shall be submitted in accordance with Section 
9795 of the Government Code. 
 
(f) For purposes of this section, “nonquantitative treatment limitations” or “NQTL” means those 
limitations described in the implementing regulations of the MHPAEA. 
 
SEC. 4. Section 10144.42 is added to the Insurance Code, to read: 
10144.42. Notwithstanding any other law, a health insurer that provides prescription drug 
benefits for the treatment of substance use disorders shall place all prescription medications 
approved by the federal Food and Drug Administration (FDA) for the treatment of substance 
use disorders on the lowest tier of the drug formulary developed and maintained by the health 
insurer, and shall not do any of the following: 
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(a) Impose any prior authorization requirements on any prescription medication approved by 
FDA for the treatment of substance use disorders. 
 
(b) Impose any step therapy requirements before authorizing coverage for a prescription 
medication approved by the FDA for the treatment of substance use disorders. 
 
(c) Exclude coverage for any prescription medication approved by the FDA for the treatment of 
substance use disorders and any associated counseling or wraparound services on the grounds that 
those medications and services were court ordered. 
 
SEC. 5. No reimbursement is required by this act pursuant to Section 6 of Article XIII B of the 
California Constitution because the only costs that may be incurred by a local agency or school 
district will be incurred because this act creates a new crime or infraction, eliminates a crime or 
infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 
of the Government Code, or changes the definition of a crime within the meaning of Section 6 of 
Article XIII B of the California Constitution. 
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APPENDIX B LITERATURE REVIEW METHODS 
This appendix describes methods used in the medical effectiveness literature review conducted for this 
report. A discussion of CHBRP’s system for grading evidence, as well as lists of MeSH Terms, publication 
types, and keywords, follows. 
Studies of the effects of prescription medications approved by the United States Food and Drug 
Administration (FDA) for the treatment of substance use disorders were identified through searches of 
Web of Science, PubMed, the Cochrane Library, EMBASE, Scopus, and PsycINFO. Websites maintained 
by the following organizations were also searched: Agency for Healthcare Research and Quality (AHRQ), 
Scottish Intercollegiate Guideline Network, International Network of Agencies for Health Technology 
Assessment (INAHTA), the National Health Service (NHS) Centre for Reviews and Dissemination, and 
the National Institute for Health and Care Excellence (NICE). 
The search was limited to abstracts of studies published in English.  
Reviewers screened the title and abstract of each citation retrieved by the literature search to determine 
eligibility for inclusion. The reviewers acquired the full text of articles that were deemed eligible for 
inclusion in the review and reapplied the initial eligibility criteria. 
For studies on tobacco use disorder, the search was limited to studies published from 2014 to present 
(AHRQ Evidence Review synthesized literature through July 2014). For studies on opioid use disorder, 
the search was limited to studies published from January 2018 to present (CHBRP report AB 2384 
synthesized literature through December 2017). For studies on alcohol use disorder, the search was 
limited to studies published from November 2013 to present (AHRQ Evidence Review synthesized 
literature through October 2013). Of the 947 articles found in the literature review, 65 were reviewed for 
potential inclusion in this report on SB 11, and a total of 56 studies were included in the medical 
effectiveness review for this report. The other articles were eliminated because they were of poor quality, 
did not report findings from clinical research studies, or did not address use of prescription medication for 
substance use disorders. 
CHBRP also reviewed literature on how prior authorization and step therapy affect substance abuse 
disorder treatment (including opioid abuse disorder, alcohol abuse disorder, andtobacco use disorder) 
utilization. 
CHBRP did not review literature on the effectiveness of any prescription medication for substance use 
disorders that is not approved by the FDA for the treatment of substance use disorders. 
Evidence Grading System 
In making a “call” for each outcome measure, the medical effectiveness lead and the content expert 
consider the number of studies as well the strength of the evidence. Further information about the criteria 
CHBRP uses to evaluate evidence of medical effectiveness can be found in CHBRP’s Medical 
Effectiveness Analysis Research Approach.26 To grade the evidence for each outcome measured, the 
team uses a grading system that has the following categories: 
• Research design; 
• Statistical significance; 
                                                     
26 Available at: www.chbrp.org/analysis_methodology/docs/medeffect_methods_detail.pdf.  
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• Direction of effect;  
• Size of effect; and 
• Generalizability of findings.  
The grading system also contains an overall conclusion that encompasses findings in these five domains. 
The conclusion is a statement that captures the strength and consistency of the evidence of an 
intervention’s effect on an outcome. The following terms are used to characterize the body of evidence 
regarding an outcome: 
• Clear and convincing evidence; 
• Preponderance of evidence; 
• Limited evidence; 
• Inconclusive evidence; and  
• Insufficient evidence. 
A grade of clear and convincing evidence indicates that there are multiple studies of a treatment and that 
the large majority of studies are of high quality and consistently find that the treatment is either effective 
or not effective.  
A grade of preponderance of evidence indicates that the majority of the studies reviewed are consistent in 
their findings that treatment is either effective or not effective.  
A grade of limited evidence indicates that the studies had limited generalizability to the population of 
interest and/or the studies had a fatal flaw in research design or implementation. 
A grade of inconclusive evidence indicates that although some studies included in the medical 
effectiveness review find that a treatment is effective, a similar number of studies of equal quality suggest 
the treatment is not effective. 
A grade of insufficient evidence indicates that there is not enough evidence available to know whether or 
not a treatment is effective, either because there are too few studies of the treatment or because the 
available studies are not of high quality. It does not indicate that a treatment is not effective. 
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Search Terms  
Smoking cessation  
Smoking prevention  
Smoking cessation agents  
Tobacco cessation  
Tobacco use cessation 
Varenicline 
Bupropion hcl 
Nicoderm CQ 
Nicorette 
Nicotrol 
Nicotine replacement therapy 
Alcoholism 
Alcohol disorders 
Disulfiram 
Acamprosate 
Lofexidine 
Bupreorphine  
Buprenorphine plus naloxone 
Drug abuse 
Medication assisted therapy 
Medication assisted treatment 
Methadone 
Naloxone 
Naltrexone 
Narcotic dependence 
Opiate substitution treatment 
Opiates 
Opioid-related 
disorders/therapy 
Opioid treatment 
Opioids 
Opioid use disorders 
Prior authorization 
Step therapy 
Utilization management 
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APPENDIX C COST IMPACT ANALYSIS: DATA 
SOURCES, CAVEATS, AND ASSUMPTIONS 
The cost analysis in this report was prepared by the members of the cost team, which consists of CHBRP 
task force members and contributors from the University of California, Los Angeles, the University of 
California, Davis and the University of Maryland, as well as the contracted actuarial firm, Milliman, Inc. 
(Milliman).27  
Information on the generally used data sources and estimation methods, as well as caveats and 
assumptions generally applicable to CHBRP’s cost impacts analyses are available at CHBRP’s website.28 
This appendix describes analysis-specific data sources, estimation methods, caveats, and assumptions 
used in preparing this cost impact analysis. 
Analysis-Specific Caveats and Assumptions 
This subsection discusses the caveats and assumptions specifically relevant to the requirements for 
pharmacy benefit coverage of outpatient medications for the treatment of substance use disorder (SUD) 
per SB 11. The impact of SB 11 is limited to medications related to the treatment of opioid use disorder 
(OUD), alcohol use disorder (AUD) and tobacco use disorder (TUD); these are the three SUDs for which 
the FDA has approved medications as treatments. 
A number of analytic assumptions are mentioned in the Policy Context section of the report. 
Following are descriptions of methodology and additional assumptions used to develop the estimates of 
cost impacts: 
• SUD prescription drugs used National Drug Codes (NDC) codes and reviewed by a content 
expert. Additionally, the SUD drug list excluded pain-related use of certain medications and only 
focused on the medication for SUD based on a content expert’s review.   
o CHBRP excluded AUD drugs gabepentin and topiramate due to the high prevalence of for 
non-AUD conditions.   
o Other SUD medications which are not available through a pharmacy benefit as outpatient 
prescription drugs due to the need for a clinician to be involved for injections, etc., such as 
naltrexone intramuscular, were also excluded from the analysis.   
o CHBRP excluded lofexedine from the analysis. This drug received FDA approval in May 2018 
and based on CHBRP’s content expert’s opinion, is not yet in widespread use by clinicians. It 
is not expected to have a cost impact in 2019 that is attributed to SB 11. 
                                                     
27 CHBRP’s authorizing statute, available at www.chbrp.org/docs/authorizing_statute.pdf, requires that CHBRP use a 
certified actuary or “other person with relevant knowledge and expertise” to determine financial impact.  
28 See 2017 Cost Impact Analyses: Data Sources, Caveats, and Assumptions, available at 
www.chbrp.org/analysis_methodology/cost_impact_analysis.php.  
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Table 11. Outpatient Prescription Medications for SUD and Overdose Reversal Medications 
Substance Use 
Disorder  Category Drug Name (Generic) Drug Name (Brand) Formulation 
Opioid Maintenance Buprenorphine Subutex Sublingual Tablet  
 Maintenance Buprenorphine N/A Sublingual Tablet  
 Maintenance Buprenorphine Probuphine Subdermal Implant 
 Maintenance Buprenorphine XR Sublocade SubQ pre-filled syringe 
 Maintenance Buprenorphine; Naloxone N/A Sublingual Tablet  
 Maintenance Buprenorphine; Naloxone Bunavail Buccal Film 
 Maintenance Buprenorphine; Naloxone Suboxone Sublingual Film 
 Maintenance Buprenorphine; Naloxone Zubsolv Sublingual Tablet  
 Maintenance Naltrexone N/A Tablet 
 Emergency Naloxone Narcan Nasal Spray 
 Emergency Naloxone Evzio Auto-injector Solution 
 Emergency Naloxone N/A Injection Solution 
Alcohol Maintenance Acamprosate Campral Tablet DR 
 Maintenance Disulfiram Antabuse Tablet 
 Maintenance Naltrexone N/A Tablet 
Smoking 
Cessation Maintenance Nicotine Nicoderm CQ Patch 24 Hour 
 Maintenance Nicotine Nicorette Gum 
 Maintenance Nicotine Nicorette Lozenge 
 Maintenance Nicotine Nicotrol Inhaler 
 Maintenance Varenicline Chantix Tablet 
 Maintenance Bupropion HCL SR Zyban Tablet SR 12 Hour 
Source: California Health Benefits Review Program, 2019. 
 
 
The following tables list the HCPCS and CPT codes used to identify counseling services for Substance 
Use Disorders. 
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Table 12. CPT/HCPCS Codes Used for Behavioral Therapy Services for Substance Abuse 
CPT/HCPCS Code Description 
99406 – 99407, 4000F - 4004F, G0436 - G0437, G9016, 
G9458, G9906, D1320, C9801 - C9802, G8402, G8453 
Smoking and Tobacco Use Cessation 
Counseling 
4158F, 4320F, G0443, G9621, T1006 Alcohol Use Counseling 
4306F Opioid Use Counseling 
H0004 Behavioral Health Counseling 
H0005, H0015  
 
Alcohol and/or Drug Counseling 
Source: California Health Benefits Review Program, 2019. 
 
CHBRP used the Substance Use Disorder diagnosis codes to identify the Substance Use Disorder 
Outpatient Drug users in Milliman’s proprietary 2016 Consolidated Health Cost Guidelines Sources 
Database (CHSD), which contains both Commercial and Medi-Cal claims and encounters.  
 
Table 13. Diagnosis Codes Used for Substance Use Disorder 
Diagnosis Code (ICD-10) Description 
F10.10-F10.99 Alcohol Abuse/Dependence/Use  
F11.10-F11.99 Opioid Abuse/Dependence/Use  
F17.200-F17.2999 Nicotine Dependence 
Source: California Health Benefits Review Program, 2019. 
 
CHBRP identified all individuals with SUD diagnosis codes throughout the year to establish a baseline 
estimate of the number of diagnosed individuals with a SUD. CHBRP relied upon the NDC codes to 
establish the utilization levels for each medication dosage and formulation prescribed for treatment of a 
SUD. CHBRP used the CPT/HCPCS codes to identify SUD counseling for members identified as using 
one or more of the specified SUD medications. 
Baseline medication unit costs were trended at an annual rate 7.5% per year from 2016 to 2019 (Milliman 
2018 Commercial Health Cost Guidelines™). The 7.5% trend represents the 2017 drug trends for the 
commercial enrollees represented within the report. As the increase in utilization seems unlikely to impact 
it, the unit cost per script is expected to be unchanged by SB 11, postmandate.  
Based on 2017 Mental Health and Substance Abuse Treatment Trends analysis performed by Truven 
Health Analytics (Health Leaders Media, 2017), baseline behavioral therapy services unit cost were 
trended at an annual rate 10% per year from 2016 to 2019. The analysis projects utilization rates per 
1,000 enrollees changing postmandate due to the removal of utilization management and for the inclusion 
on tier 1 of plan formularies for some drugs for some enrollees (see Table 13). Baseline utilization rates 
per 1,000 were developed based on CHSD data for members who use SUD medications. 
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Postmandate Offset Services – Inpatient, Outpatient, and Professional 
There are likely to be changes in the utilization of non-SUD-related services as a result of receiving SUD 
treatment. Mohlman et al. (2016) indicated reductions in inpatient days and emergency department visits 
associated with treatment of opioid use disorder. Mark et al. (2010) provided estimated reductions in 
detoxification days, inpatient days and emergency department visits associated with use of medications 
to treat alcohol use disorder. 
Unit costs were estimated using a combination of the Mohlman estimates, CHSD data, and relationships 
between commercial and Medi-Cal unit costs. CHBRP relied upon CHSD data for commercial and Medi-
Cal utilization and cost estimate. SB 11 will not cause a significant change in average cost per service 
postmandate. 
Determining Public Demand for the Proposed Mandate 
This subsection discusses public demand for the benefits SB 11 would mandate. Considering the criteria 
specified by CHBRP’s authorizing statute, CHBRP reviews public demand for benefits relevant to a 
proposed mandate in two ways. CHBRP:  
• Considers the bargaining history of organized labor; and 
• Compares the benefits provided by self-insured health plans or policies (which are not regulated 
by DMHC or CDI and therefore not subject to state-level mandates) with the benefits that are 
provided by plans or policies that would be subject to the mandate. 
On the basis of conversations with the largest collective bargaining agents in California, CHBRP 
concluded that unions currently do not include cost-sharing arrangements for treatment or service. In 
general, unions negotiate for broader contract provisions such as coverage for dependents, premiums, 
deductibles, and broad coinsurance levels. 
Among publicly funded self-insured health insurance policies, the preferred provider organization (PPO) 
plans offered by CalPERS currently have the largest number of enrollees. The CalPERS PPOs currently 
provide benefit coverage similar to what is available through group health insurance plans and policies 
that would be subject to the mandate.  
To further investigate public demand, CHBRP used the bill-specific coverage survey to ask carriers who 
act as third-party administrators for (non-CalPERS) self-insured group health insurance programs 
whether the relevant benefit coverage differed from what is offered in group market plans or policies that 
would be subject to the mandate. The responses indicated that there were no substantive differences.  
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APPENDIX D PHARMACY BENEFITS AND STATE-LEVEL 
MANDATES 
As noted in Table 1, for 2019, CHBRP estimates that approximately 1.4% of enrollees in plans regulated 
by the California Department of Managed Health Care (DMHC) or policies regulated by the California 
Department of Insurance (CDI) have no pharmacy benefit and 3.0% of these enrollees have pharmacy 
benefit coverage that is not regulated by DMHC or CDI.  
Table 14. Pharmacy Benefit Coverage, 2019 
 
 
Enrollees in DMHC-Regulated 
Plans and in CDI-Regulated 
Policies 
 
 
 
Total 
 
 
Enrollee Counts 
Total enrollees in plans/policies subject to state 
Mandates (a) 
 
 
 
23,433,000 
 
 
Pharmacy Benefit Coverage 
 
 
 
DMHC or CDI regulated brand name and generic 
medication coverage 
 95.5% 
 
DMHC or CDI regulated generic only coverage 
 0.1% 
 
No pharmacy benefit 
 1.4% 
 
Other pharmacy benefit 
 3.0% 
Source: California Health Benefits Review Program, 2019.  
Notes: (a) This population includes both persons who obtain health insurance using private funds (group and 
individual) and through public funds (e.g., CalPERS HMOs, Medi-Cal Managed Care Plans). Only those enrolled in 
health plans or policies regulated by the DMHC or CDI are included. Population includes all enrollees in state-
regulated plans or policies aged 0 to 64 years, and enrollees 65 years or older covered by employer-sponsored 
health insurance. 
Key: CalPERS HMOs = California Public Employees’ Retirement System Health Maintenance Organizations; CDI = 
California Department of Insurance; DMHC = Department of Managed Health Care; HMO = Health Maintenance 
Organization 
Additional detail about the presence and absence of pharmacy benefit coverage in various market 
segments is presented below, in Table 15, Table 16, and Table 17. 
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Relevant State and Federal Law 
• A number of overlapping state and federal laws require broad pharmacy benefit coverage or 
coverage for particular medications, but the requirements are not applicable to all forms of health 
insurance 
• Some (but not all) small group and individual market health care service plans and health 
insurance policies are required to provide coverage for medications as part of coverage for 
Essential Health Benefits (EHBs).29 
• Some (but not all) large group, small group, and individual market health care service plans and 
health insurance policies are required to provide pharmacy benefit coverage for particular 
medications as part of preventive services, but not for all medications.30 
• Some state-level mandates, applicable to some or all plans and policies regulated by DMHC or 
CDI, require pharmacy benefit coverage for particular medications. For example, there is a 
mandate that requires coverage for insulin and prescription medications for the treatment of 
diabetes but does not require coverage for medications that treat diabetes-related conditions.31  
However, this mix of laws does not require that all enrollees in plans and policies regulated by DMHC or 
CDI have a pharmacy benefit. 
Presence or Absence of Pharmacy Benefit Coverage for Outpatient 
Medications and Related Regulation 
Pharmacy benefit coverage of medications was estimated through surveys and queries. For enrollees in 
the privately funded markets regulated by DMHC and CDI, coverage was determined by responses to a 
survey of the largest providers of health insurance in California. Responses to this survey represent 95% 
of enrollees in these markets. The California Public Employees’ Retirement System (CalPERS) was 
queried regarding coverage among DMHC-regulated plan enrollees associated with CalPERS. The 
California Department of Health Care Services (DHCS) was queried about coverage among Medi-Cal 
beneficiaries enrolled in DMHC-regulated plans. 
From this information, CHBRP concluded that most enrollees have pharmacy benefit coverage through 
their DMHC-regulated plan or CDI-regulated policy. These enrollees’ pharmacy benefit is generally used 
when acquiring medications at an outpatient pharmacy or mail order service. When pharmacy benefit 
coverage is handled through a subcontracting pharmacy benefit management (PBM) organization, the 
plan or policy, licensed by DMHC or CDI, requires the subcontracting PBM to comply with relevant state-
level health insurance benefit mandates. 
As pharmacy benefit coverage is not universally required, some enrollees in DMHC-regulated plans and 
CDI-regulated policies have no pharmacy benefit. Although these enrollees’ health insurance covers 
prescription medications delivered during a hospital (or other facility) admission and some prescription 
medications that are dispensed through a clinician’s office, these enrollees’ health insurance would not 
generally help them acquire medications intended for outpatient use. As noted above, there are some 
                                                     
29 California Health & Safety Code: 1367.005, 1367.006, 1367.0065; California Insurance Code: 10112.27, 10112.28, 10112.285; 
Federal Affordable Care Act of 2010: Section 1301, 1302, and Section 1201 modifying Section 2707 of the PHSA 
30 California Health & Safety Code: 1367.002; California Insurance Code: 10112.2; Federal Affordable Care Act of 2010: Section 
1001 modifying Section 2713 of the PHSA 
31 California Health & Safety Code: 1367.51 and California Insurance Code: 10176.61 
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medication-specific exceptions, such as insulin, but coverage would be limited to those specific outpatient 
medications. 
In terms of alternate regulation, some enrollees who have no pharmacy benefit through their DMHC-
regulated plan or CDI-regulated policy still do have a pharmacy benefit — but have it through another 
source, one that is not regulated by DMHC or CDI. Such a circumstance can occur if, for example, an 
employer arranges for a large group plan to exclude pharmacy benefit coverage and then contracts 
separately with a PBM to administer a pharmacy benefit. In this example, the PBM is not a subcontractor 
to a plan or insurer; it is directly contracting with the employer. If the contracting PBM is not licensed by 
either DMHC or CDI, it is not subject to state-level health insurance benefit mandates (see enrollees with 
“other pharmacy benefit” in the tables in this appendix). 
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Table 15. Pharmacy Benefit Coverage in the Large Group and Publicly Funded Markets, 2019 
  DMHC-Regulated Plans  CDI-Regulated Policies 
  
Privately Funded 
Large Group  Publicly Funded Plans  
Privately Funded 
Large Group 
    
 
Grand-
fathered 
 
Non-Grand-
fathered 
 CalPERS HMOs 
(a) 
MCMC  
(Under 65) 
(b) 
MCMC (65+) (b) 
 
 Grandfathered 
Non-
Grand-
fathered 
Enrollee Counts 
         
 
Total enrollees in 
plans/policies subject to 
state mandates (c) 1,860,000 7,511,000   887,000 6,832,000 678,000   5,000 209,000 
Pharmacy Benefit 
Coverage 
 
 
                  
 
DMHC or CDI 
regulated brand name 
and generic 
medication coverage 95.9% 90.5%   79.5% 100.0% 100.0%   80.3% 86.8% 
 
DMHC or CDI 
regulated generic only 
coverage 0.0% 0.0%   0.0% 0.0% 0.0%   0.0% 0.0% 
 
No pharmacy benefit 
3.8% 3.0%   0.0% 0.0% 0.0%   14.9% 2.2% 
  
Other pharmacy 
benefit 0.3% 6.5%   20.5% 0.0% 0.0%   4.8% 11.0% 
Source: California Health Benefits Review Program, 2019.  
Notes: (a) As of September 2017, 56% of CalPERS HMO members were state retirees under age 65, state employees or their dependents. CHBRP assumes the same ratio for 2019. 
(b) Medi-Cal Managed Care Plan expenditures for members over 65 include those who are also Medicare beneficiaries. This population does not include enrollees in COHS.. 
(c) This population includes both persons who obtain health insurance using private funds (group and individual) and through public funds (e.g., CalPERS HMOs, Medi-Cal Managed Care Plans). 
Only those enrolled in health plans or policies regulated by the DMHC or CDI are included. Population includes all enrollees in state-regulated plans or policies aged 0 to 64 years, and enrollees 
65 years or older covered by employer-sponsored health insurance. 
Key: CalPERS HMOs = California Public Employees’ Retirement System Health Maintenance Organizations; CDI = California Department of Insurance; DMHC = Department of Managed Health 
Care; COHS = County Operated Health Systems; MCMC = Medi-Cal Managed Care. 
 
  
Analysis of California Senate Bill 11 
Current as of February 13, 2019 www.chbrp.org D-9 
Table 16. Pharmacy Benefit Coverage in the DMHC-regulated Small Group and Individual Markets, 2019 
  
Privately Funded 
Small Group  
Privately Funded 
Individual  
    
Grand-
fathered 
Non-Grand-
fathered 
Covered 
California(a) 
Non-Grand-
fathered 
Mirror 
Plans (b) 
Other Non-
Grand-
fathered 
  Grand-fathered 
Non-Grand-
fathered 
Covered 
California(a) 
Non-Grand-
fathered 
Mirror Plans 
(b) 
Other Non-
Grand-
fathered 
Enrollee Counts                     
 
Total enrollees in 
plans/policies subject to state 
mandates (c) 355,000 49,000 687,000 2,026,000   103,000 1,157,000 611,000 210,000 
Pharmacy Benefit Coverage                    
 
DMHC regulated brand name 
and generic medication 
coverage 99.9% 100.0% 100.0% 100.0%   90.7% 100.0% 100.0% 100.0% 
 
DMHC regulated generic only 
coverage 0.0% 0.0% 0.0% 0.0%   0.0% 0.0% 0.0% 0.0% 
 
No pharmacy benefit 
0.0% 0.0% 0.0% 0.0%   9.3% 0.0% 0.0% 0.0% 
  Other pharmacy benefit 0.0% 0.0% 0.0% 0.0%   0.0% 0.0% 0.0% 0.0% 
Source: California Health Benefits Review Program, 2019. 
Notes: (a) The Affordable Care Act (ACA) requires the establishment of health insurance exchanges in every state, now referred to as health insurance marketplaces. In California, the 
marketplace is called “Covered California.” 
(b) “Mirror Plans” are qualified health plans (QHPs) available outside of Covered California. 
(c) This population includes both persons who obtain health insurance using private funds (group and individual) and through public funds (e.g., CalPERS HMOs, Medi-Cal Managed Care Plans). 
Only those enrolled in health plans or policies regulated by the DMHC or CDI are included. Population includes all enrollees in state-regulated plans or policies aged 0 to 64 years, and enrollees 
65 years or older covered by employer-sponsored health insurance.  
Key: CalPERS HMOs = California Public Employees’ Retirement System Health Maintenance Organizations; CDI = California Department of Insurance; DMHC = Department of Managed Health 
Care; COHS = County Operated Health Systems; MCMC = Medi-Cal Managed Care. 
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Table 17. Pharmacy Benefit Coverage in CDI-regulated Small Group and Individual Markets, 2019 
  
Privately Funded 
Small Group  
Privately Funded 
Individual 
    
Grand-
fathered 
Non-Grand-
fathered 
Covered 
California (a) 
Non-Grand-
fathered 
Mirror 
Plans (b) 
Other 
Non-
Grand-
fathered 
  Grand-fathered 
Non-Grand-
fathered 
Covered 
California (a) 
Non-
Grand-
fathered 
Mirror 
Plans (b) 
Other 
Non-
Grand-
fathered 
Enrollee Counts                
 
Total enrollees in 
plans/policies subject to state 
mandates (c) 1,000 3,000 23,000 106,000   186,000 3,000 22,000 26,000 
Pharmacy Benefit Coverage                    
 
CDI regulated brand name 
and generic medication 
coverage 96.5% 100.0% 100.0% 100.0%   50.9% 100.0% 100.0% 100.0% 
 
CDI regulated generic only 
coverage 0.0% 0.0% 0.0% 0.0%   39.1% 0.0% 0.0% 0.0% 
 
No pharmacy benefit 
0.0% 0.0% 0.0% 0.0%   10.0% 0.0% 0.0% 0.0% 
  Other pharmacy benefit 0.0% 0.0% 0.0% 0.0%   0.0% 0.0% 0.0% 0.0% 
Source: California Health Benefits Review Program, 2019. 
Notes: (a) The Affordable Care Act (ACA) requires the establishment of health insurance exchanges in every state, now referred to as health insurance marketplaces. In California, the 
marketplace is called “Covered California.” 
(b) “Mirror Plans” are qualified health plans (QHPs) available outside of Covered California. 
(c) This population includes both persons who obtain health insurance using private funds (group and individual) and through public funds (e.g., CalPERS HMOs, Medi-Cal Managed Care Plans). 
Only those enrolled in health plans or policies regulated by the DMHC or CDI are included. Population includes all enrollees in state-regulated plans or policies aged 0 to 64 years, and enrollees 
65 years or older covered by employer-sponsored health insurance.  
Key: CalPERS HMOs = California Public Employees’ Retirement System Health Maintenance Organizations; CDI = California Department of Insurance; DMHC = Department of Managed Health 
Care; COHS = County Operated Health Systems; MCMC = Medi-Cal Managed Care.
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